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Peri-operative medicine is an area that is increasingly important in terms of increasing 
population size and therefore increasing volume of surgeries completed. The assessment 
of risk and the communication of this risk to patients and their families is vital to shared 
decision making which is one of the key considerations for practising realistic medicine. 
Oesophageal cancer was responsible for 3% of the total number of cancer cases in the 
UK in 2015 and affected 921 patients in Scotland in 2015 which was 10% of the total 
number of oesophageal cancer cases in the UK that year. Studies have shown that atrial 
fibrillation is associated with increased morbidity and mortality and it can occur 
following operations such as those undertaken in the management of oesophageal 
cancer. Several cardiovascular biomarkers exist, some of which have been associated 
with the development of atrial fibrillation and the question I sought to explore was 
whether it was possible to begin to understand which patients developed atrial 
fibrillation following their operation for oesophageal cancer and also whether the 
development of atrial fibrillation, in combination with other cardiovascular biomarkers, 
in the context of cardiopulmonary exercise testing results would assist in the prediction 
of the morbidity and mortality of this patient group. 
Based on the existing literature, I created the concept for the study and then co-ordinated 
and implemented the study.  
In the work I have presented in this thesis I have shared some of the challenges which I 
faced during the study and how I dealt with those. I have also shared some of the results 
including biomarker levels and cardiopulmonary exercise testing results in the context of 
the onset of AF in patients and the subsequent morbidity and mortality. I have also 
discussed the challenges I encountered when the study did not go according to plan and 
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1 CHAPTER 1  
1.1 INTRODUCTION 
Cancer of the oesophagus is the eighth most common cancer worldwide with an estimated 
462,000 new cases (4.2% of the world total) in 20021. It is also the sixth most common cause 
of death from cancer with 386,000 deaths (5.7% of the world total). It affected 8900 people in 
2014 in the UK with approximately twice as many cases occurring in men as in women. For 
people diagnosed in England and Wales in 2010-11, the 5 year survival rate was only 15%. 
Oesophageal cancer is frequently diagnosed at an advanced tumour stage and this in addition 
to co-morbidity means that only 30-40% cases are suitable for curative resection2.Although 
early post-operative mortality rates have decreased during recent years due to the 
development of surgical technique and peri-operative care, they are still as high as 4-14%3,4. 
Operations involving patients with oesophageal cancer are amongst those with the highest 
morbidity and mortality. 
Oesophageal surgery, whether for benign or neoplastic disease is a major undertaking 
associated with significant morbidity and mortality. Stratifying and assessing the patients pre-
operatively so that the appropriate level of intervention is offered is important in helping 
reduce these risks. 
1.2 Peri-operative medicine and clinical risk scoring systems  
Peri-operative medicine describes the practice of multidisciplinary, integrated, patient-centred 
medical care of patients from the contemplation of surgery until full recovery5.Surgery is an 
important treatment option for a wide range of acute and chronic diseases and for most 
patients it is a success, however; the population is changing and so must our current services. 
The peri-operative care of patients undergoing major surgery is recognised as an area that 
significantly affects public health and one in which needs are unmet. Predicting and 
preventing morbidity and mortality peri-operatively is of vital importance as populations age 




million major surgical operations are performed worldwide each year6 and approximately 8 
million of those are in the UK7. For many years the care received by patients undergoing 
surgery of major importance has been titrated to the operation and the disease treated by the 
procedure as opposed to the patient and their co-morbidities. The Confidential Enquiry into 
Perioperative Deaths (CEPOD) was published in 1987 in response to professional concern 
about peri-operative deaths8. Following publication of the work the Department of Health 
announced that it would fund the National Confidential Enquiry (NCEPOD) to repeat the 
work and it published its first report in 19899. The name was subsequently changed and in 
2011, the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) entitled 
‘ Peri-operative care-Knowing the Risk’ highlighted the process care of patients aged 16 
years and over who underwent elective and emergency inpatient surgery and evaluated their 
outcome at 30 days. It was an observational study of over 16,000 surgical patients in the Isle 
of Man, Jersey, Guernsey, England, Wales and Northern Ireland10 and it is estimated that 
20,000-25,000 deaths per year occurred in hospital after a surgical procedure. Approximately 
80% of these deaths occurred in a small population of patients who were deemed to be high 
risk. These high-risk patients are estimated to comprise about 10% of the overall inpatient 
surgical workload and are a major source of morbidity, mortality and resource utilisation. 
There are concerns that UK outcomes may be poorer than in other countries as when 
compared with centres in similar sized hospital and patient populations in the United States of 
America (USA), the NHS has poorer outcomes as a whole11,12. The 2011 report led to pre, 
peri and post-operative recommendations. Pre-operatively, it suggested that all elective high-
risk surgical patients should be seen and fully investigated in pre-assessment clinics. It 
advised that there should also be greater assessment of a patient’s nutritional status and 
consideration of requirement of fluid optimisation. Peri-operatively there should be 




availability of high dependency and intensive care beds. Overall, the report revealed that 
there was a lack of consensus as to what constituted high peri-operative risk. 
Accurately predicting peri-operative risk is an ideal goal, which would allow informed 
consent for patients prior to surgery and guide clinical decision-making during the peri-
operative period. Factors to consider include the interplay between the inflammatory response 
to the tissue injury during surgery, the type and quality of the surgery and the patient’s 
physiological reserve as these have been shown to contribute to the outcome13. Optimal 
assessment and management of patients peri-operatively will ideally lead to reduction in post-
operative complications and improved long term survival. Methods already exist which 
assess peri-operative risk for individual patients.  
1.3 Risk stratification tools 
One method of assessing risk peri-operatively is by using risk stratification tools. These are 
models or scoring systems that predict or adjust for mortality or morbidity after surgery, 
based on different risk factors. These risk stratification tools complement investigations to 
identify high-risk patients such as cardiopulmonary exercise testing and biomarker 
assays14.Functional testing such as cardiopulmonary exercise testing is not routinely available 
and is not practical in urgent or emergency cases10,15. The role of biomarkers such as NT-
proBNP and BNP in the identification of high-risk patients is still emerging16,17,18. Risk 
stratification tools remain the most readily available means of determining peri-operative 
risk. 
Risk stratification tools can be divided into risk scores and also risk prediction models. 
1.4 Risk scores 
These assign a weighting to factors identified as independent predictors of outcome. The sum 
of the weightings in the risk score reflects increasing risk. These scores are easier to use in 
the clinical setting, but they do not provide an individualised risk prediction of an adverse 




scores include the Lee Revised Cardiac Risk Index and the American Society of 
Anaesthesiologists Physical Status score (ASA-PS).  
The original Cardiac Risk Index or the Goldman Index was developed in 1977 by Goldman 
and included nine variables associated with an increased risk of peri-operative complications. 
The Revised Cardiac Risk Index (RCRI) by Lee et al 199919 is a tool that is used for 
predicting a patient’s risk of peri-operative cardiac complications following major non-
cardiac surgery. It uses six independent variables, which cumulatively increase a patient’s 
risk for peri-operative cardiac complications. It has been found that its predictive power could 
be improved significantly by adding CRP and NT-proBNP to it (adjusted RR 4.6 p<0.001).  
Table 1.1 Revised Cardiac Risk Index (RCRI) 19 
 
Revised Cardiac Risk Index 
History of ischaemic heart disease 
History of congestive heart failure 
History of cerebrovascular disease (Stroke or Transient Ischaemic Attack) 
History of diabetes requiring pre-operative insulin use 
Chronic kidney disease (Creatinine > 2mg/dL) 
Undergoing suprainguinal, vascular, intraperitoneal or intrathoracic surgery 
Risk for cardiac death, non fatal MI, non fatal cardiac arrest 
0 predictors: 0.4%, 1 predictor 0.9%, 2 predictors 6.6%, >/- 3 predictors > 11% 
 
The RCRI has been incorporated in a modified form into the 2007 pre-operative cardiac risk 
evaluation guideline from the American Heart Association (AHA) and the American College 
of Cardiology (ACC).  
American Society of Anaesthesiologists Physical Status score (ASA-PS) 
The ASA-PS is a five point classification system that was developed in 1963 to assess fitness 
of patients before surgery. A sixth class was added later to denote brain dead patients whose 
organs were being removed for donation purposes20. ASA-PS shows good correlation with 
post-operative outcome for patient populations in a number of surgical settings but does not 




that the procedure will cause, the experience of the doctors caring for the patient or the peri-
operative optimisation that may occur. 
1.5 Risk prediction models  
These estimate an individual probability of peri-operative risk by entering the patient’s data 
into the multivariable risk prediction model. These models are more accurate when compared 
to risk scoring, however they are more complex to use in the daily clinical setting. 
A qualitative systematic review published in October 201321 looked at summarising the 
available risk prediction methods, to report on their performance and to identify their 
strengths and weaknesses. Twenty-seven studies evaluating thirty-four risk stratification tools 
were identified which met inclusion criteria. 
1.6 Examples of Risk prediction models 
The 2014 pre-operative cardiac risk evaluation guideline from the American Heart 
Association (AHA) and the American College of Cardiology (ACC) stated that two newer 
risk prediction models; the American College of Surgeons National Surgical Quality 
Improvement Programme (N 
SQIP) Myocardial Infarction or Cardiac Arrest (MICA) risk prediction calculator and the 
NSQIP surgical risk calculator22 had been created by the American College of Surgeons 
(ACS). 
Other risk prediction models include the Donati Surgical Risk Score, Charlson Age Co-
morbidity Index (CACI), Surgical Risk Scale and Physiological and Operative Severity Score 
for the EnUmeration of Mortality and Morbidity (POSSUM). These have been validated in 
multiple studies. The surgical outcomes risk tool (SORT) and the Nottingham hip fracture 
score are also examples of risk prediction models. The Surgical Risk Scale and the Surgical 
Risk Score contain the ASA-PS.  
The NSQIP MICA risk prediction tool includes adjusted odds ratios for different surgical 




cardiac arrest or MI. The NSQIP surgical risk calculator uses procedure specific risk 
assessment for a diverse group of outcomes. Limitations to the NSQIP calculator include the 
lack of validation in an external population and the use of the Anaesthesiology Physical status 
classification which has poor inter-rater reliability. NSQIP also has definitions of functional 
status, with which clinicians would need to familiarise themselves23. 
Donati Surgical Risk Score 
The surgical risk score was published by Donati et al in 200424 and was introduced as a 
model to evaluate pre-operative risk. The endpoint of the study was death or survival at 
hospital discharge in 1936 surgical patients. It included patients having all types of surgery 
apart from cardiac surgery and Caesarean sections. The model was validated in a further 1849 
patients. It incorporates ASA-PS, age, type of surgery (eg. elective) and degree of surgery 
(eg. major). In estimating the degree or severity of surgery the score uses the modified Johns 
Hopkins surgical classification system25 which was adapted from five original levels to three. 
Levels one and two were combined to produce minor surgery and levels four and five 
combined to produce level three; major surgery.  
Charlson Co-morbidity Index (CCI) and Charlson Age Comorbidity Index (CACI) 
The Charlson Co-morbidity Index (CCI) is a medical risk stratification tool which was 
developed for risk adjustment and prediction in non-surgical settings. It is a weighted score 
assigned to 17 co-morbidities based on the risk of 1 year mortality. In the tool’s original 
validation, increasing CCI scores were significantly correlated with increased 10 year 
mortality in medical patients26.  It is the most extensively validated measure of the prognostic 
impact of multiple chronic conditions. The Charlson Age Comorbidity Index (CACI) which 
is a combined age-comorbidity score was validated for the prediction of long-term mortality 
in patients undergoing non-cardiac elective surgery who had essential hypertension or 




International Classification of Diseases (ICD) diagnosis codes. The CACI has been validated 
in a number of surgical cohorts and it has been found to be a moderately accurate tool28. In a 
colorectal surgery cohort, it was found to be a predictor of in hospital morbidity, duration of 
hospital stay and mortality29. It has predictive ability but its disadvantages include lack of 
information regarding the surgical procedure and also the subjectivity involved in defining 
patients’ co-morbidities. Since 1984, when the original Charlson weighted scoring was 
developed, there have been improvements in treatments and advances in technology and 
consequently patients survive longer than they did previously. The Charlson Index has been 
updated to include 12 co-morbidities instead of 17. The updated weight was shown to be 
lower than the Charlson weighting for AIDS/HIV, diabetes with complications and renal 
disease and higher for dementia, liver disease and congestive heart failure. This increased 
weighting may be related to an ageing population. The updated index has shown a good 
ability to discriminate outcome with regard to hospital mortality in 6 developed-country 
databases but needs validation in other developing-country settings in disease specific or 
procedure specific cohorts28. 
Surgical Risk Scale 
The Surgical Risk Scale (SRS) was published by Sutton in the British Journal of Surgery in 
2002. It is a cumulative score which adds the Confidential Enquiry into Perioperative Deaths 
(CEPOD) category to the American Society of Anesthesiologists Physical Status (ASA-PS) 
score and the British United Provident Association (BUPA) category scores. This means that 
a patient undergoing emergency complex major surgery, with an ASA of 5 dictated the 
highest rate of in hospital mortality. The benefit of this scoring system is that it can be used at 
the bedside prior to surgery30. However, previous validation studies are limited to two 
analyses from the same collaborators30,31 and an external validation that included urgent or 




Physiological and Operative Severity Score for the EnUmeration of Mortality and 
Morbidity (POSSUM) 
To address the limitations and the poor ability of the ASA-PS to identify individuals at risk of 
complications post-operatively, Copeland et al33 developed the Physiological and Operative 
Severity Score for the EnUmeration of Mortality and Morbidity (POSSUM) scoring system. 
It was developed as a post hoc audit tool for surgery. It uses 12 pre-operative physiological 
parameters and 6 surgical or operative variables. Morbidity and mortality is calculated by 
using the sum of the physiological and surgical variables and entering them into two 
mathematical equations. 
Table 1.2 A summary of the physiological and surgical variables used in the 
original POSSUM score33. 
 
Physiological Parameters Operative Parameters 
Age Operation type 
Cardiac Number of procedures 
Respiratory Operative blood loss 
ECG Peritoneal contamination 
Systolic BP Malignancy status 
Pulse rate CEPOD 
Haemoglobin   
White cell count   
Urea   
Sodium   
Potassium   
Glasgow Coma Scale   
(CEPOD = defines the urgency of surgery) 
POSSUM was further developed when researchers identified a need to adjust the logistic 
regression analysis used in POSSUM scoring and weighting to better predict inpatient 
mortality. This resulted in the Portsmouth version (P-POSSUM) which uses the same 18 
physiological and operative parameters as the original but a different calculation is used to 
determine predicted mortality34. It also includes some subjective variables such as 




Several researchers have found the predictive ability of P-POSSUM to be more accurate than 
POSSUM. While some studies have found that POSSUM AND P-POSSUM predict risk of 
morbidity and mortality for individual patients, others have found overestimation of mortality 
using this score, especially in low risk patients35. Other risk models have been developed 
including V-POSSUM (vascular surgery) CR-POSSUM (colorectal surgery) and O-POSSUM 
(oesophagogastric surgery)36. O-POSSUM has been found to be superior to other POSSUM 
models for predicting mortality in oesophageal-gastric surgery37. It has 16 parameters and has 
performed better than P-POSSUM when predicting post-operative mortality. P-POSSUM and 
its variations remain the scoring systems which have been globally validated for predicting 
individual risk. Both POSSUM and P-POSSUM have had variable success of being 
incorporated into clinical practice. Difficulty using them may be due to complexity or 
accessibility if a blood test is required. In 2013, a qualitative systematic review of risk 
stratification tools for predicting morbidity and mortality, validated in heterogeneous patient 
cohorts was published. The P-POSSUM and Surgical Risk Scale (SRS) were found to be the 
most widely validated and accurate risk stratification tools available, based on published data 
but both were noted to have limitations22. 
Surgical Outcome Risk Tool (SORT) 
SORT was developed using data from an observational study of over 16,000 patients 
conducted by the NCEPOD ‘Knowing the Risk’ study7. It is based on six pre-operative 
variables and does not require blood tests. It gives a 30 day mortality risk for adult inpatients 
undergoing non-obstetric, non-cardiac, non -transplant and non-neurological surgery and has 
been validated for use in predicting post-operative morbidity when used pre-operatively in 
addition to clinical judgement, for major elective surgical patients38. In the validation cohort, 
the SORT demonstrated better discrimination than the ASA-PS and Surgical Risk Scale. Its 




centre cohort of adult patients undergoing major elective surgery39. A SORT App is now 
advertised on the NCEPOD website40. 
1.7 Models based on biochemical and haematological data 
The Glasgow Prognostic scoring system (GPS) and the Modified Glasgow Prognostic scoring 
system (mGPS) are the most extensively validated of the systemic inflammation-based 
prognostic scores with more than 60 studies having examined their use41. The GPS evaluates 
C-reactive protein (CRP) and albumin levels and assigns a score. It has independent 
prognostic value in patients with cancer and an incrementally worsening prognosis is 
suggested by an increasing score. The mGPS weighs the inflammatory component more 
heavily and does not assign a score for an isolated low albumin. Another model, the 
Biochemistry and Haematology Outcome Model (BHOM) includes, age, sex, mode of 
admission, physiological parameters such as haemoglobin, white cell count, British United 
Provident Association (BUPA) operative severity score and 30 day mortality. The BHOM 
has the advantage of having variables that are mostly available pre-operatively, apart from 
operative severity. The Vascular BHOM has also been shown to be feasible after index 
arterial operations. The BHOM has been shown to have similar predictive accuracy to P-
POSSUM in one study32 however, it has not been validated in multicentre cohorts.  
1.8 Functional Testing: Cardiopulmonary exercise testing (CPET) and surgery 
Cardiopulmonary exercise testing is a non invasive clinical tool that assesses an individual’s 
functional capacity or fitness and also the performance of the cardiorespiratory system. It can 
help to identify risk in patients pre-operatively and as a result, the stratification of patients 
pre-operatively using CPET in cardiopulmonary and non-cardiopulmonary surgery is 
increasingly widespread. It allows the objective assessment of exercise capacity pre-
operatively and identifies the causes of exercise limitation by means of the calculation of a 
number of diagnostic and prognostic variables. It can identify pathophysiology not apparent 




demands of major surgery. It can inform peri-operative planning, including the use of 
invasive monitoring, pre-operative optimisation and allocation of post-operative critical care 
resources. CPET therefore has the capacity to identify patients at risk of adverse outcome 
before a range of non-cardiopulmonary surgical procedures42. In the mid 1990’s, Older et al43 
completed an Australian study of 548 elderly patients who were undergoing major non 
cardiac surgery and assessed the functional capacity of their heart and lungs by carrying out 
pre-operative CPET. There were no deaths attributable to cardiopulmonary causes in any 
patient with adequate ventricular function, defined as an anaerobic threshold (AT) above 
11ml.kg-1.min-1 even if myocardial ischaemia was present. The conclusion was that the 
functional capacity of the heart and lungs as defined by CPET influences morbidity and 
mortality by determining the ability to deal with increased post-operative oxygen demand 
after major surgery. Patients with an AT below 11ml.kg-1.min-1 were deemed to be high risk. 
With the uptake of CPET it is important that there is standardisation to ensure valid, 
reproducible results to inform clinical decision-making. Recently the Peri-operative Exercise 
Testing and Training Society (POETTS) has been established, which promotes high standards 
for patients undergoing training and testing in the peri-operative period. Guidelines have been 
developed by consensus following a systematic literature review44. There are many 
physiological variables obtained from CPET testing but three have been shown to identify 
high risk patients; VO2 peak or max, anaerobic threshold (AT) and ventilator equivalent for 
carbon dioxide (VE/VCO2)43,44. VO2 max is also known as the maximal oxygen 
consumption and is the maximum rate of oxygen consumption measured during incremental 
exercise. It can be expressed as an absolute rate eg. litres of oxygen per minute or it can be 
expressed as a relative rate in millilitres of oxygen per kilogram of body mass per minute 
(ml/kg/min). The AT is the point at which aerobic metabolism is no longer adequate and 




not cease, but anaerobic metabolism supplements aerobic production of adenosine 
triphosphate (ATP) as the work rate increases45. 
1.9 CPET and Oesophageal surgery 
The link between upper gastrointestinal (GI) surgery and CPET derived variables and 
outcomes initially was investigated by two studies in Japan which looked at 
thoracolaparotomy for thoracic oesophageal cancer and the other which looked at 91(3 of 
which were female) patients who had undergone oesophagectomy with lymphadenectomy for 
squamous cell carcinoma (SCC)46. They revealed that a VO2 max of 800ml/min/m2 was the 
optimal threshold to discriminate those at a high risk of post-operative cardiopulmonary 
morbidity. Locally in Scotland, 108 patients were studied from 2008-2010 with oesophageal 
cancer and gastric cancer and had CPET as a formal fitness assessment. This showed that 
patients with a lower AT and a cut-off value of 9ml/min/kg had a higher risk of developing 
cardiopulmonary complications. One of the limitations of the study was its size and the 
resultant need for the results to be validated in a larger cohort and also the heterogeneity of 
the study population with some patients undergoing oesophagectomy and some undergoing 
gastrectomy47. Another CPET study prospectively evaluating 78 patients suggested that an 
association may exist between V02 peak and outcome following oesophagectomy, although 
capacity to predict those at increased risk is low and again study size was a limitation in this 
cohort48. Pre-operative cardiopulmonary exercise testing is routinely carried out for patients 
requiring oesophagectomy. Studies have shown that pre-operative VO2 max and anaerobic 
threshold measurements from CPET have been used to help predict risk of post-operative 
morbidity and mortality in non cardiopulmonary surgery patients, however, further larger 
studies are needed49. 
1.10 Oesophageal Cancer 
There are two main types of oesophageal cancer in the UK; adenocarcinoma, which accounts 




Squamous cell carcinomas mostly arise in the middle third of the oesophagus and the 
majority of adenocarcinomas arise in the lower third of the oesophagus. There are several risk 
factors for developing the disease including smoking tobacco which is causally associated. 
However, despite a reduction in smoking, the incidence of this cancer has risen in England 
and Wales. This is thought to be due to the additive effects of alcohol consumption and 
smoking tobacco. In Western countries, the main risk factors for SCC are smoking and 
alcohol consumption, however, adenocarcinoma predominantly occurs in patients with 
chronic gastro-oesophageal reflux disease. This risk is correlated with the patient's body mass 
index (BMI), with a higher risk for obese people50,51. 
Treatment for oesophageal cancer depends on the size, location and extent of the tumour and 
these are described by Tumour Node Metastasis (TNM) staging. Management often involves 
surgery, chemotherapy and sometimes radiotherapy. Resection of smaller tumour size in 
oesophageal cancer at stage T1-2 results in long-term survival but prognosis for oesophageal 
surgery alone is poor for stages T3-4 where the cancer has spread further. Neoadjuvant 
chemotherapy or chemoradiotherapy improved the overall survival of patients with advanced 
carcinomas of the oesophagus by about 10% over 5 years, according to Cochrane analysis 
and the prospective randomised Chemoradiotherapy for Oesophageal cancer followed by 
Surgery Study (CROSS) trial. In a study of 78 patients, neoadjuvant chemotherapy did not 
produce any significant differences in the incidence of cardiopulmonary and 
noncardiopulmonary complications, unplanned ICU admission rates or length of hospital 
stay48. The patient’s nutritional status and history of weight loss should also be assessed, 
according to The European Society for Clinical Nutrition and Metabolism (ESPEN) 
guidelines52. More than half of patients lose >5% of their body weight before admission for 
oesophagectomy and 40% lose >10%. This weight loss, independent from the BMI, confers 




survival in advanced disease. Nutritional support according to the ESPEN guidelines53 is an 
important part of the medical care for patients with oesophageal cancer in the curative and in 
the palliative setting. The five-year survival rate from all stages of oesophageal cancer 
remains 20-25%. A US study involving Surveillance, Epidemiology and End results (SEER) 
database analysis of 62,523 patients with cancer of the oesophagus suggested that 10 year 
survival is only 14%. Patients younger than 65 years and those receiving surgical therapy 
have the highest chance of survival54. The presence of a systemic inflammatory response is a 
prognostic indicator in patients with this type of cancer. This inflammatory response is linked 
to the development of atrial fibrillation in up to 30% of patients undergoing 
oesophagectomy55. This was a large retrospective study, however it is difficult to say whether 
the findings in a US population, can be fully extrapolated to a UK population due to 
differences in deprivation, ethnicity and access to healthcare. 
1.11 Atrial Fibrillation 
A normal heart pumps blood in a synchronised manner from the atria to ventricles. This 
regular or sinus rhythm leads to electrical activity that can be recorded in the form of an 
electrocardiogram (ECG). An abnormal rhythm or arrhythmia results when the synchronicity 
of the atria and ventricles is impaired. Many arrhythmias exist which affect both the atria and 
ventricles but the most commonly occurring rhythm disturbance in the general population is 
atrial fibrillation (AF). At a consensus conference in Scotland in 2012 it was stated that in our 
society, the incidence of AF is greater than 6% in those over 65 years of age56. It is a 
significant public health issue as it is associated with an increase in rates of stroke, other 
thrombo-embolic events, heart failure, hospitalisations and death57.  
AF is an abnormal heart rhythm which is characterised by rapid and irregular beating of the 
atria. It is defined as having three main characteristics including irregular RR intervals, no 




less than 200ms or greater than 300bpm. Figure 1.4 is an ECG illustrating AF and Figure 1.5, 
is an ECG demonstrating sinus rhythm. 
 
Fig 1.1 & 1.2 Normal cardiac conduction pathways and ECG trace and abnormal 







Figure 1.3: ECG waves and R-R interval59 
 





















Figure 1.5: 12 lead ECG demonstrating sinus rhythm rate approximately 75 
bpm61 
 
There are five types of AF based on the presentation and duration of the arrhythmia. These 
include permanent, long-standing persistent, persistent, paroxysmal and first diagnosed57.  
Patients often do not have symptoms with atrial fibrillation, however, some may suffer from 
palpitations, lightheadedness, chest pain and shortness of breath. 
1.12 Risk factors for atrial fibrillation 
AF is linked to cardiovascular disease but also can occur in hearts that are otherwise normal. 
Risk factors for development of chronic or paroxysmal atrial fibrillation in the general 
population include obesity, having a pericardial fat pad,62 being male, white and being older. 
Cardiovascular factors associated with AF include hypertension, coronary artery disease, 
pericarditis, previous cardiac surgery, mitral stenosis, mitral valve regurgitation and 
ischaemic heart failure. In terms of risk factors for cardiovascular disease, which may 
precede AF, the data is not consistent for the association of triglycerides, high and low-
density lipoprotein (LDL) cholesterol and cholesterol with AF. A recent study in the 
community noted that higher concentrations of LDL and total cholesterol were associated 




Experimental studies suggest that long-chain n-3 polyunsaturated fatty acids (n-3 PUFAs) 
may reduce the risk of AF. The n-3 PUFAs are eicosapentaenoic acid and docosapentaenoic 
acid and docosahexaenoic acid. As part of the Cardiovascular Health Study which involved 
3326 US men and women > 65 years old and AF free at baseline, higher circulating total 
long-chain n-3 PUFA and docosahexaenoic acid levels were associated with a lower risk of 
incident AF when evaluated non parametrically64. Respiratory diseases such as lung cancer, 
pulmonary embolus and pneumonia also play a role in its aetiology. Endocrine disorders 
including diabetes and hyperthyroidism are also associated with an increased risk of 
developing AF65. Renal problems such as Chronic Kidney Disease (CKD), regardless of 
severity have been associated with an increased prevalence of AF66. Patients who are 
admitted to Intensive Care Units (ICU) with sepsis are at risk of developing new onset AF. 
The development of this rhythm is independently associated with increased mortality67,68. 
1.13 Prevention of development of atrial fibrillation 
Most clinical efforts have been aimed at preventing the complications of AF. As we have a 
limited understanding of the pathophysiology of atrial fibrillation and lack of preventive 
strategies in the general population, up to this point we have concentrated efforts at 
modifying cardiovascular risk factors as much as possible. This has proved useful for 
explaining some of the population attributed risk factors, but novel risk factors are still being 
studied. A better understanding of the other factors that underlie the development of AF is 
required and genomics and monitoring of electrocardiographic precursors of AF are evolving 
areas of research. Genome-wide association studies have successfully identified 3 genetic 
loci, amongst others (4q25 near transcription factor PITX2 and 16q22 near ZFHX3 and 1q21 
at the small-conductance calcium-activated potassium channel KCNN3)69. The truth is that 




1.14 Atrial fibrillation, inflammation and surgery 
As mentioned previously, patients can develop atrial fibrillation post-operatively which can 
significantly affect morbidity and mortality. Out of 370,447 patients in the USA who 
underwent major non-cardiac surgery at 375 US hospitals in 2008, those that developed post-
operative atrial fibrillation (POAF) had significantly increased length of stay and 
significantly increased mortality rates of 14.1% compared with 2.1% in those who did not 
develop AF (p < 0.01)70. 
Following cardiothoracic surgery, AF occurs in up to 60% of patients following Coronary 
Artery Bypass Grafting (CABG) procedures, whereas in non-cardiac thoracic surgery, the 
incidence of atrial arrhythmias ranges from 9 to 46%71,72. The morbidity and mortality 
following the development of AF in patients may be explained by the decrease in cardiac 
output and blood pressure that occurs in many patients due to reduced filling of the left 
ventricle. The presence of rapid ventricular response rates can result in haemodynamic 
compromise and heart failure. AF has also been associated with the development of intra-
cardiac thrombi, which can pose a subsequent risk of systemic embolisation and stroke73. 
Biochemically, AF is associated with inflammatory activation and impairment of nitric oxide 
signalling74. Investigations have reported associations between AF, circulating levels of 
cytokines, CRP, complement and the activation state of leucocytes. However, whether 
inflammation is the cause or consequence of AF and which inflammatory mediators may 
increase the atria’s susceptibility to fibrillation remain elusive.  
The link between inflammation and AF was initially made by observing an increased 
frequency of AF after coronary artery bypass surgery. The peak incidence of AF occurred on 
the second and third post-operative day, coinciding with the peak elevation of CRP75,76.  
To support the link between inflammation and AF, when right atrial appendages have been 
taken from patients in permanent AF who are undergoing cardiac surgery and compared with 




within the atrial tissue. Additionally, there was oxidative damage and endothelial dysfunction 
in those with AF. Surgery causes a depletion of plasma antioxidants and this, combined with 
the associated acute inflammatory process is known to affect the electrophysiological 
properties of the myocytes in the atrium77. A retrospective observational study of 583 patients 
published in 2016 showed that development of POAF in oesophagectomy patients 
independently predicted increased mortality a year following hospital discharge78. There are 
multiple factors involved in the inflammatory process and a relatively small retrospective 
study is subject to confounding and due to its nature, some risk factors associated with 
increased inflammation may not have been measured. Additionally, retrospective studies can 
only determine association and not causation. 
   Table 1.3 Risk factors for atrial fibrillation post-operatively79 
 






Pulse oximetry, arterial 
blood gas (ABG), CXR 
Cardiovascular 
Underlying ischaemic heart 
disease,valvular heart 
disease, sinus node disease 





Low potassium, magnesium 
and calcium levels and high 
potassium levels 




ABG, thyroid function 







1.15 Peri-operative prevention of atrial fibrillation 
A Cochrane review of data from 58 trials including over 8500 patients acknowledged that 
beta blockers, amiodarone and atrial overdrive pacing all reduce the risk of post-operative AF 
in patients undergoing cardiac surgery80. A trial published in 2005 called Prophylactic Oral 
Amiodarone for the Prevention of Arrhythmias That Begin Early After Revascularization, 




in young and old patients. The problem was that nearly a week of pre-treatment with 
amiodarone was specified. Additionally, amiodarone was given to patients with a variable 
risk of developing AF81. The problem with this is exposing a significant number of patients to 
the adverse effects of this therapy, which can include peripheral neuropathy and pneumonitis. 
This reinforces the need for pre-operative stratification of patients at risk of developing AF. 
1.16 Oesophageal cancer surgery and atrial fibrillation 
In patients with oesophageal cancer who undergo oesophagectomy, cardiac complications 
can occur in up to 40%. Atrial arrhythmias were the most frequent complication and occurred 
in 33% of patients in one study which looked at 146 patients over a 16 year period 
undergoing either Minimally Invasive Oesophagectomies (MIE) and also ‘open’ 
procedures82. The most frequently occurring atrial rhythm is atrial fibrillation which can 
occur in up to 30% of patients. Several factors have been found to be associated with the 
development of post-operative arrhythmias and the pre-operative risk factor that is 
persistently identified for post-oesophagectomy atrial fibrillation (poAF) is advanced age. 
Age can lead to chronic, progressive re-modelling of the heart including changes such as left 
atrial enlargement.  Other factors associated with increased risk of poAF include being male, 
having pre-operative chemoradiotherapy, a history of COPD and a history of cardiac disease. 
Acute peri-operative factors include inflammation, sympathetic activation and oxidative 
stress. Additionally, damage to the vagus nerve can also be a factor55. Stawicki and 
colleagues found that in the multivariate analysis of a retrospective cohort of 156 
oesophagectomy patients, anastomotic leaks, pulmonary complications and a number of other 
complications were significantly associated with AF83. It is useful if we briefly consider 
different types of surgery and their association with onset of POAF. In the majority of studies 
looking at cardiac surgery, POAF peaks during the second post-operative day and then 
declines. In this setting there is clearly a role for surgical trauma, inflammation and structural 




admissions and an increase in hospital mortality83,84. As mentioned, a retrospective study of 
583 patients has shown that the development of POAF in an oesophagectomy patient group 
independently predicted increased mortality a year following discharge from hospital78. The 
development of POAF has also been shown to independently predict long term survival 
following non-oesophageal thoracic surgery such as coronary bypass, lung transplantation, 
aortic valve replacement and pulmonary lobectomy55. 
Following oesophagectomy most patients develop POAF within the first 72 hours. This is 
reinforced by a retrospective review of 156 patients undergoing oesophagectomy over an 11 
year period in the USA83. It follows that it might be useful to monitor markers of 
inflammation in patients during this period and ascertain whether there is any relationship 
between these and the development of POAF. Echocardiographic studies of atrial size and 
specifically increased left atrial diameter in relation to AF are associated with an increase in 
markers of inflammation77. Correlating echocardiogram findings with evidence of 
inflammation in oesophagectomy patients with AF may serve to enhance understanding of 
the pathophysiological processes involved in its development. Despite this, until recently, 
there has been little evidence regarding longer-term prognosis in oesophagectomy patients 
who develop this rhythm.  
It may be that POAF also predicts longer-term survival in patients undergoing 
oesophagectomy for oesophageal cancer. This was suggested by a recently published 21 year 
retrospective observational study from New Zealand in 89 patients undergoing Ivor Lewis 
oesophagectomies for cancer. Ivor Lewis oesophagectomies are performed by removing the 
oesophageal tumour through an abdominal incision and a right thoracotomy. The study 
suggested that post-operative AF may be an independent predictor of poorer longer-term 
survival. This may be because new onset atrial fibrillation is a marker of severity of disease55. 




eliciting what the implications of a small study should be. If new onset AF is indeed a 
predictor of poorer long-term survival, then studying markers of inflammatory change peri-
operatively in patients undergoing oesophagectomy may help to shed light on some of the 
ways in which these biomarkers may pre-dispose them to developing POAF. Ultimately, an 
increased understanding regarding the onset of atrial fibrillation in this group of patients 
could potentially lead to not only decreased morbidity but also decreased mortality by means 
of contributing to an optimal strategy to help prevent this arrhythmia. 
1.17 Previous departmental studies regarding atrial fibrillation 
In the Intensive Care Unit (ICU) of Glasgow Royal Infirmary, which is part of a tertiary 
teaching hospital in Scotland, a retrospective observational cohort study has been carried out 
with respect to the incidence of first diagnosis and pre-existing AF and outcomes. Over a 41-
month period, 193 patients with atrial fibrillation were admitted to the ICU and data was 
analysed according to their peak inflammatory markers and outcomes. A sub-group analysis 
of 100 surgical patients with AF assessed haemodynamic factors, inflammatory markers and 
their association with outcomes. Hospital mortality in the surgical patients with first 
diagnosis AF was 44.16% compared with 21.74% in those with pre-existing AF. The AF 
patients that died in hospital spent a longer period of time at a systolic BP  90mmHg 
compared with those patients with AF who survived. They also tended to have a heart rate 
that was greater than 100 beats per minute (bpm) for a longer period of time. Additionally, 
the AF patients that died had a higher peak CRP than those that survived. Overall hospital 
mortality in patients with new onset AF was 54.1% compared with 30.4% in those patients 
with pre-existing AF. Limitations of this study included the variation in the cohort studied, 
which included surgical and medical patients and potential confounding factors that had not 
been fully accounted for such as age, sex and medications that patients were taking. 




investigation into why patients were developing AF and how this arrhythmia might be 
predicted and prevented. 
1.18 Biomarkers, inflammation and atrial fibrillation 
Biomarkers are characteristics of an organism that reflect a particular physiological state and 
in medicine they can be compounds which are isolated from serum, urine or other fluids that 
can be used as an indicator of the presence of a particular disease state. Biomarkers hold great 
promise for personalised medicine as information can be used to titrate treatment for the 
individual. In the setting of AF they could be used as novel instruments to enhance prediction 
and also to help understand the pathophysiology of the disease85. In a community-based 
population of 5445 older adults NT-proBNP was a strong predictor of incident AF, adjusting 
for other risk factors including age, sex, medication use and blood pressure (adjusted HR, 4.0; 
95% CI, 3.2-5.0; p <0.001)86. 
Schnabel et al87 chose a panel of 10 candidate AF biomarkers which represented 
pathophysiological processes including inflammation (CRP and fibrinogen), endothelial 
dysfunction (homocysteine) and neurohormonal activation (BNP and NT proatrial natriuretic 
peptide). In 3120 Framingham heart study patients65 they found that the panel was associated 
with incident AF (p <0.0001). After multivariable adjustment, CRP (p=0.004) and log 
transformed BNP (p <0.0001) remained associated with AF. Adding BNP and CRP 
separately and together to an AF risk score based on clinical covariates demonstrated that 
only BNP improved risk stratification beyond clinical risk factors that were well established. 
Asymmetrical dimethylarginine (ADMA), Symmetrical dimethylarginine (SDMA), 
homoarginine, myeloperoxidase (MPO), interleukin 6 (IL-6) and BNP are biomarkers which 
have been associated with cardiovascular outcomes. An elevated pre-operative BNP 




noncardiac surgery. BNP has been investigated as a biomarker for incident AF and elevated 
levels have been found in patients with AF. 
1.19 Asymmetrical dimethylarginine (ADMA) 
ADMA is a derivative of arginine which is a semi essential, naturally occurring amino acid 
that is found in all protein containing foods.  Arginine is a precursor for the synthesis of nitric 
oxide. Increased serum levels of ADMA have been associated with AF recurrence in patients 
with persistent AF. Plasma concentrations of ADMA have been shown to be elevated in 
patients with heart failure, diabetes, hypertension, renal impairment, cardio-embolic 
cerebrovascular disease and in persistent AF88,89. 
Figure 1.6 Outline of dimethylarginine synthesis and metabolism90 
 
1.20 Arginine, dimethylarginines, nitric oxide and nitric oxide synthase 
Arginine is a semi-essential amino acid and in addition to dietary intake it is released 
endogenously as a result of protein degradation. It is also synthesised from citrulline by the 




arginosuccinate lyase (ASL). It exists in two isomeric forms, dextro (D) and laevo 
(L)arginine. L-arginine is the form that is of interest. Arginine is used as a substrate in 
metabolic pathways including degradation by the enzyme arginase to urea and ornithine and 
also in the production of nitric oxide (NO). In healthy volunteers intravenous arginine 
infusion decreased systolic and diastolic blood pressure and increased heart rate and plasma 
catecholamine levels91.   
Nitric oxide is a key regulator of cardiovascular endothelial function. It inhibits the adhesion 
of inflammatory cells to the vascular wall, the aggregation of platelets and the proliferation of 
smooth muscle cells. Reduced synthesis and reduction in availability of NO has been 
recognized in combination with risk factors for cardiovascular disease and may promote 
hypertension, thrombus formation, atherogenesis and atrial fibrillation. NO and citrulline are 
synthesized from L-arginine by nitric oxide synthase (NOS). Mechanisms that may lead to 
endothelial dysfunction include reduced nitric oxide synthase (NOS) expression and activity, 
decreased NO bioavailability and increased production of oxygen radicals and endogenous 
NOS inhibitors92. The breakdown products of NO are found in the urine of patients. 
There are three different isoforms of NOS; neuronal NOS (nNOS), inducible NOS (iNOS) 
and endothelial NOS (eNOS). Cardiac tissue normally expresses nNOS and eNOS, whereas 
iNOS is inducible and is only expressed in inflammatory or pathological states such as 
hypertrophy or heart failure93.A reduction in endothelial nitric oxide synthase (eNOS) in the 
cellular region with platelet adhesion and thrombus formation suggests endothelial 
dysfunction and this may contribute to thrombogenesis in AF. 
Symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) are formed 
from the methylation of L-arginine residues in proteins by enzymes called protein arginine 
methyltransferases (PRMT) see figure 1.6.  Both PRMT 1 and PRMT 2 are associated with 




In forming SDMA and ADMA, N monomethyl L-arginine (NMMA) is formed as an 
intermediate product as a result of protein incorporated arginine being methylated. They also 
originate from protein degradation.  
SDMA has been shown to have weak inhibitory potency towards nNOS and may compete 
with L-arginine for cellular uptake, therefore limiting NO production94. NMMA and ADMA 
are endogenous inhibitors of NOS, however ADMA is thought to be most significant 
physiologically as only small amounts of NMMA exist in plasma95,96. ADMA competitively 
inhibits nNOS and eNOS and in prospective studies it has been confirmed to be an 
independent risk factor for cardiovascular disease. Evidence suggests that the amount of NO 
produced may be indicated by the ratio between arginine and ADMA97,98. 
The inhibition of NOS by ADMA is an intracellular process, however, despite clinical studies 
frequently reporting on plasma ADMA levels, there are few studies concerning the 
relationship between plasma and intracellular levels of ADMA. ADMA competes with L-
arginine and homoarginine for NOS binding and causes NOS uncoupling which leads to 
impairment of NO synthesis. Uncoupling of NOS means electron transfer is shifted from L-
arginine to a produce a superoxide anion (O2-). Tetrahydrobiopterin (BH4) is a co-factor for 
NOS activity and in times of low BH4 and arginine bioavailability relative to NOS or BH4, 
(O2-) is produced and leads to NOS uncoupling to 7,8 dihydrobiopterin (BH2). This 
superoxide reacts with NO to produce peroxynitrite (ONOO-) which continues to propagate 
NOS uncoupling. Depletion of BH4 and NOS uncoupling contribute to hypertension, heart 
failure and atrial fibrillation99. Peroxynitrite formation in human atrial fibrillation has been 
examined and 3-nitrotyrosine, which is a marker for ONOO- formation is increased in atrial 
tissues from patients with persistent AF77. There was also induction of  iNOS and increased 
3-nitrotyrosine expression in the right atrium in patients with permanent AF compared with 




uncoupling that has recently been described is S-glutathionylation of eNOS, where 
glutathione is bound to a protein thiol101.Acute inhibition of endogenous nitric oxide 
production may lead to vasoconstriction and contribute to the thrombotic events by causing 
platelet activation102,103. 
 ADMA is mainly metabolized by the enzyme dimethylarginine dimethylaminohydrolase 
(DDAH) and to a lesser extent alanine glyoxylate aminotransferase 2 (AGTX2). Renal 
excretion represents a less important route of excretion for ADMA. SDMA is metabolised by 
AGTX2 to (α-keto-δ-(N,N-dimethylguanidino) valeric acid (DMGV) and its major route of 
excretion is by the kidneys. DDAH has two isoforms; DDAH 1 and DDAH 2. DDAH 1 is 
located mainly in the proximal renal tubules and liver and studies have shown significant 
elimination occurring via these organs. DDAH 2 is found in smooth muscle cells and 
vascular endothelial tissue, where it is probable that it has an effect on vascular responses and 
ADMA concentrations. DDAH has been estimated to metabolize approximately 80% of the 
300 micromoles of ADMA generated daily in humans.  In animal studies, on 7 mongrel dogs, 
increased PRMT-1 protein expression localized to the left atrium and left atrial appendage 
and decreased DDAH activity in the atria in these dogs who had AF induced may cause an 
elevation of plasma ADMA level 104. Impaired activity of DDAH has been related to 
inflammation, oxygen free radicals and endothelial injury. The breakdown of ADMA by 
DDAH produces citrulline and dimethylamine. Due to the liver and kidneys being largely 
responsible for clearance of ADMA, dimethylamine, which is the major metabolite, can be 
measured in the urine105.Plasma ADMA can accumulate due to increased synthesis, reduced 
renal clearance or inhibition of its degradation by dimethylarginine dimethylaminohydrolase 
(DDAH) and alanine-glyoxylate aminotransferase 2 (AGXT2). Due to the distribution of 
ADMA and SDMA between compartments being governed by system y+ which is one of the 




intracellular compartments are not in equilibrium and cellular concentrations of ADMA can 
be ten or twenty times greater than those in plasma. Elevated ADMA plasma levels have been 
found in critically ill patients and a reduced ratio of L-arginine to ADMA is associated with 
atherosclerotic disease and all-cause mortality95.  
A double-blinded randomised placebo controlled study in 12 healthy volunteers demonstrated 
that those having an intravenous infusion of ADMA (3mg/kg up to 250mg) had a reduced 
heart rate (p< 0.001), cardiac output (p< 0.001) an higher mean blood pressure (p< 0.005) and 
systemic vascular resistance (p< 0.001) compared with those having a placebo infusion 
(sterile physiological saline)106. 
In terms of effects of an operation on dimethylarginine levels, a study of 38 patients 
undergoing an elective knee arthroplasty demonstrated that plasma ADMA concentration 
decreased rapidly during the first 48 hours following surgery and SDMA level remained 
unchanged. These findings question whether this is due to the intracellular movement of 
ADMA via CAT and an increased partitioning of ADMA within cells. Also, an increase in 
SDMA levels in the urine from day 1 post-operatively, suggests increased net production or 
mobilization from cells. A decrease in ADMA and arginine concentrations was associated 
with a decrease in urinary nitrate levels (used as a surrogate marker of NO metabolism) and a 
transient decrease in urinary dimethylarginine (DMA). In light of the increased SDMA levels 
in the urine and the concurrent reduction in urinary nitrate levels, this may support the 
hypothesis that SDMA decreases NO availability94. In a study of 32 male Wistar rats, who 
underwent either left anterior descending coronary artery ligation to induce myocardial 
infarction or sham operation, ADMA concentration within the left ventricle was increased 
one week after infarction. This was unexpected, considering the increase in DDAH levels in 
the left ventricle.  The reason for the increase in ADMA levels was not accounted for by an 




suggests that NOS activity will be partially inhibited by ADMA in vivo. Plasma ADMA was 
also increased after MI however the cause of this was unclear and further studies are required 
to confirm the source of ADMA. Some limitations of this study include small study numbers 
and the fact that it involved animal models105. 
Endothelium-dependent vasodilatation is improved after L-arginine administration in patients 
with congestive heart failure who had elevated ADMA concentrations. However, L-arginine 
did not affect endothelium-dependent vasodilation in healthy human subjects who had low 
ADMA concentrations. 
In a Scandanavian study of 258 healthy blood donors, methylarginine levels were analyzed 
using high performance liquid chromatography (HPLC). A reference range for plasma 
ADMA levels was 0.4-0.77 micromoles/ litre for the whole population. In women aged 
greater than 45 years the range was 0.41-0.84 micromol/L compared with 0.38-0.73 
micromol/L in those less than 45 years. This age related difference was not present in men107. 
1.21 Asymmetric dimethylarginine and AF 
In a study of 42 patients with atrial fibrillation, single sample ADMA levels were higher in 
those with first diagnosis AF for < 24hr (n=17), compared with those who had pre-existing 
AF for > 1yr (n=25) (p=0.002). ADMA concentration was evaluated in a prospective cohort 
study of 138 patients with persistent AF who had blood taken 1 day prior to catheter ablation 
and were monitored for up to 258 days assessing recurrence of AF (58%). In the 
multivariable Cox regression model higher serum ADMA, Hazard Ratio (HR): 4.59 (95% CI, 
1.81–11.62; p=0.001) and increase in left atrial diameter HR 1.35 (95% CI, 1.18–1.55; 
p<0.001) were independent factors associated with AF recurrence post catheter ablation108. 
This was another small study and despite a long follow up duration there are multiple 
markers of inflammation that were unable to be measured which inevitably would have an 
effect on the development of AF. Another study which was a double blinded, placebo 




receive candesartan 8 mg once daily or placebo for 3–6 weeks before cardioversion and 
candesartan 16 mg once daily or placebo for 6 months after cardioversion. Plasma levels 
of L-arginine and ADMA were measured at baseline and at the end of the study. It 
demonstrated that AF patients who remain in sinus rhythm post cardioversion have increased 
L-arginine to ADMA ratios after 6 months compared with those who have recurrent AF and 
that candesartan treatment has no effect(p=0.008)103. 
To help understand what effect the acute inflammatory response following an operation has 
on daily biomarker levels in the absence of the development of AF, two recent studies have 
found that ADMA declines initially and then begins to rise105. One single centre prospective 
German study investigated the changes in plasma L-arginine, ADMA, C-reactive Protein 
(CRP) and IL-6 in 24 healthy living kidney donors. ADMA levels decreased compared with 
baseline (0.488 ± 0.075 vs. 0.560 ± 0.060 μmol/l, p < 0.05). One day after the operation the 
change was more significant compared with baseline levels (0.478 ± 0.083 μmol/l, p < 0.01). 
This correlated with a peak in IL-6 levels and CRP. L-arginine levels decreased 1 hour after 
nephrectomy compared with baseline (97.5 ± 22.5 μmol/l p< 0.01). Changes in L-arginine 
were similar to changes in ADMA after this point. After 168 hours when the inflammatory 
markers were returning to normal, ADMA and L-arginine levels were both elevated 
compared with baseline (p< 0.001). It was unclear whether the reduction in ADMA after 
unilateral nephrectomy could be the reduction of ADMA synthesis and proteolysis pathways. 
Limitations of this study include its small size and the lack of data regarding urine 
concentration of the compounds studied109. 
1.22 Homoarginine, arginine and nitric oxide 
Homoarginine is an endogenous amino acid and low circulating concentrations of it have 
been reported to be a prognostic marker for mortality and cardiovascular events in a variety 
of diseases, including heart failure, stroke and CKD110,111. Homoarginine has an additional 




1818 patients, 1649 of whom were studied at 3 German tertiary care centres with chest pain, 
low plasma homoarginine was identified as a risk marker for incident major adverse 
cardiovascular events (MACEs) including all cause death, myocardial infarction or stroke. 
Impaired homoarginine was also associated with prevalent AF112. It was unclear whether 
homoarginine levels were lower because of the presence of AF or whether it preceded the 
development of AF. In two large cohorts of patients, levels of homoarginine were 
independently associated with cardiovascular and all cause mortality in patients referred for 
coronary angiography and those undergoing haemodialysis. In one cohort, 3305 patients who 
were undergoing coronary angiography had levels of homoarginine taken at baseline and 
were followed for a median of 9.9 years. In total, 991 patients died, including 258 sudden 
cardiac deaths, 148 heart failure deaths and 105 fatal myocardial infarctions113. 
Homoarginine may also have a role to play in increasing the availability of NO by acting as a 
competitive substrate of NOS, along with L-arginine. Conversely, by competing with 
arginine for cellular uptake, high homoarginine levels may limit the amount of intracellular 
arginine and therefore production of NO may be reduced at a high homoarginine to arginine 
ratio. 
1.23 B type Natriuretic Peptide (BNP) and N-Terminal Pro B Type Natriuretic Peptide 
(N-T proBNP) 
Brain or B type natriuretic peptide is one of a family of cardiac peptides which is secreted by 
the myocardium of the left ventricle in response to wall stress in association with ventricular 
dilatation and pressure overload114. Small amounts of a precursor protein (pre pro-BNP) are 
continuously produced by the heart and after a volume or pressure overload, it is cleaved into 
an 108 amino acid (AA) pro BNP. Pro BNP is then cleaved to release the active hormone 
BNP (32 AA) and an inactive fragment NT-pro BNP (76 AA) into the blood. BNP has 
physiological effects on the heart, kidneys, adrenal glands and adipose tissue. At a renal level, 




and diuresis (increased urination). In the central nervous system the inhibition of salt and 
water intake, in addition to vasopressin secretion takes place which leads to a decrease in 
systemic vascular resistance via relaxation of vascular smooth muscle and a decrease in 
cardiac output. Due to the association of BNP with myocardial stress, it has been developed 
as a biomarker of cardiovascular failure, with levels of BNP being directly related to left 
ventricular mass and inversely related to ventricular ejection fraction. In a study looking at 
determinants of NT pro BNP; consecutive patients were recruited in an Emergency 
department or an outpatient clinic of the same hospital. There were 45 patients with 
paroxysmal AF, 41 patients with permanent AF and 48 controls. Plasma NT-pro-BNP levels 
were significantly higher in patients with paroxysmal and permanent AF compared to those 
with sinus rhythm in the setting of preserved left ventricular systolic function. NT pro-BNP 
levels were independently predicted by left ventricular ejection fraction (LVEF) and left atrial 
diameter (LAD) on echocardiogram, in patients with paroxysmal and permanent AF115. 
The relation between N-terminal pro-B-type natriuretic peptide (NT-proBNP) and AF was 
studied in 5,445 Cardiovascular Health Study (CHS) participants.  The CHS was a 
longitudinal study of 5,888 men and women aged 65 and older, who were randomly selected 
from 4 communities in the United States and enrolled during two time periods; 1989–1990 
and 1992–1993. It showed that elevated peri-operative plasma NT pro-BNP level is an 
independent predictor of AF in the community independent of any other previously described 
risk factor 116. In a prospective observational cohort study of 142 patients it was demonstrated 
that elevated peri-operative NT-proBNP plasma levels in oesophagectomy patients are an 
independent predictor of post-operative AF117. Again this is a small study, but one of the 
advantages of prospective cohort studies, is that they reduce the possibility that the results 




vs ones that do not, because in a cohort study the outcome is not known at baseline when 
exposure status is established. 
There have been recommendations from the European Society of Cardiology and 
Anaesthesiology regarding the use of BNP in pre-operative testing for high-risk cardiac 
patients undergoing non-cardiac surgery. However, further research is required to determine 
the benefits of BNP guided management as evidence is lacking118,119. 
There are several causes of raised BNP, see table below. 
Table 1.4 Potential causes of raised BNP levels120 
 
Cardiac Non cardiac 
Heart failure Acute Pulmonary Embolus 
Diastolic dysfunction  Pulmonary hypertension 
Acute coronary syndromes Sepsis 
Hypertension with Left Ventricular 
hypertrophy 
Chronic obstructive pulmonary 
disease 
Valvular heart disease Hyperthyroidism 
AF Acute or chronic kidney injury 
 
1.24 Potential uses of BNP and NT-proBNP measurement and laboratory testing 
BNP assays are a potential aid in the diagnosis of heart failure, as levels correlate closely 
with the New York Heart Association (NYHA) classification of heart failure. BNP testing 
allows a rapid assessment for those patients warranting an echocardiogram and also has the 
potential to enable rapid changes in therapy for those receiving treatment for failure. In a pilot 
study, BNP levels were the single most reliable variable in predicting short term outcomes in 
patients with heart failure. In a prospective study of 3346 people without heart failure, 
increased levels of BNP have been shown to be associated with an increased risk of death, 
atrial fibrillation and cardiovascular events in people after adjustment for traditional risk 
factors. Excess risk was apparent at levels well below thresholds used to diagnose heart 
failure. The strengths of this study include the large, community-based sample, the use of 




high-sensitivity assays. Another consideration is that the Framingham Study cohort is of 
predominantly white ethnicity and the results may not be generalizable to other populations. 
Due to the size of the study there was limited statistical power to perform separate analyses of 
high-risk subgroups, such as people with diabetes. As with other studies, the findings should 
be confirmed in other cohorts121. 
Brain natriuretic peptide may help in identifying people at risk of stroke and atrial fibrillation. 
In a representative population of 958 men (46-65 years) from Finland who were followed up 
for 9.6 years, the multivariable adjusted risks for any stroke or ischaemic stroke for log-
transformed standard deviation (SD) (0.237 pmol/l) increment in N-terminal fragment of 
proB-type natriuretic peptide, the respective risks were 1.36-fold (95% CI 1.05 to 1.76, p = 
0.010) and 1.50-fold (95% CI 1.12 to 2.02, p = 0.007). The multivariate adjusted risks for 
future atrial fibrillation were 1.68-fold (95% CI 1.38 to 2.07, p< 0.001) for each log-
transformed SD increment in N-T pro B-type natriuretic peptide. This suggested that N-
terminal fragments of pro B type natriuretic peptide might help in identifying subjects at risk 
for stroke and AF122. 
To give some background context regarding BNP values with respect to patients who have 
heart failure; the threshold value for this is different in various laboratories but the suggested 
decision threshold for the Abbott AxSYM® platform assay is 100pg/ml for acute 
symptoms123.A study was performed to compare the Abbott ARCHITECT® platform BNP 
assay to the AxSYM® BNP assay in 171 individuals with and without heart failure. The 
results showed a significant correlation between the two methods124.More recently the 
ARCHITECT® BNP assay was compared with other automated BNP assays including 
AxSYM® with which it correlated well125.Comparatively the expected BNP values in the 
non-heart failure population based on 465 females and 425 males with diabetes, hypertension, 




dialysis, were not statistically significant compared with BNP values in a population of 
apparently healthy individuals. 
1.25 NT-proBNP, BNP and AF 
The relationship between NT-proBNP and AF was studied in 5445 Cardiovascular Health 
study participants. Of these, 5021 participants had no history of AF. A baseline NT pro-BNP 
> 290pg/ml (5th quintile) had an AF prevalence of 11.75% at baseline, compared with those 
with a baseline of < 50pg/ml who had a prevalence of 0.1%. The unadjusted hazard ratio was 
5.2 (95% CI 4.3-6.4; p< 0.001) for the development of AF in the highest quintile compared 
with the lowest. Following adjustment for covariates (including age, sex, medication use, 
blood pressure, diabetes and heart failure), NT-proBNP remained the strongest predictor of 
incident AF with an adjusted HR of 4 (95% CI, 3.2-5.0; p< 0.001) for the highest versus the 
lowest quintile. As mentioned earlier, it follows that NT-proBNP predicts AF in a 
community-based population of older adults116. 
As part of the Framingham study, it was confirmed that BNP levels predict the development 
of AF. The study included 3120 AF free participants, 54% of whom were women with an 
average age of 58 years. They were extensively investigated in 1995-1998 and were followed 
up for a median of 10 years. Ten biomarkers which might be important in development of AF 
were studied, including CRP and BNP. At the end of a median of 9.7 years, 209 (6.7%) of 
study participants had been diagnosed with AF. In addition to confirming the conventional 
risk factors for AF including age, sex, increased BMI and cardiovascular disease, the 
researchers noticed that those who developed AF had significantly higher baseline levels of 
CRP, BNP and Atrial Natriuretic Peptide (ANP). CRP was statistically significantly 
associated with the outcome of AF but did not markedly improve risk prediction beyond 
BNP.  Correlates of BNP are left ventricular size and ejection fraction115 but even after 




function, BNP retained its strength of association with AF. The conclusion was that BNP is a 
useful predictor of future AF87. 
1.26 N-T Pro BNP and high sensitivity CRP (hs CRP) for cardiac risk stratification 
A study of 592 patients listed for non-cardiac vascular surgery recorded the cardiac history, 
hs CRP and NT-proBNP, pre-operatively. Hs-CRP levels of at least 6.5mg/L and NT proBNP 
of 350pg/ml at least were defined as the optimal cut off values for the prediction of post-
operative cardiac events. The end point was the composite of 30 day cardiovascular death, Q 
wave myocardial infarction (MI) and troponin T release. Troponin is a protein in the blood 
which is released into the bloodstream when the heart muscle has been damaged. 
Multivariable regression analysis evaluated the association between hs-CRP, NT-proBNP and 
the end point. Elevated levels of hs-CRP (OR 2.54; 95% confidence interval 1.50-4.30) and 
NT-proBNP (OR 4.78; 95% CI 2.71-8.42) remained independent risk factors for post-
operative cardiac events. When hs CRP and NT proBNP were added to the cardiac risk score 
the C statistic improved from 0.79 to 0.84. This suggests that hs CRP and NT-proBNP have 
additional value in predicting post-operative cardiac events in vascular patients126.BNP and 
NT-proBNP are useful pathophysiological markers of neurohormonal activation.  
1.27 BNP, NT-proBNP and non-cardiac surgery 
Many studies have examined the peri-operative role of BNP in elective non-cardiac surgery 
and there is an association between higher levels of BNP and NT-proBNP and risk of post-
operative events127 which suggest they could be a useful tool to stratify risk. However, 
various thresholds have been quoted for BNP and this is likely due to differences in age, 
gender, co-morbidity, BMI (lower levels are often seen in obese patients) and degree of pre-
existing cardiac failure. Several studies have looked at determining the optimal values which 
could assist prediction of post-operative cardiac events including haemodynamic compromise 
from cardiac arrhythmias, heart failure, non fatal MI and cardiac death but the identification 




from 15 publications including 4,856 patients revealed that pre-operative BNP elevation was 
associated with an increased risk of short-term major adverse cardiovascular event (MACE) 
(OR 19.77; 95% confidence interval [CI] 13.18-29.65; p < 0.0001), all-cause mortality (OR 
9.28; 95% CI 3.51-24.56; p < 0.0001), and cardiac death (OR 23.88; 95% CI 9.43-60.43; p < 
0.00001). Results were consistent for both BNP and NT-proBNP. Pre-operative BNP 
elevation was also associated with an increased risk of long-term MACE (OR 17.70; 95% CI 
3.11-100.80; p < 0.0001) and all-cause mortality (OR 4.77; 95% CI 2.99-7.46; p < 
0.00001)128. 
1.28 BNP and vascular surgery 
A Glasgow based study regarding MACE following elective Abdominal Aortic Aneurysm 
(AAA) repairs, suggested that BNP might provide valuable information regarding risk 
stratification in patients undergoing this procedure. The median (interquartile range) BNP 
concentrations in 16 patients (15%) who suffered immediate post-operative MACE was 206 
(118-454) vs 35 (17-61) pg/ml in the remainder (p=0.001). ROC analysis indicated a BNP 
concentration of 99.5 pg/ml optimally predicted MACE (area under the curve 0.927), with 
sensitivity of 88% and specificity of 89%. The BNP in patients who suffered cardiac death 
was significantly higher than in those that did not (median BNP 496 {280-881} vs 38 {18-
84} pg/ml, p=0.043). ROC analysis revealed a cut-off of 448 pg/ml (AUC 0.963), with 
sensitivity 80%, specificity 100%, positive predictive value 100% and negative predictive 
value 99%. Not only did higher values of BNP predict MACE, but it was also found to 
predict all-cause mortality in the immediate (median BNP 100 [84-521] vs 35 [17-81], 
p=0.028), intermediate (median BNP 201 [97-496] vs 35 [17-73], p< 0.001) and long-term 
(median BNP 98.5 [58-285] vs 32 [17-71.5], p< 0.001) post-operative periods129. 
1.29 BNP, NT-proBNP and thoracic surgery 
In a study involving 55 patients undergoing major thoracic surgery, levels of NT pro-BNP 




monitored to detect the occurrence of AF. Baseline NT-proBNP was more than two fold 
higher in patients that went on to develop AF (506.1+/-108.4 pg/mL versus 197.7+/-54.9 
pg/mL; p=0.001). Patients with NT-proBNP level above the median (113.0 pg/mL) had an 8-
fold increased risk of developing AF130. 
In patients with lung disease, NT-proBNP or BNP is independently associated with low peak 
VO2. A score combining blood gases, NT-proBNP or BNP and spirometry has a high 
accuracy for prediction of a peak VO2 < 15ml/kg/min which is the cut-off indicating an 
increased risk of complications during lung resection surgery131. As previously mentioned, a 
systematic review and meta-analysis of observational studies showed that pre-operative BNP 
or NT-proBNP measurement is an independent predictor of adverse outcomes within 30 days 
of non-cardiac surgery132. 
1.30 BNP, thoracic and oesophageal surgery 
As mentioned previously, first diagnosis AF is a common arrhythmia following 
oesophagectomy and the incidence varies from 9-46%71,72. 
A study which looked at 415 patients aged 60 years or older, who had undergone lung or 
oesophageal surgery during a 1-year period, compared pre-operative BNP levels between 
patients who developed post-operative atrial fibrillation during hospitalisation and those who 
did not. After anatomic lung resection or oesophagectomy, 46 of the 135 patients with BNP 
levels ≥ 30 pg/mL developed post-operative atrial fibrillation compared with only 12 of 134 
patients with BNP levels less than 30 pg/mL (p < 0.0001). The rates of post-operative atrial 
fibrillation in patients undergoing other thoracic procedures were low and not associated with 
the BNP levels. Of note, post-operative atrial fibrillation complicating general thoracic 
surgery is a marker of increased morbidity and stroke risk. Multivariate logistic regression 
analysis showed that in patients undergoing oesophagectomy or anatomic lung resection, 




p = 0.04), male gender (OR, 2.61; 95% CI: 1.12-4.17: p =0.02), and BNP level 30 pg/mL or 
greater (OR, 4.52; 95% CI:2.19-9.32: p < 0.0001) were independent risk factors for post-
operative atrial fibrillation. The length of hospital stay was significantly increased in patients 
who developed post-operative atrial fibrillation compared with those who did not (p < 
0.0001). In patients undergoing lung resection or oesophagectomy, male gender, increased 
age and a pre-operative BNP level of 30 pg/mL or greater were significant risk factors for the 
development of post-operative atrial fibrillation133.  The decision regarding approach for 
oesophagectomy depends on factors such as the location of the tumour, prior operations, 
radiation treatment, body habitus and surgical preference. There appears to be no difference 
in incidence of post-operative AF in trans-hiatal oesophagectomies compared with the Ivor 
Lewis method, however, when thoracic dissection is restricted below the level of the carina 
and an anastomosis placed in the low chest, the incidence of AF is lower. It is unclear why 
this is the case but compared with the Ivor Lewis method, less time is spent on single lung 
ventilation and there is relative lack of dissection of vagal nerves which lie cephalad to the 
inferior pulmonary veins using this technique. These could both contribute to a lower 
incidence of AF134. 
1.31 Myeloperoxidase 
 
Myeloperoxidase (MPO) is a haemoprotein bactericidal enzyme abundantly expressed in 
polymorphonuclear neutrophils and secreted during leukocyte degranulation. MPO kills 
bacteria by generating hypochlorous acid (HOCl) from hydrogen peroxide (H2O2) and 
physiological chloride (Cl-) concentrations. It also has an oxidative function which activates 
latent forms of pro matrix metalloproteinases (MMP) 8 (collagenase 2) and 9 (gelatinase B) 
and inactivates Tissue Inhibitors of Metalloproteinases (TIMPs). Matrix metalloproteinases 
(MMPs) are a large multigene family of structurally and functionally similar calcium 




and remodelling in addition to pathological processes. They are classified into substrate 
specificity including the collagenases, gelatinases, stromelysins, matrilysins, Membrane-Type 
MMPs and seven other unclassified groups135. Matrix metalloproteinases are implicated in a 
wide variety of cardiovascular diseases136. They have been regarded as potential etiologic 
agents in atrial remodelling and studies in animal models have demonstrated effects of MMPs 
on the course of cardiac dilation and heart failure137. MPO appears to play an important role 
in structural remodelling of the myocardium and is mechanistically linked to atrial fibrosis 
and fibrillation and it has been associated with a wide variety of cardiovascular diseases. 
MPO catalyses the generation of hypochlorous acid which affects intracellular signalling in 
various cells and deposition of atrial collagen which results in atrial arrhythmias138.It 
consumes nitric oxide and supporting its association with AF, a study of MPO deficient mice 
pre-treated with angiotensin II to promote leucocyte activation, showed lower atrial tissue 
abundance of 3-chlorotyrosine, a MPO by-product, and reduced incidence of atrial fibrosis, 
as compared to normal mice. Myeloperoxidase deficiency decreases atrial fibrosis and 
protects mice from AF, which was reversed after restoring myeloperoxidase. In the same 
study, human patients with AF had higher plasma concentrations of MPO and more MPO in 
their right atrial tissue compared with patients without AF139. Elevated plasma MPO levels 
have been associated with a variety of clinical conditions including systemic inflammation, 
severity of coronary artery disease and vascular endothelial dysfunction. High levels of 
myeloperoxidase have also been linked to an increased risk of AF recurrence in patients who 
have undergone catheter ablation. In a study, there was adjustment for age, sex, left atrial 
diameter and hs CRP. Findings suggested that there was a higher risk of AF in subjects with 
the highest MPO quartile compared with those with the lowest quartile (hazard ratio, 3.18; 
95% confidence interval, 2.12–5.23; p=0.024). MPO was also an independent predictor of 




 Lymphomononuclear cells are found to infiltrate the myocardium of patients in those with 
structural heart disease and in those with AF and co-morbidities. This would suggest that 
these patients have chronic inflammation. These cells secrete high levels of tumour necrosis 
factor (TNF), transforming IL-6 and transforming growth factor (TGF)-beta 1, which lead to 
atrial fibrosis and electrical remodelling141. A study has also shown that significantly 
increased levels of MPO independently increased risk for major adverse cardiac events 
including myocardial infarction, reinfarction, need for revascularisation. It also increased the 
risk of death at 30 days or 6 months138. 
1.32 C-Reactive Protein (CRP), Interleukin-6 (IL-6) and AF 
CRP is synthesised primarily by the liver in response to IL-1 and IL-6 which both have pro 
inflammatory and cyto-protective effects. The association between IL-6 and AF is less 
consistent compared with CRP and AF142. 
In the ARMYDA-3 study, which looked at the use of atorvastatin in trying to reduce post- 
operative AF in patients undergoing cardiac surgery, high post-operative C-reactive protein 
levels were linked to an increased risk of AF. On the second day following Coronary Artery 
Bypass Graft (CABG) surgery, CRP levels which have reached their peak are associated with 
development of AF (R2=0.41, p=0.0037)76. A systematic review and meta-analysis were 
conducted to examine the association between baseline CRP and recurrence of AF after 
successful cardioversion. Seven prospective studies with 420 patients were analysed. This 
suggested that CRP levels were greater in patients who experience a recurrence of AF143. The 
limitations included the significant heterogeneity across the studies which could likely be 
attributed to the differences in CRP assays. The use of CRP levels in predicting sinus rhythm 
maintenance appeared promising but requires further study. In the Cardiovascular Health 
Study, a population-based longitudinal study of coronary heart disease and stroke in 5,806 




higher CRP levels (>3.41 mg/l) were associated with the presence of AF compared with 
lower levels (<0.97 mg/l; adjusted OR 1.8, 95% CI 1.2–2.5). Baseline CRP could be used to 
predict the risk of developing AF (adjusted HR 1.24 for 1 SD increase, 95% CI 1.11–1.40). A 
large Danish study tested whether the association of C-reactive protein with increased risk of 
atrial fibrillation is a robust and perhaps even causal association. It looked at 10,276 
individuals from the prospective Copenhagen City Heart Study, including 771 individuals 
who had atrial fibrillation during follow-up, and another 36,600 people from the cross-
sectional Copenhagen General Population Study, including 1,340 cases with atrial 
fibrillation. Individuals were genotyped for 4 CRP gene polymorphisms and had high-
sensitivity CRP levels measured. It found that genotype combinations of the 4 CRP 
polymorphisms were associated with up to a 63% increase in plasma CRP levels (p < 0.001), 
but not with increased risk of atrial fibrillation. This suggests that an elevation in CRP levels 
as such, does not increase the risk of AF development. A CRP level in the upper versus lower 
quintile was associated with a 2.19 times (95% confidence interval [CI]: 1.54 to 3.10) 
increased risk of atrial fibrillation. Risk estimates after multifactorial adjustment decreased to 
1.77 (95% CI: 1.22 to 2.55), and after additional adjustment for heart failure and plasma 
fibrinogen level to 1.47 (95% CI: 1.02 to 2.13) and 1.63 (95% CI: 1.21 to 2.20), respectively. 
Elevated plasma CRP was robustly associated with increased risk of atrial fibrillation; 
however, genetically elevated CRP levels did not. The study concluded that elevated plasma 
CRP as such did not increase atrial fibrillation risk, however, the study had several 
limitations. These included potential selection bias and misclassification of plasma CRP 
levels, CRP genotype, and atrial fibrillation. Potentially misclassifying a diagnosis of atrial 
fibrillation would result in an underestimation of the risk estimates, and therefore more 
conservative estimates for the association of plasma CRP levels with risk of atrial fibrillation 




patients undergoing oesophagectomy for cancer and albumin and C-reactive protein are 
indicators of a systemic inflammatory response. The modified Glasgow Prognostic score 
combines these into a risk stratification score for predicting clinical outcome in patients with 
cancer of the lung, gastric tract and colorectal cancer. The potential value of pre treatment 
mGPS in patients with squamous cell carcinoma of the oesophagus who are undergoing 
chemoradiotherapy was evident in one study where higher mGPS scores correlated with 
lower overall 3 year survival145. 
IL-6 is a pleiotrophic cytokine which means it acts on multiple cell types. Many cells express 
IL-6 including endothelial cells (under the influence of endothelins), sympathetic neurons, 
cerebral cortex neurons, adrenal medulla chromaffin cells, retinal pigment cells, mast cells, 
Langerhans cells, neutrophils, monocytes, eosinophils, colonic epithelial cells and pancreatic 
islet beta cells. IL-6 production is generally correlated with cell activation and is normally 
kept in control by glucocorticoids, catecholamines, and secondary sex steroids. The value of 
measuring cytokines in patients undergoing coronary artery bypass grafts in relation to the 
development of AF has been confirmed in several studies146. Patients that undergo off-pump 
CABG surgery, have levels of IL-6 and IL-8 which are elevated immediately after surgery 
(IL-6 from 0 to 435pg/ml). The increase in the level of IL-6 after surgery is associated with 
post–operative AF. Logistic regression analysis indicated that the highest quartile of 
IL-6 level immediately after the surgery (if IL-6 >401pg/ml) (odds ratio 7.63; 95% CI, 
1.06-54.9; p=0.04) and age independently predict post-operative AF. (OR 7.63, 
p=0.04)147. Cytokines such as IL-6, which are pro-inflammatory and can induce platelet 
activation, are associated with adverse cardiovascular outcomes in patients with AF. In 
clinical studies, high levels of CRP, and IL-6, and low levels of IL-18, are associated with 
increased atrial size, which further supports a role for inflammation in atrial fibrillation148. In 




modulate the pathogenesis of AF149. The association between IL-6 and AF is less consistent 
compared with CRP and AF142. 
1.33 Cardiopulmonary Exercise Testing (CPET) and the Modified Glasgow Prognostic 
Score (mGPS) pre and post-operatively 
Cardiopulmonary exercise testing is routinely carried pre-operatively out for patients 
requiring oesophagectomy. Studies have shown that pre-operative VO2 max (maximal 
oxygen consumption) and AT measurements from CPET can be used to help predict risk of 
post-operative morbidity in oesophagectomy patients48.As mentioned previously, in a local 
study, patients with a lower pre-operative AT with a cut-off value of 9ml/min/kg had a higher 
risk of developing cardiopulmonary complications but this study required validation in a 
larger cohort47.It has been shown that all post-operative cardiopulmonary deaths occur in 
patients with an anaerobic threshold (AT) of <11ml/min/kg and/or with significant 
myocardial ischaemia on CPET150. A literature search revealed no studies that have quantified 
post-operative fitness in this population. Quality of life (QoL) is a factor that is very 
important to patients when considering the possible outcomes of an operation and it has been 
named the ‘missing axis’ in morbidity risk prediction and information provided for patients.  
Whilst QoL pre-operatively and post-operatively have been compared in this population, 
comparing post-operative QoL with post-operative fitness in patients undergoing 
oesophagectomy has not been studied before. 
1.34 Improving prognostication in patients with oesophageal cancer having surgery 
It is clear that for patients who undergo oesophageal cancer surgery, knowledge about 
mechanisms leading to the development of AF and increased mortality is still lacking. A 
Swedish population based cohort study which included 609 patients undergoing surgical 
resection for oesophageal or gastro-oesophageal junctional cancer over a 4 year period found 
that cardiac disease and a Charlson comorbidity score of ≥2 appeared to increase the risk of 
severe and early post-operative complications in patients with oesophageal cancer while 




of 1822 patients in Sweden undergoing oesophageal cancer surgery over a 23 year period 
suggested that overall cause mortality was increased in patients with a Charlson score of 2 or 
more (HR 1.24, 95% CI 1.08-1.42) and those with a history of MI (HR 1.2, 1.01-1.49) or 
congestive cardiac failure (HR 1.31, 1.04-1.67). Exposure to peripheral vascular disease, 
chronic pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes mellitus 
and liver disease did not increase mortality151. 
1.35 Aims and research questions  
I propose to evaluate the mechanisms associated with the development of AF and increased 
mortality following oesophagectomy. I wish to evaluate the CACI, in addition to biomarkers 
including dimethylarginines, CRP, BNP, myeloperoxidase, homoarginine and IL-6 in the 
context of pre-operative Cardiopulmonary Exercise Testing (CPET) results. This may aid 
prognostication in this patient group. 
In this thesis the lead researcher hopes to address some of the following questions. In chapter 
3 the question the aim of the study was to ask; Are pre-operative plasma concentrations of 
dimethylarginines and homoarginine associated with the development of atrial fibrillation in 
adult patients following oesophageal surgery? Are low levels of homoarginine associated 
with increased levels of BNP?152,153. In chapter 4, the aim was to evaluate whether BNP, NT-
pro BNP, left atrial diameter is associated with development of atrial fibrillation and 
outcomes in patients undergoing oesophageal surgery? What association do myeloperoxidase, 
IL-6 and CRP have with the development of atrial fibrillation and outcomes in patients 
undergoing oesophageal surgery? 
Chapter 5 will ask does the use of the modified Glasgow Prognostic scoring system (mGPS) 
pre-operatively and post-operatively (poGPS) assist in determination of associations with 
morbidity and mortality in oesophagectomy patients and if the results of Cardiopulmonary 
exercise (CPET) tests and the results of Quality of Life (QoL) questionnaires are associated 




cohort and use this in addition to biomarkers, CPET results and development of AF to help a 
better understanding of factors influencing the development of AF and associated morbidity 
and mortality in patients undergoing oesophagectomy. 
In chapter 7 the challenges with conducting the study and the limitations of the study will be 
addressed. 
In chapter 8 conclusions from the study will be drawn and future plans will be discussed. 
 
1.36 Key messages 
 
• New-onset AF is a complication in patients following oesophagectomy. 
 
• New-onset AF is independently associated with a risk of stroke, a prolonged length of 
stay in the ICU, and increased mortality. 
 
• AF onset in the post oesophagectomy population is potentially preventable and 
although there are multiple factors in its evolution including genetics, circulating 
biomarkers have been implicated in its development. 
 
• Early identification of patients who are at increased risk for developing AF may allow 
for pharmacological interventions to prevent this complication. 
 
• Evaluating the relationship between cardiovascular biomarkers, CPET, onset of atrial 
fibrillation and outcomes may help to better understand factors influencing increased 
mortality in patients. As a result of understanding the changes in biomarkers, it may 
help us to better identify patients at risk for AF, therefore taking a step closer to 




2 CHAPTER 2  
METHODS 
2.1 Study design 
As a result of a literature review that I completed prior to commencing the study, it appeared 
that there were no studies examining the associations between plasma and urine levels of 
dimethylarginines, homoarginine and first diagnosis AF in patients following oesophageal 
surgery. 
An observational prospective cohort study was planned to investigate the initial hypothesis as 
to whether patients who undergo oesophageal surgery and develop AF post-operatively had 
higher dimethylarginine levels compared to those who did not and whether these levels could 
assist in prognostication of outcomes for these patients. Additionally, CACI, mGPS and 
pomGPS were determined and peri-operative echocardiograms were planned, as well as 
CPET testing and also, the determination of the peri-operative levels of IL-6, CRP, 
myeloperoxidase, BNP and homoarginine of patients. Specifically, it was hypothesised that 
higher CACI, higher pre-operative mGPS and higher pomGPS, lower VO2 max and AT 
values, higher ADMA, lower homoarginine, higher IL-6 and myeloperoxidase, higher BNP 
and CRP would be related to the onset of AF and postoperative morbidity and mortality. It 
was evaluated whether the combination of these factors, in addition to the above would be 
useful in helping to identify mechanisms related to patient outcomes following oesophageal 
surgery. As previously mentioned in section1.14, I had a pre-existing interest in atrial 
fibrillation, having looked at incidence of this dysrhythmia in an ICU cohort at Glasgow 
Royal Infirmary. This led to further consideration as to how this dysrhythmia could be 
predicted and potentially prevented. In terms of patient cohorts who are at risk of developing 
this rhythm, it is widely accepted that patients undergoing oesophageal surgery are at an 




undergoing oesophageal surgery would be adequate to run a pilot prospective cross sectional 
and longitudinal observational cohort study. 
A prospective observational cohort study was planned to investigate the initial hypothesis as 
to whether patients who undergo oesophageal surgery and develop AF post-operatively had 
higher dimethylarginine levels compared to those who did not and whether these levels could 
assist in prognostication of outcomes for these patients. Additionally, CACI, mGPS and 
pomGPS were determined and a plan to carry out peri-operative echocardiograms, CPET 
testing and to determine the peri-operative levels of IL-6, CRP, myeloperoxidase, BNP and 
homoarginine of patients was made. Specifically, the hypothesis was that higher CACI, 
higher pre-operative mGPS and higher pomGPS, lower VO2 max and AT values, higher 
ADMA, lower homoarginine, higher IL-6 and myeloperoxidase, higher BNP and CRP would 
be related to the onset of AF and postoperative morbidity and mortality. It was evaluated 
whether the combination of these factors, in addition to the above would be useful in helping 
to identify mechanisms related to patient outcomes following oesophageal surgery. 
      As previously mentioned in section1.14, the lead researcher had a pre-existing interest in 
atrial fibrillation, having looked at incidence of this dysrhythmia in an ICU cohort at 
Glasgow Royal Infirmary. This led to further consideration as to how this dysrhythmia could 
be predicted and potentially prevented. In terms of patient cohorts who are at risk of 
developing this rhythm, it was known that patients undergoing oesophageal surgery were at 
an increased risk of this and the researcher was also aware that the numbers of patients 
undergoing oesophageal surgery would be adequate to run a pilot prospective cross sectional 
and longitudinal observational cohort study. 
     The study was performed according to the Research Governance Framework for Health 





2.2 Definition of study variables 
A diagnosis of atrial fibrillation was defined as irregular and uncoordinated atrial electrical 
activity on electrocardiogram. Plasma and urine levels of BNP, IL-6, CRP and 
myeloperoxidase were measured with respect to development of atrial fibrillation, and patient 
morbidity and mortality. I analysed Charlson Age-Comorbidity Index (CACI), modified 
Glasgow Prognostic Score (mGPS) and post-operative Glasgow Prognostic Score (po mGPS) 
results and considered Cardiopulmonary Exercise Testing results in these patients to assist in 
determining the effects of these combined factors on morbidity and mortality. 
2.3 Study Population 
Forty patients who had all been deemed by the multidisciplinary team to require an 
oesophagectomy or oesophagogastrectomy at Glasgow Royal Infirmary (GRI) were 
consented for the study. This number was chosen founded on the feasibility of recruitment 
based on the total number of patients undergoing oesophageal surgery each year at the GRI. 
The pilot study sample size was based on the number of patients that were likely to have 
oesophageal surgery at the Glasgow Royal Infirmary over a period of 9 months and over that 
time period, all patients undergoing elective oesophageal surgery were invited to take part in 
the study.  
 The list of patients due to undergo surgery was obtained from the secretaries working for the 
Upper GI consultants at the GRI. The patients involved were referred to the Glasgow Royal 
Infirmary as it is a specialist centre which deals with this type of surgery. There is inevitable 
bias present in this process as this cohort is a pre-selected group by definition who have a 
specific type of cancer and we know that there are certain predisposing factors and exposure 
variables which lead to this diagnosis being made. 
2.4 Identification of participants and consent 
I identified patients listed for trans-hiatal or trans-thoracic oesophagectomy at Glasgow Royal 
Infirmary by means of communications with the consultants’ secretarial team. The majority 




chemotherapy. As mentioned previously, neoadjuvant chemotherapy had been shown to 
improve the overall survival of patients with advanced carcinomas of the oesophagus over 5 
years and so most of the patients recruited into the trial had already undergone neoadjuvant 
chemotherapy. Most patients underwent the ECX regimen which was epirubicin, cisplatin 
and capecitabine also known as Xeloda. 
We already know that oesophageal cancer affects males more than females and affects most 
patients in the age range from 65-74 years. The baseline characteristics of my cohort included 
30 males and 10 females. The median age was 65.5 years and the range was 27-84 years. 2 
patients were not treated with neoadjuvant chemotherapy. There were 20 current or ex-
smokers. 
The lead researcher sent information regarding the study to the patients via post, along with a 
cardiopulmonary exercise test appointment (CPET). 
Information about the study was sent to the patients and subsequently the lead researcher 
reviewed the patients when they attended a pre-assessment clinic where they underwent 
Cardiopulmonary Exercise testing and had a nutritional assessment including referral to a 
dietician. During this appointment, a full medical history including a list of medications was 
recorded. At the appointment for CPET testing, the patient had the opportunity to ask the lead 
researcher more questions prior to the pre-operative visit with the Upper Gastrointestinal 
surgeon. 
The lead researcher obtained written consent from each study participant and explained the 
nature of the study, by means of provision of a patient information sheet and also verbally. 
This included reviewing the side effects and risks of participating in the clinical trial. The 






Originally, it was planned that a quality of life questionnaire should be undertaken at this 
point.  Where possible, baseline blood tests including full blood count, urea and electrolyte 
levels and liver function tests in addition to an electrocardiogram (ECG) were obtained. The 
baseline blood tests were recorded from the NHS Greater Glasgow and Clyde laboratory 
results system onto an anonymised encrypted Excel spreadsheet on the lead researcher’s 
University of Glasgow laptop computer. An echocardiogram was done if determined 
necessary according to the patient’s medical history. Reasons for doing an echo included 
increasing shortness of breath and a history of cardiac problems. Specific to the study, when 
the lead researcher was able to obtain fasting bloods from the patients they were analysed for 
L-arginine, homoarginine, ADMA, SDMA, BNP, high sensitivity CRP, myeloperoxidase 
(MPO) and IL-6. Urinary levels of nitrate in addition to DMA, SDMA and ADMA were 
taken at same time as the blood tests wherever possible. These specialised samples were sent 
via porter on rare occasion or hand delivered by the lead researcher to the biochemistry lab 
and analysed by colleagues using High Performance Liquid Chromatography (HPLC)155.All 
the patients received neo–adjuvant chemotherapy in the weeks prior to undergoing transhiatal 
oesophagectomy, transthoracic oesophagectomy or oesophagogastrectomy. It was difficult to 
objectively analyse the effect of neo-adjuvant chemotherapy on the patients’ inflammatory 
biomarker levels as levels of biomarkers were only taken pre-operatively and not preceding 
chemotherapy. 
There were several differing exposure variables that affected patients, including the surgeon 
carrying out the procedure, the type of surgical approach used, the anaesthetic used, the 
amount of fluid given perioperatively, in addition to medications that the patient was taking 





The operations were performed by one of three consultant surgeons working at Glasgow 
Royal Infirmary (GRI). All patients had a general anaesthetic delivered by a consultant 
anaesthetist and stayed on the Intensive Care Unit at the GRI post-operatively. The 
anaesthetic techniques were standardised for the most part with the use of epidurals for 
analgesia in most patients and volatile anaesthetic was used for the maintenance of 
anaesthesia.  
2.5 Outcome variables 
The main outcome variable in the study was the development of atrial fibrillation or not and 
its association with various biomarker levels. This outcome was chosen due to the association 
that developing this arrhythmia has with poorer outcomes for patients. 
 The haemodynamics of these patients were closely monitored peri-operatively on the 
Intensive Care Unit and the diagnosis of AF was made on the basis of a single lead printed 
rhythm strip at the time of onset and confirmed by a 12 lead ECG where possible. Prior to the 
study starting the lead researcher had ensured that the nursing and medical staff at all stages 
of the study had been fully briefed about it. They also ensured that there was an information 
leaflet (see appendix) available for staff with information regarding what investigations 
needed to be obtained on a daily basis. The lead researcher was also available via phone and 
email to answer any questions and also made themselves available on the Intensive Care Unit 
for at least two days every week to check on progress and troubleshoot problems. Plasma 
levels of arginine, homoarginine, ADMA, SDMA, CRP, MPO and IL-6 and urinary levels of 
nitrate, DMA, SDMA and ADMA were taken by the nursing staff every morning for 7 days 
or until the patient was discharged, if that was sooner. These biomarkers were measured 
according to local protocols, baseline and daily BNP was also done until day 2. Levels of 
electrolytes such as magnesium and potassium were also recorded by myself, in addition to 
fluid balance and the requirement for catecholamines, in an anonymised encrypted Excel 




fibrillation in the intensive care unit was standardised by adherence to local protocols in order 
to minimize inter-patient variation. The protocols involved clinical assessment of the patient 
and consideration of requirement for fluid supplementation and also whether magnesium and 
potassium levels required augmentation. There was also optimisation of the patient’s heart 
rate, ultimately aiming for rhythm control. When a patient developed AF, a trans-thoracic 
echocardiogram was recorded within 24 hours by an intensive care consultant who regularly 
carried out echocardiography. For the patients that had this investigation the lead researcher 
was on the intensive care unit at the time and facilitated these procedures.  
2.6 Inclusion criteria 
• Patients had to be able to give their written informed consent 
• Patients had to be males or non-pregnant females >18 years of age 
• Patients booked to have trans-hiatal or trans-thoracic oesophagectomy or 
oesophagogastrectomy. 
2.7 Exclusion criteria 
• Patients with pre-existing atrial fibrillation 
• Patients deemed to be unable to give their consent 
2.8 Withdrawal of subjects 
Patients who withdrew from the study by their own volition had no further investigations 
carried out. Patients who withdrew due to adverse events were followed up by the lead 
researcher and they liaised with the patient to ensure that they had satisfactory medical follow 
up. 
2.9 Study process and timeline 
 
Visit 1: CPET and study information  
Patients attended the Respiratory function lab in the Glasgow Royal Infirmary for CPET 
testing. In terms of equipment, the ZAN® 600 (nSpire Health, Hertford, UK) and the 
Ergoselect bicycle ergometer (Ergoline, Bitz, Germany) were used for the tests and the 




determined by pain, shortness of breath or exhaustion. Several parameters were recorded 
during the exercise, VO2 peak and AT being the readings required for my study. 
 The CPET appointment was an opportunity for me to engage patients about the study and to 
give them the patient information sheet, if they had not already received one. 
Visit 2: Pre-operative assessment visit  
 The lead researcher obtained informed consent for the study and patients were given the 
opportunity to ask them questions. Baseline bloods, ECG and urine were taken by the lead 
researcher if possible. Patients may also have had an echocardiogram requested as part of 
their pre-operative assessment by the anaesthetist or surgeon. This visit was after neoadjuvant 
chemotherapy had taken place. 
Visit 3: Admission for procedure 
 The lead researcher obtained baseline bloods and urine if these had not already been taken. 
Also, they facilitated the actualization of a pre-operative echocardiogram by an ICU 
consultant, if this had not already been done. 
Originally proposed follow up 
Visit 4: Routine surgical follow-up at 3 months post-operatively in collaboration with 
another investigator who wished to follow patients up with sequential CPET testing and 
Quality of Life assessments. 
The lead researcher planned that the surgeon assessed the patient’s general health on the day 
of the clinic appointment and if they were regarded as fit enough for further CPET testing 
they would be introduced to them or a colleague as the investigator. There was an opportunity 
for patients to meet the researchers and ask questions. Importantly, the patients were 
reminded at this point that they were not obliged to take part in the study and could withdraw 
at any time. The plan was that the lead researcher would show the patients the consent form, 




were agreeable the lead researcher would then organise a CPET appointment. The lead 
researcher gave their contact details to the patients so that they could contact them by phone 
if they changed their mind or wished to cancel the CPET.  
Visit 5: CPET and Quality of Life assessment at 6 months to coincide with surgical 
review clinic appointment 
The lead researcher planned to review the patient again to ensure that they still wished to 
participate prior to the CPET. 
Visit 6: CPET and Quality of Life assessment at 1 year 
The lead researcher planned to review the patient again at this point to ensure that they still 
wished to participate prior to the CPET. 
Visit 7: CPET and Quality of Life assessment at 2 years 
The lead researcher planned to review the patient again to ensure that they still wished to 
participate prior to the CPET. 
Unfortunately, the colleague who was going to take over running the CPET and QoL part of 




































2.10 Laboratory analytical methods for methylarginines and homoarginine. 
Collection and preparation of blood samples. 
The Department of Biochemistry at Glasgow Royal Infirmary has a research interest in 
dimethylarginines, and has well-established methods for conducting affiliated tests. 
Researchers in the department have published HPLC methods by the use of internal standard 
monoethylarginine, which is not inherent in human plasma155,156. The plasma and urine 
samples were analysed using high performance liquid chromatography (HPLC).  
Venous blood samples (EDTA) were withdrawn from 40 patients on the day of their 
preadmission (day 0) and further follow-up samples were taken daily between days 1-7 for 
the analysis of plasma ADMA, arginine, homoarginine and SDMA. Blood samples were 
centrifuged (500 g, 10 minutes), the plasma removed and stored at -70°C until analysis.  All 
the blood samples which were taken were handled according to established standard 
operating procedures in the hospital laboratory. 
2.11  Laboratory analysis 
Blood samples were obtained in EDTA tubes for the determination of ADMA arginine, 
homoarginine and SDMA were measured by isocratic reverse-phase high-performance liquid 
chromatography (HPLC) with fluorescence detection with coefficient of variation (CV) 
<3.0%156. Plasma was collected into tubes containing EDTA. Arginine, SDMA, ADMA and 
homoarginine were extracted from plasma using Isolute PRS cation exchange solid phase 
extraction (SPE) columns. The extraction columns were placed on Vac Elut extraction 
system, activated and equilibrated with 2 ml methanol followed by 2 ml of 50 mM borate 
buffer, pH 8.5. 
In a glass tube, 0.2 ml of plasma sample, quality control (QC) or aqueous calibrator was 
mixed with 80 microlitres of internal standard: monoethylarginine (MEA), 5 micromols) and 
720 microlitres of borate buffer, which was then loaded on to the equilibrated SPE column. 




(3 ml). These steps were performed under gravity, with no vacuum suction required (flow 
rate was 0.5 ml/min).  
Analytes were eluted with 3ml of a solution containing 50% methanol and 10% concentrated 
ammonia in water. The eluent was then evaporated to dryness at 80 °C under air. Using the 
Vac Elut system, 20 samples could be extracted within 2 h for overnight analysis by HPLC. 
After evaporation of the solvent under nitrogen, the amino acids, the dried extract was 
dissolved in 0.1 ml water and 0.1 ml of the derivatising agent was then added and the samples 
thoroughly mixed and equilibrated for 15 min. The derivatisation reagent was freshly 
prepared each week. Briefly, 10 mg of orthophthaldialdehyde (OPA) was dissolved in 0.2 ml 
of methanol, followed by the addition of 1.8 ml of 200 mM borate buffer (pH 8.5), and 
finally 10 microlitres of 3-mercaptopropionic acid. The reagent was stable for one week when 
stored at 4 °C, provided mercaptopropionic acid (5 microlitres) was added every 48 hr to the 
stock solution. Shortly before use, the stock solution was diluted five-fold in the same borate 
buffer. The derivatised samples were transferred to autosampler vials, maintained at 10 °C, 
and 20 microlitres injected onto the HPLC analytical column for chromatography155. 
The derivatives were separated by High-Performance Liquid Chromatography (HPLC). 
Sodium acetate dissolved in 454 ml water (pH 6.3) containing 48 ml acetonitrile was used as 
mobile phase at a flow rate of 1.0 ml/min and a column temperature of 30°C. Fluorescence 
detection was performed at excitation and emission wavelengths of 340 and 455nm, 
respectively. After elution of the last analyte, strongly retained compounds were quickly 
eluted by a strong solvent flush with 50% acetonitrile, resulting in a total analysis time of 40 
minutes. 
Reference values for ADMA, arginine, homoarginine and SDMA were obtained from plasma 




and SDMA in these individuals is normally distributed with a median value of 0.45 µmol/L, 
57.8 µmol/L, 1.9 µmol/L and 0.37 µmol/L respectively156. 
The departmental research team collaborated with me regarding my study into 
dimethylarginines, homoarginine, BNP and IL-6 levels. The University of Glasgow 
immunology department collaborated with me and analysed myeloperoxidase levels in 
patients who developed first diagnosis atrial fibrillation following oesophageal surgery. 
Echocardiography was performed pre-operatively on patients undergoing oesophageal 
surgery and post-operatively on the patients that developed AF and their left atrial diameter 
and volume were measured if possible. I also analysed the data from the cardiopulmonary 
exercise tests which patients had pre-operatively and I had then planned to repeat these at 6 
months, 12 months and 2 years after their operation. I had also planned to get patients to 
complete a quality of life questionnaire at these time intervals. 
2.12 Collection and preparation of blood samples 
All patients undergoing oesophagectomy had their blood taken at pre-operative assessment 
clinic and during their post-operative stay in ICU on days 2 and 3 as the incidence of AF is 
most likely up to 72 hours following an operation83.Whole blood samples collected in plastic 
EDTA tubes were centrifuged to remove the plasma for BNP analysis. Some samples were 
stored at 2-8 degrees Celsius and were processed within 24 hours of collection, however, not 
every sample could be processed within this time period and some samples underwent 
centrifugation and were frozen. Prior to analysis, frozen samples were thawed and thoroughly 
mixed by low speed vortexing until specimens were visually homogenous to ensure 
consistency in results.  
All the blood samples that were taken were handled according to established standard 




2.13 Laboratory analytical methods for BNP. Principles of the BNP assay procedure 
The Abbott ARCHITECT® platform BNP assay was used. It is a two-step immunoassay for 
the quantitative determination of BNP in human EDTA plasma using a Chemiluminescent 
Microparticle Immunoassay (CMIA) on the ARCHITECT® iSystem125. Briefly, the sample 
and anti-BNP (mouse, monoclonal) coated paramagnetic microparticles are combined. The 
BNP in the sample binds to the anti-BNP coated microparticles. After washing, the anti-BNP 
acridinium labeled conjugate is added to create a reaction mixture. The resulting 
chemiluminescent reaction is measured as relative light units (RLUs). There is a direct 
relationship between the amount of BNP in the sample and the RLUs detected by the 
ARCHITECT iSystem optics. 
Calibration of Assay 
The assay is calibrated using a 5-point calibration curve. The ARCHITECT® BNP assay uses 
a point-to-point data reduction method to generate a calibration curve. The ARCHITECT® 
BNP calibrators are traceable to an internal reference standard that has been prepared 
gravimetrically with synthetic BNP. The internal reference standard correlates to the AxSYM 
BNP assay with a decision threshold of 100pg/ml. There is no internationally recognized 
BNP standard currently. 
Quality Performance characteristics 
Three QC levels (low, medium and high) are used in every assay in order to verify test results 
and to monitor the performance of the assay. The imprecision (% CV) of the assay is < 12%. 
The assay has an analytical sensitivity of 10 pg/ml and is linear up to 5000 pg/ml. 
Expected values in non-heart failure population 
Normal values for BNP using the Abbott BNP kit are < 100pg/ml in patients less than 50 







The ARCHITECT® BNP assay uses a point-to-point data reduction method to generate a 
calibration curve. 
Interference 
Potential interference in the ARCHITECT® BNP assay from various drugs such as 
simvastatin and lisinopril is ≤ 10%. 
2.14 Collection and preparation of blood samples and laboratory analytical methods 
for MPO 
Venous blood samples from patients were taken into EDTA tubes prior to their surgery, on 
the day of surgery and daily for 7 days or until their discharge from HDU, depending on 
which came first. These samples were processed by the biochemistry lab at Glasgow Royal 
Infirmary and stored in freezers at -80 °C. A serum separator tube (SST) was used and 
samples were allowed to clot for 30 minutes at room temperature before centrifugation for 15 
minutes at 1000 x g. Samples were aliquoted and stored at -80 °C. Following analysis for 
BNP, dimethylarginines and homoarginine, the samples were transferred to the immunology 
laboratory at Glasgow University for MPO analysis. All samples were brought to room 
temperature prior to immunoassay. 
Assay 
The Quantikine® Human MPO Immunoassay is a solid-phase Enzyme Linked 
Immunosorbent Assay (ELISA) designed to measure human MPO in serum, platelet-poor 
plasma, cell culture supernates, cell lysates, saliva, and urine. The serum samples were 
assayed at a 1 in 50 dilution as recommended by the kit and a selection of samples was 
assayed twice for reproducibility. This assay employs the quantitative sandwich enzyme 
immunoassay technique. A monoclonal antibody specific for human MPO had been pre-
coated onto a microplate. Samples were pipetted into the wells and any MPO that was present 




away, an enzyme-linked polyclonal antibody specific for human MPO was added to the 
wells. A wash to remove any unbound antibody-enzyme reagent was followed by a substrate 
solution being added to the wells. Colour then developed in proportion to the amount of MPO 
bound in the initial step. The colour development was stopped and the intensity of the colour 
was measured184. For information regarding the precision, sensitivity and specificity of the 
assay please refer to the Appendix. 
Details of MPO assay procedure 
Precision 
Intra-assay Precision Three samples of known concentration were tested twenty times on 
one plate to assess intra-assay precision.  
Inter-assay Precision Three samples of known concentration were tested in twenty separate 
assays to assess inter-assay precision. Assays were performed by at least three technicians 
using two lots of components. 
SERUM/PLASMA/URINE ASSAY  
Intra-Assay Precision  Inter-Assay Precision  
Sample  1  2  3  1  2  3  
n  20  20  20  20  20  20  
Mean 
(ng/Ml)  
1.03  3.13  6.63  1.07  3.29  6.71  
Standard 
deviation  
0.024  0.046  0.172  0.12  0.26  0.55  
CV (%)  2.3  1.5  2.6  10.8  8.0  8.2  
SENSITIVITY  
Fifty-four assays were evaluated and the minimum detectable dose (MDD) of human MPO 
ranged from 0.003-0.062 ng/Ml. The mean MDD was 0.014 ng/Ml.  
The MDD was determined by adding two standard deviations to the mean O.D. value of 





This immunoassay is calibrated against highly purified MPO from human leukocytes. 
SPECIFICITY  
This assay recognizes natural human MPO.  
No significant cross-reactivity or interference was observed. 
2.15 Laboratory analytical method for IL-6 
 
The Quantikine® Human IL-6 Immunoassay is a 4.5 hour solid phase immunoassay designed 
to measure human IL-6 in cell culture, serum, and plasma. It contains E.Coli-expressed 
recombinant human IL-6, and antibodies raised against the recombinant protein. Natural 
human IL-6 showed dose-response curves that were parallel to the standard curves obtained 
using the Quantikine® kit standards, indicating that this kit can be used to determine relative 
levels of natural human IL-6. 
Collection and preparation of blood samples 
Plasma was collected from patients in lithium heparin tubes pre-operatively and then daily for 
up to 7 days post-operatively. These samples were centrifuged for 15 minutes at 1000 x g 
within 30 minutes of collection. They were then assayed immediately or aliquoted and stored 
at ≤ -20 °C.  
Assay 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for human IL-6 has been pre-coated onto a microplate. 
Standards and samples are pipetted into the wells and any IL-6 present is bound by the 
immobilized antibody. After washing away any unbound substances, an enzyme-linked 
polyclonal antibody specific for human IL-6 is added to the wells. Following a wash to 
remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and 
colour develops in proportion to the amount of IL-6 bound in the initial step. The colour 






This immunoassay is calibrated against highly purified E. Coli-expressed recombinant human 
IL-6 produced at R&D Systems®. The NIBSC/WHO 1st International Standard for IL-6 
(89/548), intended as a potency standard, was evaluated in this kit. The NIBSC/WHO 
standard is a CHO cell-derived recombinant human IL-6.  
Details of IL-6 assay precision 
Intra-assay Precision (Precision within an assay) Three samples of known concentration 
were tested twenty times on one plate to assess intra-assay precision.  
Inter-assay Precision (Precision between assays) Three samples of known concentration 
were tested in twenty separate assays to assess inter-assay precision. Assays were performed 
by at least three technicians using two lots of components.  
 
Intra-Assay Precision  Inter-Assay Precision  
Sample  1  2  3  1  2  3  
n  20  20  20  20  20  20  
Mean 
(pg/Ml)  
16.8  97.7  186  17.2  101  191  
Standard 
deviation  
0.7  1.6  3.8  1.1  3.3  7.2  
CV (%)  4.2  1.6  2.0  6.4  3.3  3.8  
2.16 Laboratory analytical methods for hs CRP 
The assay that was used at Glasgow Royal Infirmary biochemistry labs was the 
MULTIGENT CRP Vario assay which is intended for the quantitative immunoturbidimetric 
determination of C-reactive protein in human serum and plasma. It has variable assay ranges. 
This was used with the Abbott ARCHITECT c system190. 
Collection and preparation of blood samples 
Plasma was collected from patients in lithium heparin plastic tubes pre-operatively and then 




1000 x g within 30 minutes of collection. They were then assayed immediately or aliquoted 
and stored at ≤ -20 °C.  
Assay 
MULTIGENT CRP Vario is a latex immunoassay developed to accurately and reproducibly 
measure blood CRP levels in serum and plasma. Agglutination results when an antigen-
antibody reaction occurs between CRP in a sample and anti-CRP antibody, which has been 
adsorbed to latex particles. This agglutination is detected as an absorbance change (572 nm), 
with the rate of change being proportional to the quantity of CRP in the sample. The 
MULTIGENT CRP Vario assay should be calibrated using the correct parameters as 
suggested in the manual. The ARCHITECT c system has an automated dilution procedure. 
When using the Automated Dilution Protocol, the system performs a dilution of the specimen 
and automatically corrects the concentration by multiplying the result by the appropriate 
dilution factor. The dilution for high sensitivity CRP is 1 in 10. To manually dilute the 
sample 0.9% saline is used. The precision of the MULTIGENT CRP Vario assay is ≤ 6% 
Total CV. The limit of quantitation or detection limit was 0.1mg/L for hsCRP. At 1000mg/L 
the observed result was flagged as above the linearity of the assay190. 
 
2.17 Other laboratory tests 
Liver function tests, blood glucose levels and C-reactive protein were measured in 
accordance with the manufacturer’s instructions, using routine laboratory procedures and an 
automated analyzer. For CRP, the limit of detection was 0.5 mg/L.  The interassay co-efficent 
of variation (CV) was <5% over the sample concentration range for the analytes measured. 
The CV is defined as the ratio of the standard deviation to the mean and it is the standard 
deviation divided by the mean. The IL-6 and MPO concentrations were quantified by 




manufacturers’ instructions.  BNP in the serum was also measured by immunoassay157. The 
methods relating to the analysis of these biomarkers is detailed above. 
2.18 Statistics and data analysis 
 
The sample size was 40 patients. This was based on the number of oesophageal surgeries 
carried out every year by the Upper Gastrointestinal surgeons at Glasgow Royal Infirmary. 
The baseline demographics of the cohort were presented using descriptive statistics. The 
researcher analysed the relationship between dimethylarginines, homoarginines and the onset 
of AF using an unpaired T test as data was non normally distributed.  
The researcher originally used logistic regression to analyse the association between 
perioperative levels of several biomarkers including myeloperoxidase, CRP, IL-6 and BNP 
and onset of AF following oesophageal surgery to elicit more about the association between 
several predictor factors on the outcome of development of AF or no AF. Logistic regression 
was carried out as there was a binary dependent variable, despite having a small sample size 
following sample losses. For the original analyses, the researcher used an unadjusted, 
adjusted modelling strategy. This means that the outcome (AF or no AF) was considered in 
the context of no covariates and then the researcher used individual covariates such as age 
and post-operative values of biomarkers and CPET results to address confounding.   
The advantages of logistic regression over other tests such as Chi squared or Fischer’s exact 
test are that the researcher could include more than one explanatory variable and also it 
provided a value for the strength of the association adjusting for other variables. 
When completing logistic regression, it is suggested that data should contain at least 10 
events for each variable entered into a logistic regression model. This was not possible for the 
researcher’s study, due to lack of complete data. The researcher could have potentially used 
Firth’s logistic regression which has become a standard approach for the analysis of binary 




The examiners deemed logistic regression to be incorrect and therefore the statistical analysis 
was changed by the lead researcher. 
As the data demonstrated a non-normal distribution, the researcher chose to use the Mann 
Whitney U test which is a non parametric test, instead of a parametric test which makes 
assumptions about a population’s parameters such as the mean and standard deviation. 
Assumptions of a non parametric test include independence of observations, where no 
participants are in both groups.  
Additionally, Mann Whitney U tests are helpful as the sample size was very small and the 
data had some outliers which could not be removed. 
The software the researcher used for statistical analysis was R.158 
Confounding 
Age and sex in addition to electrolyte levels such as magnesium and potassium and also fluid 
balance are recognised potential confounding factors when looking at the development of AF. 
Confounding was controlled in the analysis of data by using stratified analysis. Stratification 
means making a separate table of disease by exposure for each confounder combination. We 
can compute a weighted average of the estimates of the risk ratios or odds ratios across the 
strata. So, for example, we can identify the relationship between sex and developing AF or 
not developing AF in patients in a certain age group (see section 2.22).  
Adjusting for confounders meant that the internal validity of the study will be more robust.  
The loss of samples caused bias by reducing the sample size and this in turn determined 
validity in terms of the statistical power required to accept or reject the working hypothesis.  
Information bias can occur as a result of having incomplete data due to loss of information at 
time of recording data such as ECG recordings of AF being misplaced. 
The small size of the pilot study resulted in challenges concerning missing data. During the 




incidence of missing data, however this was beyond their control and therefore it was decided 
that this should be addressed during the data analysis part of the study. Problems with 
missing data include bias in the estimation of parameters and it can also reduce how 
representative a sample is. The researcher considered several methods of dealing with 
missing data including methods that discard data and also those that retain data. These 
included complete case analysis, available case analysis, mean substitution, regression 
imputation and multiple imputation159.  
The researcher chose to use a complete case analysis due to data which were missing 
completely at random (MCAR). This excluded any cases for which the outcome measure was 
missing. The researcher’s data was MCAR because of equipment failure (freezer breakdown) 
and samples were also lost in transit. The researcher chose to omit the cases with the missing 
data and analyse the remaining data. There are problems with a complete case analysis as it 
discards data, also, sometimes the missing values differ from the completely observed cases 
which could potentially bias the analysis. There was a significant amount of missing data and 
so there were relatively few cases left for analysis.  
Due to small numbers of patients undergoing oesophageal surgery over the time period that 
the researcher was recruiting patients, they were unable to randomise the patients that they 
recruited as they had already been listed for oesophageal surgery. They also did not restrict 
the entry of patients with potential confounding factors into the study as restricting entry 
would have risked bias in itself. They also knew that as a pilot study it would be too small to 
match patients to ensure equal distribution of confounders. Within one year, the researcher 
recruited 40 patients, of whom, they predicted between 5 and 10 would develop AF. The 
researcher originally used logistic regression to determine the relationship between pre-
operative and day 0-day 7 values of biomarkers. The lead researcher used logistic regression 




cohort. The internal validity of a study is determined by multiple factors that can lead to 
errors or biases. Bias can be caused by several sources such as the sample selection, data 
collection and analysis. As such, bias can originate when patients are enrolled in the study. In 
the study the selection criteria were that patients had to be awaiting trans-hiatal, trans-
thoracic oesophagectomy or oesophagogastrectomy, be males or non-pregnant females > 18 
years old, not have AF and have capacity to give their written consent. This automatically 
creates selection bias. Ideally, studying a group that was matched by age and gender to the 
group undergoing oesophageal surgery, would have helped to address bias, however, this was 
not possible in this study. 
The researcher could also have trialled linear regression to estimate missing values, by using 
the best predictors of the variable as independent variables and the variable with the missing 
data as the dependent variable in a regression equation. However, when replaced values are 
predicted from other variables they fit together too well and standard error is deflated. Also, 
the assumption is that there is a linear relationship between the variables used in the 
regression equation when there may not be one. 
 
2.19 Study closure and definition of the end of the trial 
The study ended when the planned sample size was achieved. When the results were collated, 
data from 40 patients was not present, however there was no time remaining for the researcher 
to extend the trial. 
2.20 Data Handling 
Data from patients participating in the trial was anonymised, encrypted and managed in an 
Excel spreadsheet on a University of Glasgow computer by the researcher. The computer that 
was used to hold the data was in an office that was locked when not in use and was password 
protected. Access to the department building itself was by entry code during office hours. All 




No identifiable data was released for off-site working and when non-identifiable data was 
taken off-site it was transported by me using an NHS approved encrypted USB stick. Data 
has been kept securely in password-protected, encrypted electronic format by the researcher 
and will be for at least 10 years after publications have been completed. 
2.21 Record Retention 
The researcher agreed to keep records including the identity of all participating subjects (with 
sufficient information to link records) and all original signed consent forms and source 
documents. Data will be retained for a minimum of 5 years. 
2.22 Routine management of trial 
The researcher co-ordinated the trial at Glasgow Royal Infirmary. 
All aspects of the conduct and progress of the trial were monitored by the researcher and they 
ensured that the protocol was adhered to and that the quality of the trial and safety of 
participants was maintained. 
2.23  Study monitoring and auditing 
NHS Greater Glasgow and Clyde audit 10% of studies on a random basis per annum. This 
study has not been audited. 
2.24 Protocol amendments 
After further reading and consideration the researcher decided that it would be useful to 
monitor patient’s progress by means of sequential CPET testing at 6,12 and 24 months 
following their operation. At these intervals the researcher planned to conduct Quality of Life 
questionnaires to get a subjective evaluation of the patient’s progress. This change in the 
study protocol required an amendment and the proposed protocol amendment was initiated by 
the researcher following discussion with the Principal Investigator, Professor Kinsella. The 
researcher submitted the requisite amendment forms to the ethics committee and sponsor. 
The researcher also liaised with the study sponsor and determined that the amendment was 
deemed to be substantial. All amended versions of the protocol were signed by the researcher 




researcher sought approval from the original reviewing REC and Research and Development 
(R&D) office. The outcome of the amendment is included in the appendices. It was decided 
that the CPET testing and QoL questionnaires should be carried out as part of a sub-study. 
 
2.25 Ethical considerations 
 
Ethical conduct of the study and approval 
The study was carried out in accordance with the World Medical Association Declaration of 
Helsinki (1964) and its revisions (Tokyo [1975], Venice [1983], Hong Kong [1989], South 
Africa [1996] and Edinburgh [2000]). This reinforces that the health of patients was the 
researcher’s first consideration. 
The researcher sought favourable ethical opinion from the West of Scotland Research Ethics 
Service (WoS REC) before patients were entered into this clinical trial. Patients were only 
allowed to enter the study once they had provided the researcher with written consent. The 
meeting was convened on the 27th September 2012 and approval was granted via letter on 5th 
October 2012, reference 12/WS/ 0232: see appendices. 
The researcher requested an Amendment (AM02) to the study with regard to carrying  
CPET testing and completion of Quality of Life questionnaires. This was considered by the 
WoS REC and a decision was made to undertake this element as a sub-study with the 
requirement that another consent form should be completed. The researcher was responsible 







3 CHAPTER 3 
ARE PRE-OPERATIVE PLASMA CONCENTRATIONS OF 
DIMETHYLARGININES AND HOMOARGININE ASSOCIATED WITH THE 
DEVELOPMENT OF ATRIAL FIBRILLATION IN ADULT PATIENTS 
FOLLOWING OESOPHAGEAL SURGERY? ARE LOW LEVELS OF 
HOMOARGININE ASSOCIATED WITH INCREASED LEVELS OF BNP? 
3.1 Setting; SDMA, ADMA, atrial fibrillation and outcomes 
Nitric oxide (NO) is important for vascular health as it mediates vascular homeostasis and has 
antithrombotic and anti-inflammatory effects. As previously mentioned, NO is synthesized 
from L-arginine via endothelial NO synthase (e NOS). Research has indicated that increased 
presence of arginine in the circulation may improve endothelial function and contribute to 
delayed development of atherosclerosis160. ADMA and SDMA are the result of modifications 
to arginine residues. A growing number of studies have associated elevated concentrations of 
ADMA and SDMA to cardiovascular disease (CVD) and mortality. A recent systematic 
review and meta-analysis quantified associations of ADMA and SDMA with the risks of all-
cause mortality and incident cardiovascular disease accounting for different populations and 
methodological approaches of prospective studies identified in PubMed until February 2015. 
ADMA and SDMA have overlapping as well as unique biological effects. Both may alter 
transport of arginine but only ADMA appears to directly inhibit NOS. Elevated ADMA may 
represent impaired DDAH activity while elevated SDMA may reflect impaired renal function 
and impaired alanine glyoxylate aminotransferase2 (AGXT2) activity. For ADMA a total of 
34 studies (n=32,428) investigating associations with all-cause mortality events (n=5035) and 
30 studies assessing the association with incident CVD events (n=3,396) were included. 
Summary Relative Risk (RR) (95% CI) for all-cause mortality were 1.52 (1.37-1.68) and for 
CVD 1.33 (1.22-1.45) contrasting high versus low ADMA concentrations. For SDMA, 17 
studies (n=18,163) were included for all cause mortality events (n=2903) and 13 studies 




associated with increased risk of all-cause mortality summary RR (95% CI): 1.31(1.18-1.46) 
and CVD summary RR (95% CI): 1.36 (1.10-1.68). The strongest associations were observed 
in general population samples. The conclusion was that ADMA and SDMA are independent 
risk markers for all-cause mortality and CVD across different populations and 
methodological approaches161. AF is postulated to be related to pathways of oxidative stress, 
nitric oxide availability and arginine derivatives. As part of the Gutenberg health study, 
arginine in addition to NMMA, ADMA, SDMA levels were determined in association with 
ECG, and echocardiographic variables and onset of AF. ADMA (odds ratio [OR] 1.21, 95% 
confidence interval [CI] 1.11-1-32; p= 0.013) and NMMA (OR 1.17, 95% CI 1.09–1.26, p= 
0.014) were related to prevalent AF. The arginine/ADMA ratio was inversely associated (OR 
0.8, 95% CI 0.71–0.90, p=0.0082). Results were similar after adjustment for creatinine. 
SDMA was related to left atrial diameter and in Bonferroni-corrected multivariable-adjusted 
regression analyses, moderate inverse associations were observed for arginine, SDMA, and 
arginine/ADMA ratio and ventricular heart rate, and for arginine and arginine/ADMA ratio 
with QTc interval162. 
ADMA and SDMA modulate vascular function, partially by inhibiting nitric oxide generation 
and as such, may modulate the risk of thromboembolism and also cardiac death that patients 
with AF are exposed to. In 3,310 individuals from the community-based Framingham study 
levels of arginine, SDMA, ADMA and ratio of arginine/ADMA to incidence of AF were 
studied prospectively. Using proportional hazards age and sex adjusted regression models, 
ADMA and related arginine derivatives were not associated with incident AF in the 
community after accounting for other clinical risk factors and confounders163. As part of the 
2011 ‘Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 
Fibrillation’ (ARISTOTLE) trial, 4951 patients had ADMA and SDMA plasma levels 




models and were adjusted for factors including age, sex, heart failure, diabetes and previous 
stroke. Results showed that in patients with AF, ADMA and SDMA levels provided 
prognostic information, independent of other risk factors, for major bleeding, cardiac 
mortality and stroke or systemic embolism. This may suggest that impairment of nitric oxide 
generation may contribute to the risk of complications. ADMA may be useful as a biomarker 
for risk stratifying patients with AF164. 
3.2 Homoarginine levels, atrial fibrillation and outcomes 
Over the past seven years, studies have suggested that low concentrations of homoarginine 
predict a risk of adverse cerebrovascular and cardiovascular outcomes and also 
mortality113,114. Due to homoarginine being similar in structure to L-arginine, it is thought 
that it interferes with the nitric oxide (NO) pathway. It does this as it is a weak alternative NO 
synthase substrate and competes with arginine for cellular transporters and so it improves 
arginine availability and inhibits its metabolism by arginases165. 
In a German cohort of 1649 patients with chest pain, low plasma homoarginine was identified 
as a risk marker for incident major adverse cardiovascular events (MACEs) including all 
cause death, myocardial infarction or stroke. When correlated with other biomarkers, 
circulating homoarginine had the strongest correlation with BNP; low homoarginine levels 
were associated with elevated levels of BNP. This finding correlates with previous 
studies152,153,166. In 288 patients with AF, significantly more patients had homoarginine 
concentrations below or at the median compared to above the median (n=168 vs 120; 
p=0.0023). In two large cohorts of patients, levels of homoarginine were independently 
associated with cardiovascular and all cause mortality in patients referred for coronary 
angiography and those undergoing haemodialysis113. 
In support of the association between homoarginine and endothelial function, low 
homoarginine concentrations have been associated with phenotypes of subclinical 




levels have been inversely associated with prevalent AF and low homoarginine levels have 
been associated with cardiovascular outcomes in patients with acute chest pain.  
 Laboratory analytical methods for methylarginines and homoarginine and collection and 
preparation of blood samples is addressed in chapter 2. 
3.3 RESULTS 
 
         Table 3.1a Demographic data for study patients who developed AF 
compared with those who did not develop post-operative AF 
 
Age and hospital LOS figures are Median (Interquartile range). 
 
Table 3.1b   Gender and developing AF or not, in patients aged younger than 64 
years old or people aged ≥ 64 years old. 
 
 
The risk ratio (RR) for the total combined sample is 0.27, which is unadjusted for potential 
confounding factors. 
The stratum specific risk ratios are; 
Among those age < 64 years: 0.375 
Among those ≥ 64 years: 0.2 
The Cochran-Mantel-Haenszel estimate for the risk ratio is: 0.26. 
Pats developed AF( n=8) Pats who did not develop AF (n=13) Tot no of pats (n=21)
Age 63.5(11) 64(15.5) 64(14)
Male:Female 5:3 13:0 18:3
Type of cancer : Adenocarcinoma 7 12 19
Type of cancer: Squamous cell 1 1 2
Pre-op chemotherapy: Yes 8 11 19
Pre-op chemotherapy: No 0 2 2
Type of surgery :Transthoracic 2 3 5
Type of surgery : Transhiatal 3 5 8
Oesophagogastrectomy 3 5 8
60 day mortality n(%) 1(12.5%) 1(7.7%) 2(9.5%)
Hospital length of stay (LOS) days 23(16) 16(20.5) 21(19.5)
AF No AF Total AF No AF Total
Male 3 5 8 Male 2 8 10
Female 1 0 1 Female 2 0 2
Total 4 5 9 Total 4 8 12




This demonstrates that there is evidence of confounding due to age in the overall sample. 
Despite very small numbers, the table suggests that older females had a higher risk of 
developing AF than younger females. 
 
The Cochran-Mantel-Haenszel method produces a single summary measure of association 
which provides a weighted risk ratio across the different strata of the confounding factor. 
 
An Odds Ratio was unable to be calculated due to zero being in the calculations. 
 
Limitations of stratified analysis include the inability to control simultaneously for multiple 
confounding variables. As you increase the number of strata you reduce the number of people 
in each stratum, so sample size will become a major problem. 
         Table 3.2a Comparison of mean preoperative levels of ADMA, SDMA and 
homoarginine levels in patients that developed AF post-operatively and those who 
did not and the 95% confidence interval comparing the means of these 2 groups.  
 
Table 3.2b Comparison of mean perioperative levels of potassium (K+) in patients 
that developed AF and those that did not and the 95% confidence interval 
comparing the means of these 2 groups.  
 
Biomarkers Levels in control gp
Mean preop plasma 
levels in pats who 
developed AF (total 
n=8)
Mean preop plasma levels 
in pats who did not 
develop AF (total n=13)
95% Confidence 
interval for difference 
between means of the 
2 groups
ADMA (micromol/L) 0.46 (0.08) 0.50 (n=2) 0.59 (n=7) 0.09+/-0.009
SDMA (micromol/L) 0.38(0.07) 0.66 (n=2) 0.58 (n=7)  0.08+/-0.04
Homoarginine (micromol/L) 1.34(0.5) 0.92 (n=2) 1.87 (n=7) 0.956+/-0.87
Serum potassium levels 
(K+) (mmol/L) no of patients (n)
 Mean K+ level 
(mmol/L) no of patients (n)
 Mean K+ 
level 
(mmol/L)
95% CI for difference between the  
means of the 2 groups
Pre op K+ 4 4.175 10 4.14 0.035+/-0.07
Day 0 K+ 4 5.075 10 4.81 0.265+/-0.316
Day 1 K+ 4 4.775 10 4.53 0.245+/-0.22
Day 2 K+ 3 4.9 10 4.29 0.61+/-0.17
Day 3 K+ 3 4.4 10 4.01 0.39+/-1.0
Day 4 K+ 3 4.43 10 3.81 0.62+/-0.144
Day 5 K+ 3 3.86 10 3.71 0.15+/-0.08
Day 6 K+ 3 3.8 10 3.81 0.01+/-0.28
Day 7 K+ 3 4.23 10 3.99 0.24+/-0.12




Table 3.2c Comparison of mean perioperative levels of magnesium (Mg) in 
patients that developed AF and those that did not and the 95% confidence interval 







With reference to table 4.2a; in patients who developed AF, the mean preoperative ADMA 
level was lower compared with the mean preoperative ADMA level in those patients that did 
not go on to develop AF. We can conclude that there is a statistically significant difference in 
mean ADMA levels between the 2 groups as the confidence interval does not pass through 
zero. 
Also, in patients who developed AF, the mean preoperative SDMA level was higher 
compared with the mean preoperative SDMA level in those patients that did not go on to 
develop AF. The confidence interval infers that there is a statistically significant difference in 
mean SDMA levels between the 2 groups as it does not pass through zero. Mean preoperative 
homoarginine levels were lower in patients that developed AF, compared with those who did 
not and again the confidence interval does not pass through zero, suggesting a statistically 
significant difference between the mean homoarginine levels in both groups. 
The limitations include a very small sample size, which will give an imprecise estimate of the 
difference in mean ADMA, SDMA and homoarginine levels between the 2 groups. 
Serum magnesium levels 
(Mg) (mmol/L) no of patients (n)
 Mean Mg level 
(mmol/L) no of patients (n)
 Mean Mg 
level 
(mmol/L)
95% CI for difference between the  
means of the 2 groups
Preop Mg 4 0.865 11 0.879 0.014 +/-0.008
Day 0 Mg 2 0.695 6 0.628 0.067+/-0.015
Day 1 Mg 3 0.743 10 0.7 0.43+/-0.03
Day 2 Mg 3 0.926 8 0.85 0.07+/-0.04
Day 3 Mg 3 0.96 10 0.848 0.12+/- 0.04
Day 4 Mg 2 0.925 8 0.857 0.07 +/- 0.62
Day 5 Mg 2 0.95 10 0.825 0.13+/- 0.005
Day 6 Mg 3 0.753 7 0.782 0.03+/- 0.005
Day 7 Mg 3 1.09 10 0.79 0.302+/- 0.02




The researcher has chosen not to include p values in the results as confidence intervals are 
equally valid. 
The control group consisted of age range 42.5 yr +/-10.1years and comprised 42 females and 
43 males from a healthy population. However, we are unable to draw any comprehensive 
conclusions from these results as the sample size is so small and data was missing. The 
unexpected lower pre-operative plasma ADMA levels in patients who went on to develop AF 
may represent increased cellular uptake or degradation. We also may have missed 
asymptomatic AF episodes and therefore the values of biomarkers may be influenced by 
clinically undetected paroxysmal AF. This is a potential source of bias. Limitations of this 
pilot observational study included the variation in the cohort studied and potential 
confounding factors that had not been fully accounted for such as age, sex, co-morbidities 
and medications that patients were taking could have an effect on whether patients in the 
study develop AF or not.  Data concerning the patients including electrolyte levels such as 
magnesium and potassium and also fluid balance and electrolyte requirements could also be 
potential confounding factors when looking at the onset of AF.  
In tables 4.2b and 4.2c the researcher compared mean perioperative levels of potassium and 
magnesium in patients that developed AF and those that did not develop AF. 
In these small samples, patients who develop AF have higher mean potassium (K+) levels 
compared with those who do not develop AF apart from on day 6. Based on the mean values 
we can conclude that there is a statistically significant difference in mean K+ values between 
the 2 groups, apart from on days 0, 3 and 6, when the 95% CI for difference between the 
means includes the null value of zero, therefore meaning we don’t have enough evidence to 
conclude that there is a difference. 
The limitations include a small sample size, which will give an imprecise estimate of the 




Patients who develop AF have higher mean magnesium (Mg) levels compared with those 
who do not develop AF apart from on day 6. Based on the mean values we can conclude that 
there is a statistically significant difference in mean Mg values between the 2 groups, apart 
from on day 4, when the 95% CI for difference between the means includes the null value of 
zero, therefore meaning we don’t have enough evidence to conclude that there is a difference. 
The limitations include a small sample size, which will give an imprecise estimate of the 
difference in mean Mg levels between the 2 groups. 
As a pilot study it was acknowledged that it would be too small to match patients to ensure 
equal distribution of confounders. Confounding can have a significant impact on internal 
validity and so it was decided that logistic regression should be used as a way of addressing 
potential confounders. In the results, due to the small sample size following sample losses 
doing logistic regression was limited. The entry of patients with potential confounding factors 
into the study was not restricted, as restricting entry would have risked bias. The external 
validity of the results was evidently dependent on the internal validity of the study which was 
limited due to patient recruitment being restricted to patients that were due to undergo 
oesophageal surgery at Glasgow Royal Infirmary. 
 
Of note, in hospital mortality was 1 patient out of 8 patients (12.5%) who developed post-
operative AF. This patient died on day 30 post-operatively. The two patients who died in the 
group who did not develop AF died on day 58 and 6 months after their operation. The 
hospital stay was longer in the group that developed AF post-operatively but this was not 
statistically significant. Mann Whitney U test p > 0.05.   
 
3.5 Key message 
• There may be a potential role for dimethylarginines and homoarginine as biomarkers 




4 CHAPTER 4  
ARE BNP, NT-PRO BNP, LEFT ATRIAL DIAMETER ASSOCIATED WITH 
DEVELOPMENT OF ATRIAL FIBRILLATION AND OUTCOMES IN PATIENTS 
UNDERGOING OESOPHAGEAL SURGERY? WHAT ASSOCIATION DO 
MYELOPEROXIDASE, IL-6 AND CRP HAVE WITH THE DEVELOPMENT OF 
ATRIAL FIBRILLATION AND OUTCOMES IN PATIENTS UNDERGOING 
OESOPHAGEAL SURGERY? 
4.1 Setting : BNP and NT-pro BNP 
As previously mentioned, NT-proBNP has been associated with an increased risk of death, 
atrial fibrillation and cardiovascular events in people after adjustment for traditional risk 
factors. Excess risk was apparent at levels well below thresholds used to diagnose heart 
failure121.A Finnish study of 958 men suggested that N-terminal fragments of pro B type 
natriuretic peptide might help in identifying subjects at risk for stroke and AF122.The 
relationship between NT-proBNP and AF was studied in the Cardiovascular Health study and 
the results suggested that NT-proBNP predicted AF in a community-based population of 
older adults116.A systematic review and meta-analysis of observational studies showed that 
pre-operative BNP or NT-proBNP levels are an independent predictor of adverse outcomes 
within the first 30 days following non-cardiac surgery132.A study of 142 patients 
demonstrated that elevated peri-operative plasma levels of NT-proBNP in oesophagectomy 
patients are an independent predictor of post-operative AF. Multivariable logistic regression 
adjusted for age, gender, COPD, history of cardiac disease, hypertension, diabetes mellitus, 
site of anastomosis, post-operative hypoxia, thoracic-gastric dilatation and plasma NT-
proBNP showed NT-proBNP levels were associated with the highest risk factor for post-
operative AF (OR= 4.711, 95% CI = 1.212-7.644, P = 0.008)117. In a systematic review and 
meta-analysis of 742 patients who participated in 5 observational studies, where BNP or NT 
pro BNP were measured up to a month before non cardiac thoracic surgery, the combined 
incidence of postoperative AF was 14.5% (n = 108/742), and the natriuretic peptide 




peptide measurement was associated with an OR of 3.13 (95% CI 1.38-7.12; I2 = 87%) for 
postoperative AF, with the sensitivity analysis reporting an OR of 9.51 (95% CI 4.66-19.40; 
I2 = 0) 168. 
A best evidence topic regarding whether plasma level of BNP could predict the onset of post-
operative AF in patients undergoing non cardiothoracic surgery was written on the basis of 
evidence from fourteen papers that were identified; five of which represented best evidence. 
The findings suggested that if NT-pro BNP or BNP levels were increased during the pre-
operative period, then it identifies patients at risk for the development of post-operative AF 
after anatomical major lung resection or oesophagectomy169. Due to local protocols we were 
unable to test NT-proBNP levels in the laboratory which was dealing with the study samples 
and so we measured BNP levels170. 
 
4.2 AF and left atrial (LA) diameter 
In a retrospective analysis of patients undergoing cardiac surgery for correction of mitral 
regurgitation, Kernis et al found that anteroposterior LA dimension to be related to POAF171.  
However, subsequent studies have found the LA diameter to underestimate left atrial volume 
(LAV)172. Cardiac diastolic dysfunction as measured by LA size has been found to be 
associated with adverse cardiovascular events in patients undergoing stress 
echocardiography.  It can also indicate existing cardiac disease and can predict cardiovascular 
outcomes173,174,175. AF is a confounding factor in diastolic dysfunction as it is known to affect 
left atrial remodelling and geometry. LA dilation and geometric distortion may be primary or 
can be secondary to left ventricular diastolic dysfunction. The LA is usually enlarged in 
patients with AF and in a multicentre trial involving over 3,400 patients, the mean LA 
diameter was 6mm greater in those with AF compared with those in sinus rhythm at the time 
of echocardiography. The estimated independent contribution of atrial rhythm to LA diameter 




dilatation and hypertension176. In a study of 15 people, left and right atrial dimensions were 
measured at two different time points in patients who had normal atrial sizes initially and had 
AF diagnosed by two-dimensional echocardiography or by history. There were significant 
increases in calculated left atrial (45.2 to 64.1cm3 p< 0.001) and right atrial volume (49.2-
66.2cm3, p < 0.001)177. This study suggested that left atrial enlargement could occur as a 
result of AF. The population Framingham and Strong Heart studies show that increased LA 
size is an independent risk factor for AF173,174,175.Osranek’s historical cohort study of 46 
patients with lone AF observed that the patients who were diagnosed with normal atria and 
AF had a benign clinical course and patients with increased left atrial volume (>32ml/m2), 
based on blinded analysis of echocardiographic videotape recordings of left atrial volume at 
diagnosis or during follow up, experienced adverse events such as myocardial infarction, 
congestive cardiac failure and cerebral infarction178.The remodelling effect is present and 
independent of loading conditions within the LA and occurs in chronic and paroxysmal AF. It 
carries a degree of risk and therefore the maintenance of sinus rhythm may assist the risk 
reduction.  
Post-operative AF and LA size 
Atrial arrhythmias such as AF are encountered frequently after cardiac and other surgeries 
and are associated with increased incidence of systemic thromboembolism and stroke, 
haemodynamic instability and prolonged hospital stay179. More recently LA volume has been 
thought to be a more accurate measure of LA size than LA diameter although both 
parameters have been shown to be markers of cardiovascular disease175. Echocardiographic 
LA volume has been estimated by the biplanar method and has previously been used as a risk 
predictor of AF in elderly outpatients180 and as a predictor of cardiovascular outcomes in 
patients with sinus rhythm. The relationship between LA size in AF patients and 




whom 106 had paroxysmal or permanent AF at baseline181.Osranek completed a study 
assessing incidence of post-operative atrial fibrillation and LA volume (LAV). In 205 
patients undergoing cardiac surgery, 84 patients developed AF and pre-operative LA volume 
was an independent predictor of AF. Patients with LAV > 32ml/m2 had an almost 5-fold 
increased risk of POAF independent of age and clinical risk factors (Adj HR 4.84 95% CI 
1.93-12.17, p= 0.001)182. We decided to determine LA diameter and left atrial volume pre-
operatively in patients and to evaluate whether they went on to develop AF.  We also decided 
to evaluate whether this measurement correlated with an increased risk of morbidity and 
mortality. Consideration was given as to whether this could assist with enhancing pre-





















Incomplete BNP data (n=9) 
  
Detail of missing data; 
Preop BNP levels: n=4 
Day 2 BNP levels: n=3 
Day 3 BNP levels: n=6 
Reasons for this include 
underfilled samples, lost samples 
and samples not taken 







Table 4.1 Mean and Median (IQR) of pre-operative BNP values in patients who 
did not develop AF. (total n=13) 
Pre op BNP values in pts who do not develop AF (pg/ml) n=12  
Mean 44.45 
Median 32 (63.05) 
 
Table 4.2 Mean and Median (IQR) of pre-operative BNP values in patients who 
did develop AF (total n=8) 
Pre op BNP values in pts who do develop AF (pg/ml) n=5 
Mean 44.45 
Median 35 (34.6) 
A Mann Whitney U test was conducted to compare the 2 groups above. Mann Whitney U 
value: 28 and p value: 0.873. 
Table 4.3 Mean and Median (IQR) of BNP values on day 2 in patients who did not 
develop AF total n=13 and also those who did develop AF total n=8 
  
A Mann Whitney test revealed a U value of 31and p-value: 0.53. 
Table 4.4 Mean and Median (IQR) of BNP values on day 3 in patients who did not 
develop AF total n=13 and also those who developed AF total n=8 
 
Mann Whitney U test revealed a U value of 11 and p-value was 0.098. 
Table 4.5 Difference in mean left atrial diameter (cm) for patients who developed 
AF post-operatively compared with those who did not. 
Timing of Echo 
Mean left atrial diameter 
(cm) on echo in pats who 
developed AF (n=3) 
Mean left atrial diameter (cm) on 
echo in pats who did not develop 
AF (total n=6) 
Pre-operatively 3.6 3.9 
Post-operatively 3.9 3.8 (n=2) 
 
 
The BNP values are non normally distributed and therefore Mann Whitney U tests were 
conducted on the data. In tables 4.1 and 4.2, the median pre-op BNP value in the group that 
went on to develop AF was 35 pg/ml and in the group that did not develop AF it was 32 
BNP values day 2 post op in patients without AF (pg/ml) n=11 BNP values day 2 post op in patients who develop AF (pg/ml) n=7
Mean: 140.02 Mean=199.69
Median: 75.6 (126.7) Median=109.2
BNP values day 3 post op in patients without AF (pg/ml) n=10 BNP values day 3 post op in patients who develop AF (pg/ml) n=5
Mean=107.39 Mean=219.48




pg/ml. The difference in the pre-op BNP values was not statistically significant. U= 28, p: 
0.873 (two tailed). 
Out of interest, I decided to study the day 2 and 3 BNP values in patients who developed AF 
and also in those who did not. In table 4.3 the median day 2 BNP value in the group that  
developed AF was 109.2 pg/ml and in the group that did not develop AF it was 75.6 pg/ml. 
The difference in the day 2 BNP values between groups was not statistically significant. 
Mann Whitney U=31, p: 0.53. 
In table 4.4 median day 3 BNP values in the group that developed AF was 105.7 pg/ml and in 
the group that did not develop AF it was 43.85 pg/ml. The difference in the day 3 BNP values 
between groups was not statistically significant. Mann Whitney U=11, p: 0.098. 
The reason for this could be that the sample sizes are too small. Also, although Mann 
Whitney U tests can be used for groups of different sizes, their ability to detect a difference 
between groups diminishes as the group sizes become more unequal. 
 
4.4 Discussion  
 
 Pre-operatively there were three BNP values that were registered as <10 pg/ml and these were 
included in the analysis. On day 2 there was one BNP result which registered as <10pg/ml 
and on day 3 there was another BNP result <10pg/ml and both were included in the analysis 
by recording them as values of 5. The limitations were that the numbers of patients were 
small and some BNP samples were missing due to blood samples being underfilled, 
misplaced in the labs and also BNP levels not being taken post-operatively due to the work 
pressures on the nursing staff in ICU. 
Due to small numbers of patients having an echocardiogram pre-operatively and post-
operatively it was difficult to draw any conclusions regarding left atrial diameter 




unfortunately due to lack of this expertise being available when patients went into AF, an 
echocardiogram was not always possible. Left atrial volume was not able to be calculated.  
In future, larger studies with a wider scope and resources could carry out multivariable 
logistic regression to analyse details of cardiac structure and function and levels of BNP in 
the context of developing AF. In addition to not only controlling for age and sex but also 
sedentary lifestyle, smoking, obesity, diabetes mellitus, hypertension, heart failure and 
myocardial infarction.  
 
4.5 Key messages 
• Peri-operative BNP values may be a useful adjunct in clinical risk stratification for 
patients undergoing oesophagectomy however this was a small pilot observational 
study and data were missing so conclusions could not be drawn. 
• Left atrial diameter and left atrial volume may be of use in clinical risk stratification 















4.6 Setting: Role of myeloperoxidase in onset of atrial fibrillation in oesophagectomy 
patients.  
 
The phagocytic enzyme myeloperoxidase (MPO) has been strongly associated with ongoing 
inflammation, vascular endothelial dysfunction and the development of atrial fibrillation.  We 
know that nitric oxide is a key regulator of cardiovascular endothelial function and it is 
thought to inhibit the adhesion of inflammatory cells to the vascular wall, the aggregation of 
platelets and the proliferation of smooth muscle cells. Reduction in synthesis and availability 
of NO has been recognised in combination with risk factors for cardiovascular disease and 
may promote atrial fibrillation. Research has suggested that MPO catalytically consumes 
nitric oxide (NO) in the presence of hydrogen peroxide (H2O2) and that MPO may act on NO 
at sites of inflammation, influencing its bioavailability183.In patients undergoing 
oesophagectomy we hypothesized that patients who develop atrial fibrillation and adverse 
cardiovascular outcomes will have higher levels of myeloperoxidase associated with vascular 
endothelial dysfunction and inflammation. Laboratory analytical methods for MPO are 
covered in more detail in chapter 2. 
4.7 RESULTS 
 



















  Incomplete MPO data pre-op until 
day 3 post-op (n=12) 
  
Detail of missing data: 
Preop MPO levels: n=6 
Day 0 MPO levels: n=2 
Day 1 MPO levels: n=3 
Day 2 MPO levels: n=4 
Day 3 MPO levels: n=5 
Reasons for this include lost 
samples and samples not taken 









Table 4.6 Mean and Median (IQR) of preop myeloperoxidase (MPO) values in 
patients who develop AF total n=8 and also those who do not develop AF total 
n=13 
 
Preop MPO AF (ng/ml) n=5 Preop MPO no AF (ng/ml) n=11 
Mean=380.5 Mean= 445.8 
Median=365.9(339.4) Median=248(407.85) 
 




Table 4.7 Mean and Median (IQR) of Day 0 (day of operation) myeloperoxidase 
(MPO) values in patients who develop AF total n=8 and also those who do not 
develop AF total n=13 
 
MPO Day 0 AF (ng/ml) n=8 MPO Day 0 no AF (ng/ml) n=12 
Mean=735.7 Mean=685.4 
Median=909.1(465.5) Median=785.3(608.4) 
 The Mann Whitney U-value is 45. The p-value: 0.8493.  
Table 4.8 Median (IQR) of Day 1 myeloperoxidase (MPO) values in patients who 
develop AF total n=8 and also those who do not develop AF total n=13 
MPO Day 1AF (ng/ml) n=7 MPO Day 1 no AF (ng/ml) n=11 
Median=499.9(270.6) Median=1000(456) 
 The Mann Whitney U-value is 21. The p-value: 0.12356.  
Table 4.9 Median (IQR) of Day 2 myeloperoxidase (MPO) values in patients who 
develop AF total n=8 and also those who do not develop AF total n=13 
MPO Day 2 AF (ng/ml) n=8 MPO Day 2 no AF (ng/ml) n=9 
Median=1000(140.45) Median=1000(38.4) 
 The Mann Whitney U-value is 34. The p-value: 0.88866. 
Table 4.91 Median (IQR) of Day 3 myeloperoxidase (MPO) values in patients who 
develop AF total n=8 and also those who do not develop AF total n=13 
MPO Day 3 AF (ng/ml) n=6 MPO Day 3 no AF(ng/ml) n=10 
Median=622.2(524.03) Median=1000(0) 





Figure 4.3 MPO levels (ng/ml) in patients pre-operatively and up to day 7 in 
patients that developed AF, identified by their age.  
 
Figure 4.4 MPO levels (ng/ml) in patients pre-operatively and up to day 7 in 





The MPO values are non normally distributed and therefore Mann Whitney U tests were 
conducted on the data. In table 4.6 the median pre-op MPO value in the group that went on to 
develop AF was 365.9ng/ml and in the group that did not develop AF it was 248ng/ml. The 











































































































0.496 (two tailed). I also decided to study the pre operative, day 0,1 2 and 3 MPO values in 
patients who developed AF and also in those who did not to determine whether MPO had a 
role in the onset of AF or not. In table 4.7 the median day 0 MPO value in the group which 
developed AF was 909.1ng/ml and in the group that did not develop AF it was 785.3ng/ml. 
The difference in the day 0 MPO values between groups was not statistically significant. 
Mann Whitney U= 45. The p-value: 0.8493. In table 4.8 median day 1 MPO values in the 
group that developed AF was 499.9 ng/ml and in the group that did not develop AF it was 
1000 ng/ml. The difference in the day 1 MPO values between groups was not statistically 
significant. Mann Whitney U= 21. The p-value: 0.12356.  
In table 4.9 median day 2 MPO values in the group that developed AF was 1000 ng/ml and in 
the group that did not develop AF it was 1000 ng/ml. The difference in the day 2 MPO values 
between groups was not statistically significant. Mann Whitney U= 34. The p-value: 0.88866. 
In table 4.91 median day 3 MPO values in the group that developed AF was 622.2 ng/ml and 
in the group that did not develop AF it was 1000 ng/ml. Mann Whitney U= The U-value is 
11. The p-value: 0.04444 which is significant. Therefore, the difference in the day 3 MPO 
values between groups was statistically significant, with the MPO levels being higher in the 




Some of the MPO values were capped at 1000 nanograms per ml, as the values were high. 
The reason for doing this is that samples with high MPO values were above the validated 
range that the kit measured and assigning a sensible value allowed them to be included in the 
statistical analysis. Ideally these samples should be re-assayed at a higher dilution, but that 
was not possible. The limitations were that the numbers of patients were small and some 
MPO samples were missing due to blood samples being misplaced in the labs and also MPO 




could have played a part in lack of sample taking was that nursing staff working on ICU had 
not all managed to attend the meetings that were hosted by the lead researcher, which briefed 
staff on the study and introduced them to the paperwork and how to identify which blood 
tube to use. The significant p value for the day 3 MPO values, despite small numbers, 
suggests that this warrants larger numbers and further investigation. Some of the reasons for 
this result could be that theoretically short episodes of AF might have been undetected in the 
group that did not develop AF, which could have caused the rise in MPO levels. A rise in 
MPO levels could be reflective of a post operative inflammatory process and there might be 
other patient factors that may have acted as protective factors. Due to the small numbers the 
lead researcher was unable to draw definitive conclusions based on the sample size. 
 
4.9 Key messages 
• Peri-operative MPO values and day 3 MPO levels in particular may be a useful 
adjunct in clinical risk stratification for patients undergoing oesophageal surgery, 




4.10 Setting: The role of Interleukin-6 (IL-6) and C-reactive protein (CRP) in patients 
who develop atrial fibrillation following oesophagectomy for oesophageal cancer 
and evaluation of effect on outcome. 
 
 Interleukin-6 (IL-6) 
 
IL-6 is a pleiotropic cytokine which means it affects the activity of multiple cell types. It acts 
in the acute phase reaction and is also involved in inflammation, haematopoiesis, bone 
metabolism, and cancer progression185. IL-6 production is generally correlated with cell 
activation and is normally kept under control by glucocorticoids, catecholamines, and 
secondary sex steroids. Normal human circulating IL-6 is in the 1 pg/ml range, with modest 




local lesion in the initial stage of inflammation, it moves to the liver through the bloodstream, 
followed by the rapid induction of an extensive range of acute phase proteins such as C-
reactive protein (CRP), serum amyloid A (SAA), fibrinogen and haptoglobin186. When 
dysregulated it contributes to chronic inflammation in conditions such as obesity, insulin 
resistance, inflammatory bowel disease, arthritis, and sepsis. IL-6 contributes to 
atherosclerotic plaque development and destabilization. Inflammatory biomarkers, including 
CRP and interleukin IL-6 are associated with the presence, persistence and outcome of AF in 
the general population. In my cohort, I wanted to determine whether there was any 
association between IL-6, AF and outcomes. Laboratory analytical methods for IL-6 are 
detailed in chaper 2. 
4.11 RESULTS 
 



























  Incomplete IL-6 data pre-op until 
day 3 post-op (n=12) 
  
Detail of missing data: 
Preop IL-6 levels: n=5 
Day 0 IL-6 levels: n=1 
Day 1 IL-6 levels: n=3 
Day 2 IL-6 levels: n=4 
Day 3 IL-6 levels: n=5 
Reasons for this include lost 
samples and samples not taken 






Table 4.92 Pre-op IL-6 values in patients who develop AF total n=8 and also those 
who do not develop AF total n=13 
 
Preop IL6 (ng/ml) no AF 
n=11 









2.0   
2.0   
4.2   
2.1   
Mean=2.6   
Median=2.1   
 
Conparing both groups preoperatively, the Mann Whitney U-value is 21.5. The p-value is 
.53526.  
Table 4.93 Day 0 IL-6 values in patients who develop AF total n=8 and also those 
who do not develop AF total n=13 
IL-6 Day 0 (pg/ml) no 
AF n=12 










600.0   
600.0   
600.0   
600.0   
Day 0 The Mann Whitney U-value is 35.5. The p-value is .35238. 
Table 4.94 Day 1 IL-6 values in patients who develop AF total n=8 and also those 
who do not develop AF total n=13 
IL-6 Day 1(ng/ml) no 
AF n=11 












144.7   
600.0   
379.8   
372.3   
Day 1 IL-6 The Mann Whitney U-value is 30.5. The p-value is .4965.  
 
Table 4.95 Day 2 IL-6 values in patients who develop AF total n=8 and also those 
who do not develop AF total n=13 
IL-6 Day 2 (ng/ml) no 
AF n=9 










473.6   
Day 2 The Mann Whitney U-value is 30.5. The p-value is .63122.  
 
Table 4.96 Day 3 IL-6 values in patients who develop AF total n=8 and also those 
who do not develop AF total n=13 
 
IL-6 Day 3(ng/ml) no 
AF n=10 








36.4   
214.7   
374.5   




Day 3 The Mann Whitney U-value is 21. The p-value is .35758.  
Table 4.97 Median IL-6 levels (pg/ml) in patients that did develop AF post-
operatively (total n=8) 
 
 
Timing of sample 
Median IL-
6(pg/ml) 
IQR Total patients n=8 
Pre-op 2.1 (2-299)297 n=5 
Day 0 590.35  (513.8-600)86.20 n=8 
Day 1 458.4 (239.3-600)360.70 n=7 
Day 2 117.35 (77.6-600)522.40 n=8 
Day 3 386.65 (50.8-600) 549.20 n=6 
Day 4 284.2 (49.5-600) 550.50 n=7 
Day 5 287.4 (112-600)488 n=7 
Day 6 166.95 (581.4-148) 433.40 n=8 
Day 7 397.4 (84.1-600)515.90 n=6 
 
 
Table 4.98 Median IL-6 levels (pg/ml) in patients that did not develop AF post-
operatively (total n=13) 
 
Timing of sample 
Median IL-
6(pg/ml) 
IQR Total patients n=13 
Pre-op 2.1 (2-2.8)0.80 n=11 
Day 0 600 (574.2-600)25.80 n=12 
Day 1 370.1 (280-600) 320 n=11 




Day 3 128.25 (62.9-214.7)151.80 n=10 
Day 4 73.7 (35.9-145.6)109.70 n=12 
Day 5 70.1 (45.4-144.8)99.40 n=10 
Day 6 50.9 (39-139)100 n=11 











Figure 4.6 IL-6 levels (pg/ml) in patients pre-operatively and up to day 7 in 






Figure 4.7 IL-6 levels (pg/ml) in patients pre-operatively and up to day 7 in 
patients that did not develop AF, identified by their age (total n=13) 
 
4.12 Setting: The role of Hs (high sensitivity) CRP in patients who develop AF 
following oesophagectomy for oesophageal cancer and evaluation of effect on 
outcome  
The large Danish study that was previously mentioned in the thesis found that elevated 
plasma CRP was robustly associated with increased risk of atrial fibrillation, although 
genetically elevated CRP levels were not. This suggested that elevated plasma CRP as such, 




























































association between inflammation and atrial fibrillation144.CRP is produced by hepatocytes in 
response to inflammatory cytokines such as IL-6188.CRP has been associated with 
cardiovascular, cerebrovascular and all-cause mortality. Conventional CRP assays that can 
accommodate very large increases have not been optimized for the highly sensitive detection 
of the low-level increases in values. CRP levels in apparently healthy individuals can be 
below 0.2 mg/L which requires high sensitivity or hs-CRP assays189. Laboratory analytical 
methods for hs CRP are detailed in chapter 2. 
 
4.13 RESULTS 































  Incomplete CRP data pre-op until 
day 3 post-op (n=12) 
  
Detail of missing data: 
Preop CRP levels: n=8 
Day 0 CRP levels: n=3 
Day 1 CRP levels: n=1 
Day 2 CRP levels: n=1 
Day 3 CRP levels: n=0 
Reasons for this include lost 
samples and samples not taken 





Table 4.99 Pre-op CRP values in patients who develop AF total n=8 and also those 
who do not develop AF total n=13 
Preop CRP (mg/L) 
AF n=5 









  3.8 
  Mean=1.56 
  Median=2.85 
The Mann Whitney U-value is 9. The p-value is .12356. 
 
Table 4.99.1 Day 0 CRP values in patients who develop AF total n=8 and also 
those who do not develop AF total n=13 
CRP Day 0 (mg/L) AF 
n=6 








  1.7 
  10 
  11 
  32 
  7.8 
  49 
The Mann Whitney U-value is 30. The p-value is .60306.  
Table 4.99.2 Day 1 CRP values in patients who develop AF total n=8 and also 
those who do not develop AF total n=13 
CRP Day 1 (mg/L) 
AF n=8 










  127 
  106 




  120 
The Mann Whitney U-value is 33.5. The p-value is .28014.  
 
Table 4.99.3 Day 2 CRP values in patients who develop AF total n=8 and also 
those who do not develop AF total n=13 
CRP Day 2 (mg/L) 
AF n=8 










  317 
  317 
  305 
  306 
The Mann Whitney U-value is 29. The p-value is .15272.  
Table 4.99.4 Day 3 CRP values in patients who develop AF total n=8 and also 
those who do not develop AF total n=13 
CRP Day 3 (mg/L) AF 
n=8 










  333 
  287 
  289 
  344 
  282 


















Median CRP(mg/L) IQR Total patients n=8 
Pre-op 0.7 (0.4-3.15) 2.75 n=5 
Day 0 12 (7.3-14) 6.70 n=6 
Day 1 94  (67.5-148.5)81 n=8 




Day 3 211 (154-264)110 n=8 








Day 6 167 (122-350)228 n=7 
Day 7 193 (149-314)165 n=7 
 
 


























Day 4 242 (182-258)76 n=13 


















The IL-6 results are non normally distributed and therefore Mann Whitney U tests were 
conducted on the data. In table 4.92 the median pre-op IL-6 value in the group that went on to 
develop AF was 2.1ng/ml and in the group that did not develop AF it was also 2.1ng/ml. U 
value: 21.5 and the p-value is .53526 (two tailed). Therefore, the difference in the pre-op IL-6 
values was not statistically significant. In a similar manner to other biomarkers, I also decided 
to study the day 0,1 2 and 3 IL-6 values in patients who developed AF and also in those who 
did not to determine whether IL-6 may have been associated with the onset of AF or not. In 
table 4.93 the median day 0 IL-6 value in the group which developed AF was 590.35 ng/ml 
and in the group that did not develop AF it was 600 ng/ml. The U-value is 35.5 and the p-
value is.35238. The difference in the day 0 IL-6 values between groups was not statistically 
significant. In table 4.94 the median day 1 IL-6 value in the group which developed AF was 
458.4 ng/ml and in the group that did not develop AF it was 370.1ng/ml. The U-value is 30.5 
and the p-value is .4965 which is not statistically significant. In table 4.95 the median day 2 
IL-6 value in the group which developed AF was 117.35ng/ml and in the group that did not 
develop AF it was 303.6ng/ml. The U-value is 30.5 and the p-value is .63122. In table 4.96 
the median day 3 IL-6 value in the group which developed AF was 386.65ng/ml and in the 
group that did not develop AF it was 128.25 ng/ml. The U-value is 21 and the p-value is 
.35758, which again does not reach statistical significance. Table 4.97 illustrates the median 
pre-operative IL-6 levels and also the daily IL-6 levels and interquartile ranges in those who 
develop AF post-operatively and table 4.98 demonstrates the results for those who do not. 
Figures 4.5 and 4.6 illustrate IL-6 levels (pg/ml) in patients pre-operatively and up to day 7 in 
patients that developed AF and those that did not. 
The CRP results do not follow a normal distribution. In table 4.991 the median pre-op CRP 




develop AF it was 2.85mg/L. The U-value is 9 and the p-value is .12356 (two tailed). I 
studied the day 0,1 2 and 3 CRP values in patients who developed AF and also in those who 
did not to determine whether CRP may have been associated with the onset of AF. 
In table 4.992 the median day 0 CRP value in the group which developed AF was 12mg/L 
and in the group that did not develop AF it was also 12mg/L. The U-value is 30 and the p-
value is .60306. The difference in the day 0 CRP values between groups was not statistically 
significant. In table 4.993 the median day 1 CRP value in the group which developed AF was 
94 mg/L and in the group that did not develop AF it was 108.5mg/L. The U-value is 33.5 and 
the p-value is .28014, which is not statistically significant. In table 4.994 the median day 2 
CRP value in the group which developed AF was 203.5mg/L and in the group that did not 
develop AF it was 287.5mg/L. The U-value is 29 and the p-value is .15272. In table 4.995 the 
median day 3 CRP value in the group which developed AF was 211 mg/L and in the group 
that did not develop AF it was 281 mg/L. The U-value is 30.5 and the p-value is .12852, 
which again does not reach statistical significance. Tables 4.996 and 4.997 illustrate the 
median pre-operative CRP levels and also the daily median CRP levels from days 0-7 and 
interquartile ranges in those who develop AF post-operatively and these values for those who 
do not.  
4.14 Discussion 
 In the analysis for IL-6, some of the very high extrapolated values were capped to 2 x the top 
standard; this value was 600pg/ml. The reason for doing this is that very high sample values 
are above the validated range that the kit will measure and assigning a sensible value allows 
them to be included in the statistics. Ideally these samples should be re-assayed at a higher 
dilution, but that was not possible. We know that IL-6 levels are raised in certain types of 
cancer and following surgery and it would be useful to have a baseline level of increases 




The limitations were that the numbers of patients were small and some IL-6 samples were 
missing due to blood samples being misplaced in the labs and also IL-6 levels not being taken 
post-operatively due to the work pressures in ICU. 
The main limitation for CRP analysis was the missing samples which mainly affected the pre-
operative values as detailed on figure 4.7. This happened due to clinical commitments and 
personally not being able to attend every preoperative clinic to take bloods so this task was 
delegated to the pre assessment nursing staff. I had met with the staff and we had discussed 
the study and the bloods required and the location of the pre labelled request forms. However, 
the large pool of nursing staff meant that these forms were not used and therefore CRP was 
not requested as it is not a routine pre operative test.  
 
4.15 Key messages 
• Perioperative IL-6 and CRP may be helpful in clinical risk stratification for patients 
undergoing oesophageal surgery, however the numbers in the cohort were small and  




5 CHAPTER 5 
DOES THE USE OF THE MODIFIED GLASGOW PROGNOSTIC SCORING 
SYSTEM (MGPS) PRE-OPERATIVELY AND POST-OPERATIVELY (POGPS) 
ASSIST IN DETERMINATION OF ASSOCIATIONS WITH MORBIDITY AND 
MORTALITY IN OESOPHAGECTOMY PATIENTS?  ARE THE RESULTS OF 
SERIAL POST OESOPHAGECTOMY CARDIOPULMONARY (CPET) TESTS AND 
QUALITY OF LIFE (QOL) ASSOCIATED WITH EACH OTHER? 
5.1 Setting: Evaluation of use of modified Glasgow Prognostic scoring system 
(mGPS) pre-operatively and post-operatively (pomGPS) to look at 
associations with morbidity and mortality in oesophagectomy patients 
The presence of malignancy is known to be associated with systemic inflammatory response. 
There is evidence that markers of systemic inflammatory response such as CRP and albumin 
have independent prognostic value in patients with cancer191,192.The mGPS has been shown 
to be more sensitive than GPS where 0 points are allocated for CRP </=10mg/L and albumin 
≥ 35g/L. CRP >10mg/L allocates 1 point and CRP >10mg/L and albumin <35g/L allocates 2 
points193.The post-operative mGPS has been utilised to independently predict overall 
survival in patients with localised clear cell renal cell cancer194 and in light of the fact 
that the mGPS has been validated in a wide range of cancer scenarios I wanted to 
evaluate the use of the scoring systems in this cohort. 
5.2 RESULTS 
 

















  Incomplete albumin data pre-op 
until day 3 post-op (n=11) 
  
Detail of missing data: 
Preop albumin levels: n=8 
Day 0 albumin levels: n=2 
Day 1 albumin levels: n=0 
Day 2 albumin levels: n=1 
Day 3 albumin levels: n=0 
Reasons for this include lost 
samples and samples not taken 













Table 5.0 Pre-op albumin (Alb) values in patients who develop AF total n=8 and 
also those who do not develop AF total n=13 
Pre-op Alb (g/L) 
AF n=5 







Mean: 36.2 39 
Median: 37 37 
  36 
  Mean=38.88 
  Median=38 








Table 5.1 Day 0 albumin (Alb) values in patients who develop AF total n=8 and 
also those who do not develop AF total n=13 
Day 0 Alb (g/L) AF 
n=7 











  20 
  30 
  24 
  Mean=27.58 




 Mann Whitney U-value is 38. The p-value is .76418.  
 
Table 5.2 Day 1 albumin (Alb) values in patients who develop AF total n=8 and 
also those who do not develop AF total n=13 
Day 1 Alb (g/L) 
AF n=8 












  19 
  29 
  23 
  Mean=23.92 
  Median=23 






Table 5.3 Day 2 albumin (Alb) values in patients who develop AF total n=8 and 
also those who do not develop AF total n=13 
Day 2 Alb (g/L) 
AF n=7 











  22 
  21 
  25 
  20 
  Mean=22.69 
  Median=24 




Table 5.4 Day 3 albumin (Alb) values in patients who develop AF total n=8 and 
also those who do not develop AF total n=13 
Day 3 Alb (g/L) 
AF n=8 












  18 
  24 
  20 
  Mean=21.23 
  Median=21 
The Mann Whitney U-value is 46. The p-value is .68916. 
 
Table 5.5 Post-operative Glasgow Prognostic Scores (po mGPS) from day of 
operation  (D0) up to day 7 (D7) post-operatively in patients who develop AF (n=5) 
 
Table 5.6 Post-operative Glasgow Prognostic Scores (po mGPS) from day of 
operation (D0) up to day 7 (D7) post-operatively in patients who do not develop 
AF (n=10)  
 
Sex Age  D0 po GPS  D1 po GPS  D2 po GPS  D3 po GPS  D4 po GPS  D5 po GPS  D6 po GPS  D7 po GPS
Male 62 yr 2 2 2 2 2 2 2 2
Female 65 yr 2 2 2 2 2 2 2
Male 73 yr 0 2 2 2 2 2 2
Male 53 yr 2 2
Male 60 yr 0 2 2 2 2 2 2
Sex Age  D0 po GPS  D1 po GPS  D2 po GPS  D3 po GPS  D4 po GPS  D5 po GPS  D6 po GPS  D7 po GPS
Male 53yr 2 2 2 2 2 2 2 2
Male 53yr 2 2 2 2 2 2 2 2
Male 54yr 2 2 2 2 2 2 2 2
Male 56yr 2 2 2 2 2 2 2
Male 60yr 2 2 2 2 2 2 2
Male 64yr 0 2 2 2 2 2 2 2
Male 64yr 2 2 2 2 2 2 2 2
Male 65yr 1 2 2 2 2 2 2 2
Male 66yr 2 2 2 2 2 2 2 2
Male 69 yr 0 2 2 2 2 2 2 2
Male 72yr 2 2 2 2 2 2 2 2
Male 73yr 0 2 2 2 2 2 2 2





The data was non normally distributed and so the Mann Whitney U test was used. In 
comparing the patient group that developed AF and the one that did not, from pre operatively 
to day 3 post-operatively, none of the p-values were statistically significant. One of the 
reasons for this was the small sample size. 
All patients who developed AF post-operatively had a pre-operative mGPS score of 0 and 
one patient had a score of 0 on day 0. Six patients developed AF on day 2, the 53 year old 
patient developed AF on day 3 and the 73 year old patient on day 4. The 73 year old patient 
died on day 30. Three patients had cardiorespiratory complications. In the group that did not 
develop AF, one patient had an mGPS score of 1 pre-operatively and three patients had a 
score of 0 on day 0.  Two patients died, one at 58 days and 5 patients had cardiorespiratory 
complications. The calculation of po mGPS is incomplete due to lack of albumin and CRP 
levels resulting from blood tests being unable to be completed and blood samples being lost. 
Regarding the usefulness of poGPS in patients undergoing oesophageal surgery, due to the 
small numbers in this cohort we are unable to draw any conclusions. More recently studies 
concerning 12,000 patients have resulted in an optimised score (termed the optimised 
Glasgow Prognostic Score, oGPS) composed of high sensitivity C-reactive protein (>3mg/l), 
albumin (<35g/l), neutrophil (>7.5 x 109) and platelet (>400 x 109) counts that had a superior 
predictive value when compared with the established GPS.193 This could form the basis of 
future work with a larger cohort. 
5.4 Setting: Pre-operative Cardiopulmonary (CPET) testing, sequential testing and 
evaluation of relationship with Quality of Life (QoL). 
As previously mentioned, regarding sequential CPET testing, a literature search revealed no 
studies that have quantified post-operative fitness and quality of life in this population. 
We originally wanted to assess whether there were differences in serial CPET tests at 6 
months, 1 year and 2 years following oesophagectomy, compared with baseline pre-operative 




possible outcomes of an operation as it is important in morbidity risk prediction and 
information provided for patients. Whilst QoL pre-operatively and post-operatively have 
been compared in this population, comparing post-operative QoL with post-operative fitness, 
as determined by CPET test results in patients who have undergone oesophagectomy, had not 
been studied before and so we wanted to determine whether a relationship existed between 
CPET results and patient’s reported QoL. 
5.5 RESULTS 
Table 5.7 Pre-operative Cardiopulmonary Exercise Test (CPET) results for 
patients who develop AF. Anaerobic Threshold (AT) (ml/min/kg) and maximum 
rate of oxygen consumption (VO2 peak) (ml/kg/min) (n=5) Mean AT: 12.0 
ml/min/kg. Mean VO2 peak: 19.2ml/kg/min. 
AGE (yrs) CPET:AT (ml/min/kg)   VO2 peak(ml/kg/min) 
53 15.4 22.1 
57 13.2 17.8 
60 NO CPET   
62 NO CPET   
65 11.9 18.8 
66 10.1 20.9 
73 10.3 16.3 
76 NO CPET   
Mean=64 Mean=12.18 Mean=19.18 
Median=63.5 Median=11.9 Median=18.8 
 
Table 5.8a Post-operative medical and surgical complications in all patients who 
develop AF (n=8) 
 
Age Medical complicn Details: Cardiorespiratory/ Non cardioresp Surgical complicn Details Deceased at 30 days
(yr)
53 Y Non cardiorespiratory: raised WCC/ CRP N N
57 Y Cardiorespiratory: pleural effusions Y Anastomotic leak N
60 Y Cardiorespiratory: chest sepsis Y Hydropneumothorax N
62 Y Cardiorespiratory and AKI Y Dehiscence of roof top incision N
65 Y Cardiorespiratory: respiratory failure+ delirium Y  Pneumothorax N
66 N N N
73 Y Cardiorespiratory: sepsis Y Intraop splenectomy+ blood transfusion Y





Table 5.8b Binomial logistic regression to determine relationship between pre-
operative maximum rate of oxygen consumption (VO2 peak) (ml/kg/min) and 
development of medical complications post-operatively in patients who develop 
AF. 
 
  Coefficient Std error z value p value (Wald) 
Intercept 13.25 14.95 0.89 0.38 
VO2 peak -0.59 0.73 -0.82 0.41 
 
Table 5.8c Binomial logistic regression to determine relationship between pre-
operative Anaerobic Threshold (AT) (ml/min/kg), age of patient and development 
of surgical complications post-operatively in patients who develop AF.  
  Coefficient Std error z value p value (Wald) 
Intercept -41.87 50.29 -0.83 0.41 
AT 1.14 1.53 0.74 0.46 
Age( yr) 0.46 0.52 0.87 0.38 
 
Table 5.8d Binomial logistic regression to determine the relationship between pre-
operative Anaerobic Threshold (AT) in (ml/min/kg), maximum rate of oxygen 
consumption (VO2 peak) (ml/kg/min) and age of patient with development of AF 
 
  Coefficient Std error z value p value (Wald) 
Intercept 18.03 13.45 1.34 0.18 
AT -0.54 0.49 -1.08 0.28 
VO2 peak -0.19 0.25 -0.79 0.43 
Age (yr) -0.12 0.1 -1.16 0.25 
 
Table 5.9a Pre-operative Cardiopulmonary exercise test (CPET) results for all 
patients who do not go on to develop AF. Anaerobic threshold (AT) and maximum 
rate of oxygen consumption (VO2 peak) (n=11) Mean AT:12.6ml/min/kg. Mean 
VO2 peak: 20.1ml/kg/min 
AGE (yrs) CPET:AT (ml/min/kg)   VO2 peak(ml/kg/min) 
53 11.9 19.4 
53 13.8 23.3 
54 9.7   
56 13 23.5 
60 NO CPET   
64 NO CPET   
64 14.1 22.2 
65 12.7 27.7 
66 13.7 17.6 




72 11.3 15 
73 13 15.3 
84 13.3 16.9 
Mean=64.08 Mean=12.58 Mean=20.13 
Median=64 Median=13 Median=19.9 
 
Table 5.9b Post-operative medical and surgical complications in all patients who 
do not develop AF 
 
 
Table 5.9c Binomial logistic regression to determine the relationship between pre-
operative Anaerobic Threshold (AT) in (ml/min/kg), maximum rate of oxygen 
consumption (VO2 peak) (ml/kg/min) and development of medical complications 
post-operatively in patients who do not develop AF 
  Coefficient Std error z value p value (Wald) 
Intercept -2.85 11.2 -0.25 0.79 
AT 1.14 1.06 1.07 0.28 




Table 5.9d Binomial logistic regression to determine the relationship between pre-
operative Anaerobic Threshold (AT) in (ml/min/kg), maximum rate of oxygen 
consumption (VO2 peak) (ml/kg/min) age of patient and development of surgical 
complications post-operatively in patients who do not develop AF 
  Coefficient Std error z value p value (Wald) 
Intercept 3.56 15.83 0.23 0.82 
Age
(yr)
53 Y Cardiorespiratory : pleural effusion Y Oesophageal tear on OGD, leading effusion N
53 N N N
54 N Y Discharging wound N: 58days ? PE
56 N N N
60 N N N
64 N Y Erosion of chest drain into gastric staple line and into oesophagus N
64 N N N
65 N Y Post op apical pneumothorax N 
66 Y Cardiorespiratory : pleural effusion/type 1 resp failure/ cardiac failure/ C diff N N
69 N Y Required dilatation of anastomotic stricture N
72 N Y Wound infection and collection N
73 Y Cardiorespiratory:Type 1 resp failure  N N
84 Y Cardiorespiratory: Aspiration pneumonia + delirium Y Recurrent laryngeal nerve damage: left vocal cord palsy Y




AT -2.35 1.63 -1.45 0.15 
Age (yr) 0.23 0.18 1.27 0.2 
VO2 peak 0.63 0.56 1.131 0.26 
 
Table 5.9e Pre-operative Cardiopulmonary exercise test (CPET) Anaerobic 
threshold (AT) results for all patients who do not go on to develop AF (total n=13) 
compared with those who do go on to develop AF (total n=8) 






9.7 NO CPET 
13 NO CPET 
NO CPET 11.9 
NO CPET 10.1 
14.1 10.3 
12.7   
13.7   
11.9   
11.3   
13   
13.3   
 
Comparing the groups, the Mann Whitney U-value is 23. The p-value is .65272. 
 
Table 5.9f Pre-operative Cardiopulmonary exercise test (CPET) VO2 peak results 
for all patients who do not go on to develop AF (total n=13) compared with those 
who do go on to develop AF (total n=8) 
  VO2 peak(ml/kg/min) no 
AF n=10 




    
23.5   
  18.8 
  20.9 
22.2 16.3 
27.7   
17.6   
20.4   




15.3   
16.9   
The Mann Whitney U-value is 22. The p-value is .75656.  
5.6 Discussion 
The CPET results could not be assessed in context of the QoL due to a colleague being 
unable to complete that part of the study due to ill health.  
Pre-operative Cardiopulmonary Exercise Test (CPET) AT and VO2 peak results for patients 
who developed AF and those who did not were evaluated. 
Table 5.7 illustrates the pre-operative cardiopulmonary exercise test results for patients who 
develop AF. Three, out of eight patients did not undergo CPET testing and 2 patients had 
anaerobic thresholds lower than 11ml/min/kg. Table 5.8a demonstrates that 5 patients in the 
group who developed AF post-operatively had cardiorespiratory complications and one 
patient had non cardiorespiratory complications. All of the patients who had medical 
complications also had surgical complications.  
Out of interest, I used binomial logistic regression to explore the relationship between the 
maximal rate of oxygen consumption and medical complications post-operatively in patients 
who develop AF. It was not possible to create an additive model with AT and VO2 peak in 
the context of the development of medical complications and AF. A model which combined 
VO2 peak, AT, age of patient in the context of development of AF was created. Out of 
interest, bearing in mind that the sample size was 5, a multivariable regression model was 
created to evaluate the relationship between AT, age of patient and surgical complications in 
patients who developed AF post-operatively. It was not possible to extend this model to 
include VO2 peak.  The regression model did not demonstrate statistical significance. Table 
5.9a illustrates the pre-operative cardiopulmonary exercise test results for patients who did 
not develop AF. Two out of thirteen patients did not undergo CPET testing and one patient 




patients who did not develop AF post-operatively, developed cardiorespiratory complications 
and of the 4, 2 developed surgical complications. Five patients had surgical complications 
without medical complications. To explore the relationship between the maximal rate of 
oxygen consumption and medical complications post-operatively in patients who do not 
develop AF, binomial logistic regression was used. It was possible to create an additive 
model with AT and VO2 peak in the context of the development of medical complications in 
this patient group. Again, out of interest, the relationship between AT, VO2 peak, age of 
patient and surgical complications was also evaluated in table 5.9d, but it did not demonstrate 
statistical significance. In tables 5.9e and 5.9f, I decided to compare pre-operative 
Cardiopulmonary exercise test (CPET) AT and VO2 peak results for all patients. This 
included those who do not go on to develop AF with those who do go on to develop AF, to 
see if there was a statistically significant difference between the two groups using Mann 
Whitney U tests. There was not a statistically significant difference between the AT and VO2 
peak results in patients that did develop AF when compared with those who did not. The 
limitations include small numbers and missing CPET studies and results. 
 
5.7 Challenges regarding the sub-study concerning serial CPET testing and 
relationship to QoL 
 Serial CPET testing and evaluation of QoL was determined to be a sub-study. The patient 
information leaflet, consent form, study protocol and GP information were duly changed in 
May 2013 and an application was made to the REC committee for a substantial amendment. 
The REC committee advised that a letter of invitation was developed to ensure that patients 
did not feel pressurised to consent to further CPET tests. This was developed in addition to 
ensuring that the aforementioned information was updated. 
This sub-study planned to obtain consent from patients to perform CPET tests at 6 months, 12 




paperwork to facilitate this was completed but the sub-study was never commenced due to a 









6 CHAPTER 6 
CAN WE APPLY THE CHARLSON AGE COMORBIDITY INDEX (CACI) TO THE 
COHORT AND USE THIS IN ADDITION TO BIOMARKERS, CPET RESULTS 
AND DEVELOPMENT OF AF TO HELP A BETTER UNDERSTANDING OF 
FACTORS INFLUENCING THE DEVELOPMENT OF AF AND ASSOCIATED 
MORBIDITY AND MORTALITY IN PATIENTS UNDERGOING 
OESOPHAGECTOMY? 
6.1 Setting: The Charlson Age-Comorbidity Index (CACI) 
The Charlson Age-Comorbidity Index (CACI) which is a combined age-comorbidity score 
was validated for the prediction of long-term mortality in patients undergoing non cardiac 
elective surgery that had essential hypertension or diabetes mellitus27.It accounts for the 
patient’s age and 16 conditions and uses the International Diagnosis of Diseases (ICD) 
diagnosis codes. The CACI has been validated in a number of surgical cohorts and it has been 
found to be a moderately accurate tool27. In a colorectal surgery cohort, it was found to be a 
predictor of in hospital morbidity, duration of hospital stay and mortality29.In light of this, I 
wanted to investigate whether combining biomarkers, CPET results and CACI would assist in 
understanding the mechanisms leading to the development of AF and increased mortality in 




Table 6.1 Charlson Age Co-morbidity Index (CACI), Anaerobic threshold (AT) 
and  cardiovascular biomarkers in the context of complications (table 8.2) in 
patients who did  not develop AF (n=13) 
 
Age yrs CACI score Estim RR death CPET:AT (ml/min/kg) MPO (ng/ml) (median d0-2) BNP(pg/ml)(preop) IL-6 (pg/ml)(median d0-2) CRP (mg/L) (median d0-2)
53 3 3.04 11.9 479.9 124.2 379.8 108.5
53 7 13.37 13.8 796.4 28.5 296.9 287
54 3 3.04 9.7 800.4 26.9 461.2 69
56 5 6.38 13 533.7 <10 430.8 27
60 8 19.37 NO CPET 80
64 4 4.4 NO CPET 1000 <10 144.7 69.5
64 6 9.23 14.1 1000 15.7 486.2 84.5
65 8 19.37 12.7 1000 <10 94.7 95
66 4 4.4 13.7 287.5 35.5 394.4 62.5
69 8 19.37 11.9 657.9 42.5 394.4 46.8
72 10 19.37 11.3 440.3 73.3 451.8 106
73 11 19.37 13 1000 84.4 473.6 106




Table 6.2 Medical and Surgical complications in patients who did not develop AF 




Table 6.3 Charlson Age co-morbidity index (CACI), Anaerobic threshold (AT) 
and  cardiovascular biomarkers in the context of complications in patients who 
did develop AF (n=8) 
 




Table 9.1 combines the results of Charlson Age Co-morbidity Index and the estimated 
relative risk of death with pre-operative AT values and pre-operative median values for BNP 
Age
(yr)
53 Y Cardiorespiratory : pleural effusion Y Oesophageal tear on OGD, leading effusion N
53 N N N
54 N Y Discharging wound N: 58days ? PE
56 N N N
60 N N N
64 N Y Erosion of chest drain into gastric staple line and into oesophagus N
64 N N N
65 N Y Post op apical pneumothorax N 
66 Y Cardiorespiratory : pleural effusion/type 1 resp failure/ cardiac failure/ C diff N N
69 N Y Required dilatation of anastomotic stricture N
72 N Y Wound infection and collection N
73 Y Cardiorespiratory:Type 1 resp failure  N N
84 Y Cardiorespiratory: Aspiration pneumonia + delirium Y Recurrent laryngeal nerve damage: left vocal cord palsy Y
Surgical complicn Details Deceased at 30 daysMedical complicn Details: Cardiorespiratory/ Non cardiorespiratory
Age (yrs) AF onset (day) CACI score Est RR death CPET:AT (ml/min/kg) MPO (ng/ml) (median d0-2) BNP(pg/ml)(preop) IL6 (pg/ml)(median d0-2) CRP (mg/L) (median d0-2)
53 3 3 3 15.4 994.3 180.8 127.5
57 2 3 3 13.2 872.3 35 92.9 187
60 2 4 4.4 NO CPET 763.3 304.1 86
62 2 5 6.4 NO CPET 660.6 68.5 468.4 38
65 2 8 19.4 11.9 956.5 71.2 600 102
66 2 8 19.4 10.1 794 19.6 600 7.3
73 4 9 19.4 10.3 510.2 33.9 600 62
76 2 5 6.4 NO CPET 145.9 112.4 72
Age Medical complicn Details: Cardiorespiratory/ Non cardioresp Surgical complicn Details Deceased at 30 days
(yr)
53 Y Non cardiorespiratory: raised WCC/ CRP N N
57 Y Cardiorespiratory: pleural effusions Y Anastomotic leak N
60 Y Cardiorespiratory: chest sepsis Y Hydropneumothorax N
62 Y Cardiorespiratory and AKI Y Dehiscence of roof top incision N
65 Y Cardiorespiratory: respiratory failure+ delirium Y  Pneumothorax N
66 N N N
73 Y Cardiorespiratory: sepsis Y Intraop splenectomy+ blood transfusion Y




and day 0-2 median values for MPO, IL-6 and CRP in patients who did not develop AF. 
Table 9.3 combines the results of Charlson Age Co-morbidity Index and the estimated 
relative risk of death with pre-operative AT values and pre-operative median values for BNP 
and day 0-2 median values for MPO, IL-6 and CRP in patients who did develop AF. A mixed 
effects model was attempted to analyse the data and create a risk stratification score based on 
the Charlson Age-Comorbidity Index, in addition to biomarkers, CPET results and 




7 CHAPTER 7 
THE CHALLENGES WITH CONDUCTING THE STUDY 
7.1 Background 
This study began due to my interest in patients who developed atrial fibrillation post-
operatively as I had evaluated a cohort of patients on ICU who had AF. Knowing that AF was 
associated with significant morbidity and mortality I hypothesized whether it would be 
possible to predict its development in patients post-operatively and therefore potentially 
prevent morbidity and mortality.  
I selected oesophageal surgery as I knew that oesophagectomy operations were carried out at 
the GRI and on the basis of the number of operations that were undertaken, that it might be 
possible to recruit at least 40 patients over a period of 9 months. It was clear that recruiting 
40 patients would be a suitable number for a feasibility study. On initial assessment, it 
appeared that the patients would have a distinct pathway leading to their surgery and 
therefore this could be helpful in deciding when to do investigations and when to consent 
patients. I had also read about the use of different biomarkers and their potential to predict 
AF and wanted to evaluate what role they might play in its development. I discussed my 
concept with my supervisors and I wrote the protocol for my study.  
7.2 Ethics applications and amendment 
I made an application to the Research Ethics Committee and attended the meeting which was 
held on the 27th September 2012. The members of the committee gave a favourable ethical 
opinion of the study. Research and Development approval was sought from and granted by 
the NHS host organisation prior to commencement of the study. Following further 
discussions with colleagues, I submitted an application to the Research Ethics Committee for 
an amendment to the study to evaluate the impact that oesophagectomy has on the perceived 
quality of life of the patient and also the effect it might have on cardiopulmonary exercise 




Committee agreed to this piece of work becoming a sub-study instead of an amendment and 
as such, it was approved. Unfortunately, this piece of work never came to fruition due to 
illness of a colleague, therefore meaning that they were unable to assist with it. I had also 
intended to study urinary ADMA and SDMA. Due to sample losses and therefore missing 
data, this was not feasible. Additionally, I collected blood results, including liver function 
tests and kidney function for patients and had intended to analyse these in relation to 
development of AF. 
I commenced the study with a protocol and associated paperwork which included a patient 
pathway. This initially appeared to be straightforward, however this turned out not to be the 
case. 
Monitoring and evaluation of a study’s conduct is vital. As a result of monitoring the study as 
it progressed, I was able to evaluate its quality and move towards a vision of how the study 
could be optimised. There were several important points in the study detailed below that 
provided the opportunity for improvement if the study were to be repeated in future. 
7.3 Study interventions based on perceived patient pathway from identification to 
operation  
In Scotland, there is a commitment to delivering the National Cancer Quality programme, 
‘Beating Cancer: Ambition and Action’ across NHS Scotland,198with a recognised need for 
National Cancer Quality Performance Indicators (QPI)s to support a culture of continuous 
quality improvement. Patients who require oesophageal surgery are identified at the 
multidisciplinary team (MDT) meetings which are attended by surgeons, oncologists and 
radiologists, in addition to other team members. Patients will often have ‘tumour, node, 
metastasis’ (TNM) stage and treatment intent stated at the multidisciplinary team meeting and 
those undergoing surgical resection should be offered neoadjuvant chemotherapy. 
Neoadjuvant chemotherapy or chemoradiotherapy prior to surgery provides a survival benefit 




Figure 7.1 Study interventions based on perceived peri-operative pathway for 
oesophagectomy patients  
 
  
 Contact Upper GI secretaries to get list 
of patients attending for oesophageal 
surgery. Patient study information leaflet 
(PIL) sent with Cardiopulmonary 
Exercise Testing (CPET) appointment 
information to home  
 
 
Approach patient at appointment for 
CPET testing and give opportunity to 
ask questions about study and also give 
out a PIL if required. 
 
Consent process following pre-operative 
clinic appointment with anaesthetist. 
Baseline bloods, ECG and urine if 
possible and echo might be completed. 
 
 
Evening before surgery: complete 
admission baseline bloods (if required), 




Daily patient follow-up: Post-op bloods, 
urine and ECG on ICU and echo as per 





 Identification of patients who are deemed to require oesophageal surgery required frequent 
liaison with the secretaries working with the Upper Gastrointestinal (GI) consultants, as it 
was not possible for me to attend MDT meetings where the decisions were originally made, 
due to my clinical commitments. 
7.4 Patient information and investigations 
It was challenging to discover that there was no standardised timeline and pathway for 
patients’ visits to hospital regarding pre-operative investigations such as CPET following 
their neoadjuvant chemotherapy. The next step in the pathway was to give patients 
information and also to approach them prior to their admission and ensure that they had some 
bloods taken. Due to this lack of standardisation, the number of opportunities to talk to 
patients about the study and also to give them a patient information sheet was affected. This 
also led to inconsistencies regarding the requesting and completion of pre-operative 
echocardiograms and blood tests. 
7.5 Admission to hospital 
Patients awaiting oesophageal surgery were admitted on the evening of the day prior to 
surgery. These admissions happened at inconsistent times and so it was a labour intensive 
exercise for me to attend hospital at the correct time to review the patient and to ensure that 











Figure 7.2 Perceived peri-operative investigation pathway for oesophagectomy 
patients  
Liaise with ICU nurses to 
ensure understanding of aims 







Daily collection of blood, 
urine and recording of 
patient's rhythm and ECG, 
echo if required. Blood tubes 
and urine pots provided for 
nurses. 
 
Daily completion of 
paperwork by ICU nurses. 
 
 
Transfer of samples to labs for 





For information sheet to assist nursing staff understand the practicalities of study see 
appendix (pg 173-176) 
7.6 Recording of cardiac rhythm 
Post-operatively it was challenging to record the onset of atrial fibrillation as due to my on 




on ICU regarding the study and how to record different parameters as well as sharing a 
guidance sheet for the study, however, frequently no specific time of onset or duration of AF 
was recorded. The ECGs were often not done due to patient agitation or nurses having 
insufficient time. Time pressures also led to the daily document, which was created to 
monitor these investigations being inconsistently completed by nursing staff on ICU. The 
protocol also detailed that patients who developed AF required an echocardiogram from a 
dedicated consultant whose contact details were provided. Again, due to time pressure and 
availability of the staff on ICU, inconsistent contact was made with the consultant who 
carried out echos when patients went into AF. This led to several opportunities to complete 
this investigation being missed. 
7.7 Laboratory sample collection and transport 
The collection of blood and urine samples and their transportation to the labs was not a 
standardised process and depending on the time of day that the blood and urine samples were 
taken, a porter, a nurse or sometimes the chief investigator delivered them to the labs. This 
process varied depending on whether the samples were taken in, or out of hours. As part of 
the study protocol, within the labs there was a box for samples which was specifically for the 
study. I had negotiated with the biochemistry lab and there was a verbal agreement that the 
box should be emptied regularly. However, there was inconsistent transfer of the samples into 
the study box and therefore some samples did not arrive in the labs and did not get processed. 
7.8 Storage of samples 
The study samples were stored in one laboratory freezer, which was set at -60oC. This freezer 
was situated in a hospital corridor remote from the laboratories. Prior to the study 
commencing I had not completed a risk assessment regarding the sample storage and I had 
made assumptions about how laboratories would manage their storage of study samples. The 




them defrosting as the breakdown was not picked up until Monday morning. This resulted in 
14 serum samples, in addition to multiple urine samples being unable to be salvaged. 
 
Figure 7.3 Photographs of remote laboratory freezer at the GRI 
 
7.9 Freezer breakdown 
After the event, I enquired about the cause of the freezer breakdown and I was informed that 
it was due to the compressor within it breaking. I further enquired as to the governance of the 
laboratory freezers and was told that it was the responsibility of the Clinical Pathology 
Accreditation (CPA). I was told that the freezer in question was 3 years old and that this 
freezer had not previously broken down. Due to the freezer being located at a distance from 
the laboratory this resulted in the breakdown being missed, as the alarm system for the 
laboratories was not connected to the remote freezer and over weekends and out of hours 




7.10 Governance of freezers in laboratories 
After the incident regarding the freezer breakdown, I discussed the laboratory governance 
process and whether there had been a critical incident lodged and a root cause analysis 
completed. I also enquired if there had been a contingency plan for freezer failure prior to this 
event. I was informed that a critical incident form was not lodged as there was no 
requirement in the laboratory for this, due to the lost samples not being part of a clinical trial. 
I also enquired as to whether governance guidelines had been changed or created since the 
freezer breakdown. At the time that the incident occurred there was no governance regarding 
how samples were sorted and placed in a freezer and no consideration regarding minimisation 
of the potential risk of sample loss if the freezer broke down, in terms of separating samples 
from the same study between freezers. There exists very clear mandatory guidance about 
what should happen to samples from clinical trials and how samples are stored. There was no 
clear guidance for the samples that are not involved in clinical trials, such as research samples 
and in this case, the onus is on the lab. 
Of note, there is no British regulation for laboratory freezers. I was informed that since 2017 
there has been a change in accreditation in the laboratory where the freezer was based and it 
is now United Kingdom Accreditation Service (UKAS) accredited. UKAS provides 
accreditation to the internationally recognised standard ISO 15189 which details Medical 
Laboratories requirements for quality and competence.  This has resulted in clear guidelines 
detailing how the freezers are now alarmed. The alarm system is connected to the main 
laboratory and as a result, remote freezers are now monitored 24 hours a day and 7 days a 
week. The labs are subject to annual review by UKAS and they are inspected annually as part 






Figure 7.4 Study consort diagram 
 





40 patients went forward for 
oesophagectomy 
 
1 patient: pre-existing AF 
1 patient: daughter had breast 
cancer requiring treatment 
2 patients: inoperable 
1 patient: palliation  
 
14 serum samples lost when 





In the event that a similar study might be repeated in the future, the lead researcher reflected 
on which aspects of it they might be able to improve. The ability to standardise the patient 
pathway from selection for surgery until the operation would enable a more streamlined 
consent process for the patient and also for optimising investigations. Following this study, 
the centralisation of oesophageal surgery on one site has been a key factor, resulting in 






The technology exists for the ability to record the onset of AF and measure its duration. This 
could be programmed and preset on the monitors on ICU and when patients developed this 
rhythm, an automatic rhythm print out could be produced. This would minimise work for the 
nursing staff. Frequently, dysrhythmias are empirically treated on ICU with electrolytes, 
fluids and rate controlling medication. An automated identification of AF would be helpful in 
providing information about the precise onset and duration of AF and therefore, when 
combined with analysis of biomarkers, could better inform knowledge about whether there is 
a significant relationship between them.  
Investigation pathway process 
When the lead researcher reflected upon what happened with regards to loss of serum and 
urine samples, they acknowledged that they had not given the safe storage of samples enough 
consideration, as they had incorrectly assumed that a laboratory dealing with thousands of 
daily samples would have safety mechanisms and contingency plans in the event of a freezer 
breaking down. In retrospect, they should have completed a risk assessment at the beginning 
of the study to identify the potentially critical ‘pinch’ points in the process and they should 
have made a contingency plan. 
In future, they would ensure that samples were separated and stored in different freezers to 
ensure that even if a freezer did break down or if the alarm malfunctioned and samples were 
lost, the number of lost samples relative to the total number of samples in the study would be 
small.  
7.12 Limitations   
The lead researcher reflected on the validity of their pilot study and how well the outcomes 
for the study participants would be reflected in individuals beyond the study. 
Earlier in the thesis factors affecting the internal validity of the study were mentioned and 




These factors included eg. whether all episodes of AF in the cohort studied were able to be 
detected. 
The external validity of the results was evidently dependent on the internal validity of the 
study which was limited due to patient recruitment being restricted to patients that were due 
to undergo oesophageal surgery at Glasgow Royal Infirmary. As mentioned previously this 
was due to time limitations and also the practicalities of recruiting patients when the lead 
researcher also had to fulfil a clinical commitment in a hospital several miles away. Another 
factor influencing internal validity was the loss of patient samples due to freezer breakdown. 
This left the lead researcher with a small number of samples to analyse and resulted in 
logistic regression being completed out of interest rather than having enough samples to be 
able to do more meaningful analysis. Limitations of this pilot observational study included 
the variation in the cohort studied and potential confounding factors that had not been fully 
accounted for such as age, sex, co-morbidities and medications that patients were taking 
could have an effect on whether patients in the study develop AF or not.  Data concerning the 
patients including electrolyte levels such as magnesium and potassium and also fluid balance 
and electrolyte requirements could also be potential confounding factors when looking at the 
onset of AF.  
The lead researcher knew that as a pilot study it would be too small to match patients to 
ensure equal distribution of confounders. Confounding can have a significant impact on 
internal validity and so, they decided to use logistic regression as a way of addressing 
potential confounders. In the results, due to the small sample size following sample losses 
they were limited in doing logistic regression. They also did not restrict the entry of patients 
with potential confounding factors into the study as restricting entry would have risked bias. 
Selection bias originated when patients were enrolled in the study. In the study the selection 




oesophagogastrectomy, be males or non-pregnant females > 18 years old, not have AF and 
have capacity to give their written consent. Ideally, studying a group that was matched by age 
and gender to the group undergoing oesophageal surgery, would have helped to address bias, 
however, this was not possible in my study. 
Information bias occurs as a result of having incomplete data. To deal with missing data you 
can use linear regression and if you are using logistic regression, imputation of missing data 
can be done. 
The way that was chosen to deal with missing data was to omit the cases with the missing 
data and to analyse the remaining cases. 
Problems with missing data include bias in the estimation of parameters and it can also 
reduce how representative a sample is. 
Linear regression could also have been trialled to estimate missing values, by using the best 
predictors of the variable as independent variables and the variable with the missing data as 
the dependent variable in a regression equation. When replaced values are predicted from 
other variables the assumption is that there is a linear relationship between the variables used 
in the regression equation when there may not be one. Often they fit together too well and 
standard error is deflated. 
7.13 Conclusions  
In conclusion, due to these factors, this pilot study has limited internal validity and therefore 
external validity. In future, a larger study would need to be done with collection of more data, 
including nutritional status, baseline medications, co-morbidities and also consideration of 
matching patients undergoing oesophageal surgery to those with similar characteristics who 
are not undergoing oesophageal surgery. Along with robust data collection, the statistical 
analysis would be more meaningful, ensuring greater internal and external validity and 




In general terms, this study reinforced the need for further work regarding investigation into 
why patients were developing AF and how this arrhythmia might be predicted and prevented. 
 
Positive aspects of the study 
R&D and Ethics approval resulting in the recruitment and consenting of 40 patients over a 9 
month period. This was a notable achievement. 
Additionally, regarding the investigations and samples collected on ICU, the lead researcher  
had some excellent feedback regarding communication with nursing staff about study 
conduct and clarity about what needed to be done on a daily basis for the study. 
 
7.14 Key message 
• Despite the challenges the lead researcher encountered whilst undertaking this study, 
they have been able to turn challenges into opportunities for learning that they have 









8 CHAPTER 8 
8.1 Conclusions 
In this thesis I planned to utilise peri-operative biomarker levels, combined with results from 
cardiopulmonary exercise testing, in addition to the development of AF, to explore whether it 
was possible to determine effects on morbidity and mortality in patients undergoing 
oesophageal surgery. I also included the Charlson Age Co-morbidity Index risk stratification 
tool and the modified Glasgow prognostic scoring system pre and post-operatively to explore 
the feasibility of improving risk stratification in this patient group. The concept was that if 
there was a greater understanding of the mechanisms leading to increased morbidity and 
mortality in patients undergoing surgery for oesophageal cancer then this could assist in 
moving us closer to the personalisation of care, where risk for each patient could be 
individually stratified and decision making could be better informed and truly shared. 
I conducted the study and have shown that ADMA levels were lower and homoarginine 
levels were lower in patients who had undergone oesophageal surgery and develop AF post-
operatively. Both were statistically significant. The levels of BNP, myeloperoxidase, IL-6 
and CRP were not significantly related to AF development in these patients. When 
considering the modified Glasgow prognostic scoring system pre and post-operatively, it was 
not possible to determine evidence of any difference between values in the patient group that 
did develop AF compared with the group that did not. There was no statistically significant 
relationship between VO2 peak and medical complications and no significant relationship 
between anaerobic threshold and surgical complication in patients who developed AF post-
operatively. There was also no statistically significant relationship between anaerobic 
threshold, VO2 peak and medical and surgical complications in patients who do not develop 
AF. When determining the overall connection between biomarkers, cardiopulmonary exercise 




Glasgow prognostic scoring system pre and post-operatively in the context of developing AF 
and morbidity and mortality, it was not possible to complete a mixed effects model. Being 
honest about my study and the work detailed in my thesis, a source of disappointment for me 
was that as a result of the unique challenges which I encountered, it was not possible to draw 
any robust conclusions from the study due to sample loss and small numbers. This study was 
effectively one of feasibility. The next logical step would be to implement changes in the 
planning and processes which were identified as areas of improvement in the work described 
above and to take this forward to a larger study.  
Confounders that were undetected in my dataset or have not been identified in previous 
studies were not adjusted in my statistical analyses. In contrast, there might be mediators in a 
causal pathway that were adjusted in the statistical analyses; it is difficult to discriminate 
mediators from confounders among the variables in my dataset. In addition, I could adjust 
only the data regarding the postoperative complications that were available in my dataset. 
Moreover, unfortunately there was no information regarding the accurate sequence of the 
postoperative complications and the causality between the postoperative AF and other 
complications. Therefore, caution has to be taken when interpreting the results. Despite the 
limitations of the study design, I think that my study is clinically significant as an exploratory 
research that suggests a perspective that postoperative AF might be an independent risk factor 
in oesophageal cancer patients who underwent oesophageal surgery. 
 
The learning which I have benefitted from, as a result of the challenges I encountered whilst 
undertaking the study will be applied to any academic work which I undertake in the future 
and could also be extrapolated to clinical practice and beyond. I also plan to apply the 
knowledge which I developed as a result of what went well in the study. A point worth 




compared to the rest of Europe and it is noteworthy that the study cohort may have had high 
levels of concurrent morbidity causing derangement of the variables studied. 
Further to the work that has been done in the area of oesophagectomy and AF, a study published 
in May 2016 evaluating 583 patients found that in oesophageal cancer patients who underwent 
oesophagectomy, the development of new onset AF in 63 patients during the post-operative 
period might be independently associated with mortality. Risk factors for an increased 
incidence of AF included patients that were older and those taking pre-operative calcium 
channel blocker medication. 78 Only a few studies have focused on the association between 
mortality and AF after oesophagectomy. A study by McCormack et al in 2014 found no 
significant difference in mortality after oesophagectomy with the median survival was 40 
months versus 53 months in the cohort that developed AF and the cohort that did not 
respectively (p=0.353)195. In 2015 a systematic review and meta-analysis evaluating the 
relationship between biomarkers and AF looked at 472 studies from which 16 were selected. 
These 16 studies comprised 2915 patients. The results suggested that biomarkers such as IL-6 
and CRP were significantly associated with onset of AF and states that this should be further 
investigated196. 
The RE-LY (Randomised Evaluation of Long-Term Anticoagulation Therapy) study 
compared dabigatran to warfarin in patients with AF and found that high-dose dabigatran 
reduced stroke risk without increasing the risk of major bleeding among AF patients. In a 
subset of the RE-LY study, blood samples were taken in 2514 patients for NT-pro BNP and 
cardiac troponin-I (cTnI). Persistent elevation of either or both cardiac biomarkers at baseline 
and 3 months was associated with a higher risk for cardiovascular events such as stroke and 




In terms of adding to the literature, I have evaluated the levels of several cardiovascular 
biomarkers in the context of development of atrial fibrillation, morbidity and mortality and I 
have also evaluated the conduct of the study in terms of potential areas in which there would 
be room for improvement such as streamlining identification of appropriate patients in a timely 
manner and being able to approach them at appropriate points of the patient journey. As noted 
previously, there were also challenges with requesting investigations and also with laboratory 
processes and storage of samples was a particular area that was extremely challenging. 
However, the lessons have been acknowledged and the application of related learning will be 
used in the future. 
8.2 Future plans 
Future work in this area would include running a larger study based on the feasibility study 
which I have described above. This format and planning of this study would be informed by 
the lessons learned, which are detailed in chapter 3. It would consider each stage of the 
patient pathway with respect to their oesophageal cancer and also with respect to their 
preferences and what is important to them, so that their care could truly be personalised. This 
would include commencing with taking a comprehensive history from the patient, including 
details of their co-morbidities, nutritional status and regular medications, considering the 
effect they might have on the development of AF and longer-term outcomes. I would seek to 
determine the patient’s quality of life at the outset of the pathway and ensure that they have 
honest conversations with the surgical team and also allied health professionals about what 
matters to them and to help them understand the journey that they are embarking upon and 
also to ensure that there is shared decision making based on appreciation of what is known 
about the risks of undertaking chemotherapy and also an operation. Using the baseline 
knowledge about the patients and their preferences, I would also consider the effects of 




inquire about chemotherapy complications and consider whether patients who had problems 
after chemotherapy had increased morbidity and mortality following surgery. The side effects 
of chemotherapy include predisposition to infection and inflammation. It is unclear what 
effect chemotherapy would have on levels of inflammatory biomarker baseline levels when 
completed more than 6 weeks prior to surgery, and subsequently predisposition to 
development of AF. Ideally a separate trial looking at biomarker levels in a cohort 6 weeks 
after undergoing chemotherapy compared with a cohort matched with regard to baseline 
characteristics, who did not, might be able to illicit the effect it has on biomarker levels and 
subsequent AF development. Consideration of capturing every episode of AF, no matter how 
brief, would play a part in a future study. Due to the particular limitations of the resources 
available, including monitors and nursing staff in the study described above, it was not 
possible to record and make a note of short runs of AF, which in turn may well have affected 
the biomarker results. In terms of the management of AF on the ICU, I would plan to stratify 
the treatments used, ranging from simpler interventions such giving fluids, to giving 
electrolytes and medications such as amiodarone. Additionally, recording whether any 
patients had to undergo cardioversion due to cardiovascular instability secondary to AF 
would be important. Having comprehensively evaluated patients’ nutritional status at the 
beginning of the study, I would evaluate their feeding regimes post-operatively and place this 
in the context of blood results and nutritional indicators such as weight. A risk assessment 
should be completed prior to the study, to make certain that there is a streamlined pathway to 
enable the collection of plasma and urine samples and to safeguard their delivery to the 
laboratory and ensure their subsequent processing. The follow up period would also be 
extended to five years to determine long term outcomes in these patients. Comparison of 
CPET tests at 6, 12, 18 and 24 months following oesophagectomy, in the context of quality of 




with a Likert scale. It could also include evaluation of what activities people are able to return 
to following their operation and the impact that this has on their perceived quality of life. 
Depending on the age of patients undergoing the operation this may differ in terms of either 
going back to work or being able to return to pursuing a hobby that they enjoy. It would be 
informative to discover whether there is deterioration in CPET test results following 
oesophagectomy initially at 6 months following the operation and then whether there is a 
gradual return to pre-operative levels or whether this is never achieved. It would also be 
helpful to see whether patients experience an improved quality of life after their operation, 
whether this achieved after a certain period of time or whether this is not the case at all. 
Answering the question regarding what type of relationship there is between post-operative 
CPET test results and self-assessment of Quality of Life would be informative for future 
planning in terms of rehabilitation of this patient group. Additionally, the impact of 
socioeconomic status and the access to care on this patient cohort would be a valuable area of 
study to reflect on in the future. The considerations above regarding a future study would 
help to manage risk better by engaging in decision-making that is shared, therefore leading to 
reduced harm and reduce unwanted variation in practice. A truly personalised approach 
applied to the pathway for patients undergoing treatment for oesophageal cancer would be the 
ultimate goal. These concepts could then be extrapolated to other areas of health and care to 
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APPENDIX 2: PATIENT AND GP STUDY INFORMATION  
 
Patient study information v1.3 10/8/2012  
                                                                                                               
University Department of Anaesthesia,                                                                                          
Walton Building, Glasgow Royal Infirmary.  
Castle Street, G4 OSF. 
 
Association of ADMA and new onset AF following oesophagectomy study 
 
                                   Patient information sheet 
 
We would like to invite you to take part in a research study. Before you make a decision, you 
need to understand why the research is being done and what it would involve for you. Please 
take time to read the following information carefully. Talk to others about the study if you 
wish. Please do not hesitate to ask if there is anything that is unclear or if you would like 
more information. 
 
Who is conducting the research? 
Dr. Katherina Tober and Professor John Kinsella from the University Department of 
Anaesthesia at Glasgow Royal Infirmary are conducting the research. 
 
What is the purpose of the study? 
Atrial fibrillation (AF) is an irregular heart rhythm with which many people are diagnosed 
each year. Patients in the community with AF are often managed with medication to prevent 
symptoms such as palpitations and may also be on drugs which thin the blood. 
Following an oesophagectomy, AF occurs in approximately 11-22% of patients and often 
requires medication initially but this is infrequently needed for longer term management.  
Our observational study hopes to clarify why some people develop AF after oesophagectomy 
and why others do not, by establishing whether levels of asymmetric dimethylarginine 
(ADMA), an amino acid which is naturally produced in our bodies, is associated with new 
onset atrial fibrillation (AF). 
We hope to contribute to the relatively limited knowledge that exists regarding ADMA and 
the development of AF. If a link exists, this could mean the potential to predict which patients 
may develop atrial fibrillation post-operatively and therefore prevent it occurring. 
 
Why have I been invited to participate? 
You have been invited to participate as you may have to undergo an oesophagectomy 
procedure within the next few weeks.  
 
Do I have to take part? 
It is your decision. We will describe the study and go through the information sheet, which 




have agreed to take part. You are free to withdraw from the study at any time, without giving 
any reason. This will not affect the standard of care that you receive or your future treatment. 
 
What does taking part involve? 
Once you have read the information sheet and have had the opportunity to ask any questions 
you will be asked to sign a consent form for the study. Your GP will be made aware of your 
involvement with the study. 
The study involves a small amount of extra blood (slightly more than two teaspoonfuls) being 
taken at the time of routine blood tests pre-operatively. Urine samples will also be taken for 
analysis around this time. These blood and urine samples will be taken daily for 7 days or for 
the duration of your High Dependency Unit (HDU) stay, whichever comes first. If you 
develop AF this will be treated according to the HDU protocol and you will have a 12 lead 
ECG and an ultrasound scan of your heart.  
Your GP will follow your progress post-operatively and the researchers will make you aware 
of any publications arising from the study. 
 
What happens to the information? 
Your identity and personal information will be completely confidential and known only to the 
researcher. The information obtained will remain confidential and stored within a locked 
filing cabinet. The data are held for up to 5 years in accordance with the Data Protection Act, 
which means that we keep it safely and are unable to reveal it to other people without your 
permission. 
 
What are the possible benefits of taking part? 
It is hoped that by taking part in this research you will be helping us to gain valuable insights 
regarding the biochemical pathways involved in the development of AF in patients following 
oesophagectomy. In the future we anticipate that this will help us to predict which patients 
will develop AF post-operatively and therefore we may be able to prevent it. 
 
Who has reviewed the study? 
The study has been reviewed by the West of Scotland Research Ethics Service (WoSRES). 
 
Who do I contact if I have further questions about the study? 
We will give you a copy of the information sheet and signed consent form to keep. If you 
would like more information about the study and wish to speak to someone not closely linked 
to the study, please contact:  
Dr. Malcolm Booth, Consultant in Anaesthesia and Intensive Care Medicine, Glasgow Royal 
Infirmary. 




Dr. Katherina Tober  
Clinical research fellow in anaesthesia, 
Glasgow Royal Infirmary 








Professor John Kinsella 
Academic lead, University Dept Anaesthesia 
Glasgow Royal Infirmary 
Telephone: 0141 211 4625 
 
What if I have a complaint about any aspect of the study? 
If you unhappy about any aspect of the study and wish to make a complaint, please contact 














































GP study information v 1.1 24/7/2012 
                                                                                                           
 
University Department of Anaesthesia,                                                                                          
Walton Building, Glasgow Royal Infirmary.  
Castle Street, G4 OSF. 
 
 
Re: Association of ADMA and new onset AF following oesophagectomy study 
 
Dear Dr, 
I am writing to inform you that your patient  ………………………………… 
has consented to take part in the above study which concerns the investigation of asymmetric 
dimethylarginine (ADMA) levels and their association with new onset atrial fibrillation (AF) 
following oesophagectomy. 
Participation in this study will involve some additional blood being taken from patients in 
order to analyse levels of biomarkers including ADMA, symmetric dimethylarginine 
(SDMA) and laevo (L) arginine. Urine will also be sampled and tested for ADMA, SDMA 
and dimethylarginine (DMA) levels in addition to other biomarkers. 
These tests will be carried out pre-operatively and then daily post-operatively on 
HDU for a 7 day period or for the duration of their stay, whichever is shorter. 
If a patient develops new onset atrial fibrillation then this will be managed according to our 
local protocols. 
 
Risks of participation relate to venepuncture. 
 






Clinical research fellow in anaesthesia 














1. Patient consent form and study forms for completion on ICU 
 
 
Patient study consent v 1.0 22/7/2012 
 
                                                                                                                                                                                                                         
University Department of Anaesthesia,                                                                                          
Walton Building, Glasgow Royal Infirmary.  




Association of ADMA and new onset AF following oesophagectomy study 
 
 
                                                           Consent Form                  
                                                                                                 
Please initial box                      
I confirm that I have read and understand the information sheet dated 10/08/2012 
(version 1.3) for the above study and have had the opportunity to ask questions.                
 
I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights                being 
affected. 
 
I understand that sections of my medical notes may be looked at by the research team 
where it is relevant to my taking part in the research.  I give my permission             for the 
research team to have access to my records. 
I understand that if I am unable to participate in the exercise test that the      information 
from my questionnaire will still be used for the study.                                                                         
 
I understand that my GP will be made aware of my participation in this study.                        
 
I agree to take part in the above study.                   
…………………………………………….               ………………………..       
……………………………….. 
Name of participant                                    Date                                Signature 
…………………………………………….                ………………………..       
………………………………. 







One copy to the patient, one copy to the researcher, one original for the 
























































































Association of ADMA and new onset AF following oesophagectomy study 
            




ADMA, SDMA, homoarginine, myeloperoxidase, IL-6 
 
Fill: 1x green top vacutainer and 1x red top vacutainer  
BNP: Fill: 1 x purple top vacutainer 
URINE SAMPLES 
Nitrate, DMA, SDMA, ADMA 
Fill: 1x Universal container with 10ml urine 
Send to Biochemistry: FAO Dinesh Talwar and Laura Willox (ADMA study)  
Purple, red and green top and urine sample can be sent with one biochemistry 










Street, G4 OSF. 
  











Daily checklist for ADMA study patients   
                                                                                                                              Please initial box 
Day 0 (following return from theatre) 
Bloods: Routine bloods plus triglycerides, glucose, CRP, ADMA, SDMA, homoarginine, 
BNP, myeloperoxidase, IL-6 
Urine: nitrate, DMA, SDMA, ADMA  
ECG 
Rhythm: Is patient in sinus rhythm? If in AF manage as per local guidelines 
Aim to get an echo within 24 hours if AF sustained >30min (To request echo see below) 
                                                                        
Day 1 
Bloods: as per day 0 excluding BNP 
Urine: as per day 0 
ECG and evaluate rhythm as per day 0   
 
Day 2    
Bloods: as per day 0 
Urine: as per day 0 




Bloods: as per day 0 
Urine: as per day 0 
ECG and evaluate rhythm as per day 0 
 
Day 4 
Bloods: as per day 1 
Urine: as per day 0 
Evaluate rhythm as per day 0 
 
Day 5 
Bloods: as per day 1 
Urine: as per day 0 
Evaluate rhythm as per day 0 
 
Day 6 
 Bloods: as per day 1 
Urine: as per day 0 
Evaluate rhythm as per day 0 
           
 
Day 7 
Bloods: as per day 0 
Urine: as per day 0 
Evaluate rhythm as per day 0 
 
 
If you have any questions regarding this study please do not hesitate to contact  




Many thanks for your help. 
 
Researchers: 




Professor John Kinsella 
Contact: 0141 211 4625 
 
Echo requests (in daylight hours) 
Dr. Alex Puxty 
ICU Consultant 
Glasgow Royal Infirmary 
Contact: 0141 211 4225 
 
Dr Carol Murdoch 
ICU Consultant 
Glasgow Royal Infirmary 
Contact: 0141 211 4225 
 
Dr Martin Hughes 
ICU Consultant 
Glasgow Royal Infirmary 
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